US 20100323376A1

(19) United States
(12) Patent Application Publication
Contois
(10) Pub. No.: US 2010/0323376 A1
(43) Pub. Date: Dec. 23, 2010

(54) **METHOD FOR MEASURING LIPOPROTEIN-SPECIFIC APOLIPOPROTEINS**

(75) Inventor: **John Contois**, Windham, ME (US)

Correspondence Address:
DRINKER BIDDLE & REATH
ATTN: INTELLECTUAL PROPERTY GROUP
ONE LOGAN SQUARE, SUITE 2000
PHILADELPHIA, PA 19103-6996 (US)

(73) Assignee: **Maine Standards Company, LLC**

(21) Appl. No.: **12/817,026**

(22) Filed: **Jun. 16, 2010**

Related U.S. Application Data

(60) Provisional application No. 61/187,806, filed on Jun. 17, 2009.

Publication Classification

(51) **Int. Cl.**
G01N 33/53 (2006.01)
G01N 33/566 (2006.01)

(52) **U.S. Cl.** **435/7.92**; 435/7.1; 436/501

(57) **ABSTRACT**

The present invention is directed to methods of measuring the concentration of lipoprotein particles and/or lipoprotein-specific apolipoproteins in a biological fluid using an immunoassay, without the need of preliminary physical separation of the various types of lipoprotein particles present in the biological fluid.

FIGURE 1



FIGURE 2



FIGURE 3



FIGURE 4



FIGURE 5



FIGURE 6



FIGURE 7



FIGURE 8



METHOD FOR MEASURING LIPOPROTEIN-SPECIFIC APOLIPOPROTEINS

CROSS-REFERENCE TO RELATED APPLICATION

[0001] This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application No. 61/187,806, filed Jun. 17, 2009, which application is incorporated by reference herein in its entirety.

BACKGROUND OF THE INVENTION

[0002] Lipoproteins are intricate protein-lipid structures, in which the lipids or their derivatives may be covalently or non-covalently bound to the proteins. Among the various lipoproteins that play a key role in metabolic processes are blood lipoproteins, which enable fats (lipids) to be carried in the blood stream. Blood lipoproteins may be classified based on their size and lipid content, with lipoproteins with higher lipid content tending to be larger and less dense.

[0003] Chylomicrons (density<0.95 g/ml, and diameter of 100-1000 nm) carry triacylglycerol (fat) from the intestines to the liver, skeletal muscle and adipose tissue. Very low density lipoproteins (VLDL) (density of 0.95-1.006 g/ml, and diameter of 30-80 nm) carry newly synthesized triacylglycerol from the liver to adipose tissue. Intermediate density lipoproteins (IDL) (density of 1.006-1.019 g/ml, and diameter of 25-50 nm) are intermediate in size between VLDL and LDL. Low density lipoproteins (LDL) (density of 1.019-1.063 g/ml, and diameter of 18-28 nm) carry cholesterol from the liver to cells of the body. High density lipoproteins (HDL) (density>1.063 g/ml, and diameter of 5-15 nm) collect cholesterol from the tissues of the body, and bring it back to the liver.

[0004] Lipid levels are intrinsically associated with coronary disease or coronary heart disease (CHD). CHD represents the failure of coronary circulation to supply adequate circulation to cardiac muscle and surrounding tissue. CHD is often associated with coronary artery disease, where lipid-containing plaques accumulate within the walls of the coronary arteries that supply the myocardium (the heart muscle) with oxygen and nutrients. Among the various causes for development of CHD is dyslipidemia, a condition associated with a deviation in standard amounts of lipid in the blood of a subject. Such deviation may include one of the following occurrences, or any combination thereof: increase in total cholesterol (TC) level, increase in triglyceride (TG) level, decrease in high-density lipoprotein (HDL) cholesterol level, increase in low-density lipoprotein (LDL) cholesterol level, or presence of elevated LDL particles. Medical experts generally believe that management of CHD may be achieved by close monitoring and correction of lipid levels (especially LDL levels).

[0005] HDL is sometimes referred to as the "good cholesterol" lipoprotein, and higher levels of circulating HDL are generally associated with lower risk for CHD.

[0006] On the other hand, LDL cholesterol is widely accepted as a major risk factor for coronary heart disease (CHD), and is sometimes referred to as the "bad cholesterol" lipoprotein. Intervention trials with LDL-lowering therapies have been shown to reduce the incidence of future CHD events. LDL particles are heterogeneous in their composition of cholesterol, triglycerides, and phospholipids, and individuals with the same concentration of LDL particles may present very different LDL cholesterol levels. Conversely, individuals with the same LDL cholesterol levels may present very different concentration of LDL particles.

[0007] The concentration of plasma LDL cholesterol is a good predictor of CHD in a population study, but is frequently found to be a poor predictor of CHD when dealing with an individual patient. The main reason behind this discrepancy is that the LDL particles—and not the cholesterol contained within their core—interact with the arterial wall to promote atherosclerosis (Tabas et al., 2007, Circulation 116:1832; Rudd et al., In: "Textbook Of Cardiovascular Medicine", 2nd ed.; R. J. Topal, Ed., Lippincott, Williams, and Wilkins, Philadelphia, 2002, pp. 2-12). The higher the number of LDL particles in circulation, the higher the rate of development and progression of atherosclerosis. Therefore, it follows that a better predictor of future CHD events in a patient is the concentration of circulating LDL particles in the patient. Table 1 summarizes prospective epidemiologic studies of LDL particles (measured by NMR) and CHD.

TABLE 1

Prospective studies of LDL particle concentration as a risk factor for CHD (adapted from Contois et al., 2009, Clin. Chem. 55: 407-419)

Study	Design	Subjects	Endpoint	Follow-up	Fasting	# Cases	# Controls
Cardiovascular Health Study - Kuller 2002	Nested CC	M, W age ≧ 65	MI, A	5 y	unknown	434	500
Women's Health Study - Blake 2002	Nested CC	W	CHDD, MI, S	3 y	unknown	130	130
Framingham Heart Study - Cromwell 2007	Cohort	M, W	MI, A, CI, CHDD, S, TIA, IC, CHF	14.8 y	Yes	531	2,535
EPIC-Norfolk Prospective Population Study - El Harchaoui 2007	Nested CC	M, W	CHD, CHDD	6 y	No	1,003	1,885

TABLE 1-continued

Prospective studies of LDL particle concentration as a risk factor for CHD (adapted from Contois et al., 2009, Clin. Chem. 55: 407-419)

Study	Design	Subjects	Endpoint	Follow-up	Fasting	# Cases	# Controls
Women's Health Study - Mora 2007	Cohort	W	CHD, CHDD	11 y	unknown	1,015	26,658
PLAC-I Trial - Rosenson 2002	Cohort	M, W ↑LDL	ΔMLD	3 y	unknown	241	—
VA-HIT - Otvos 2006	Nested CC	M < 74 y	MI, CHDD	5.1 y	Yes	364	697

Abbreviations:
MI, fatal or nonfatal myocardial infarction;
A, angina;
CHD, coronary heart disease;
CHDD, coronary heart disease death;
M, men;
W, women;
CC, case-control;
y, years;
A, angina;
S, stroke;
ΔMLD, change in minimum lumen diameter by angiography;
CI, coronary insufficiency;
IC, intermittent claudication;
CHF, congestive heart failure;
LDL-P, low-density lipoprotein particle concentration.

[0008] Due to the heterogeneous nature of LDL, the concentration of LDL particles (LDL-P) cannot be accurately estimated from the level of LDL cholesterol (Otvos, 1999, Clin. Cardiol. 22:1121). Various analytical methods have been used to measure LDL-P. As an example, prospective epidemiological studies using nuclear magnetic resonance (NMR) spectroscopy (Otvos, U.S. Pat. Nos. 5,343,389 and 6,576,471) to measure LDL-P showed significantly stronger associations of CHD outcomes with LDL particle concentration than with LDL cholesterol or other lipid and lipoprotein parameters (Table 2; Contois et al., 2009, Clin. Chem. 55:407-419), most notably, in the VAHIT Trial (Otvos et al., 2006, Circulation 113:1556), the Women's Health Study (Mora et al., Scientific Sessions of the American Heart Association, Orlando, Fla., November, 2007), and the Framingham Heart Study (Cromwell et al., 2007, J. Clin. Lipidol. 1:583). In the Multi-Ethnic Study of Atherosclerosis (MESA), the concentration of LDL particles correlated well with preclinical atherosclerosis (carotid intima-media thickness), even in subjects with LDL cholesterol less than 100 mg/dL (Mora et al., 2007, Atherosclerosis 2007, 192:211). Unfortunately, use of NMR technology is expensive, experimentally complicated, and not yet amenable for routine use in the clinical laboratory. Therefore, there is need in the art to quantitate the number or concentration of LDL particles in an individual patient using a method that may be routinely performed in a clinical setting.

[0009] Apolipoproteins, the protein components of lipoproteins, serve three major functions: (a) modulate the activity of enzymes that metabolize lipoproteins; (b) maintain the structural integrity of lipoproteins, and (c) facilitate the uptake of lipoprotein by binding to specific cell surface receptors. Apolipoprotein B (apo B) is a large protein with two isoforms: apo B-100, which is synthesized in the hepatocytes; and apo B-48, a truncated protein that is also derived from the apo B-100 gene but synthesized in the small intestine (Elovson et al., 1988, J. Lipid Res. 29:1461). Apo B-48 is found on chylomicrons, while apo B-100 is found on VLDL, IDL, LDL, and lipoprotein(a) [Lp(a)]. In all these lipoproteins, there is one molecule of apo B per lipoprotein particle, and therefore measurement of apo B associated with a particular lipoprotein class indicates the particle number or concentration of that particular lipoprotein class (Sniderman et al., 1991, Atherosclerosis 89:109).

TABLE 2

Prospective studies of LDL particle concentration: Comparison of relative risk with LDL cholesterol level (adapted from Contois et al., 2009, Clin. Chem. 55: 407-419)

Study	Comparison	LDL-P	LDL-C	Matching and/or Adjustment Variables
Blake 2002	Q4 v. Q1	4.17 (1.96-8.87)	2.06 (1.03-4.12)	Age, smoking, treatment group
Kuller 2002	Q4 v. Q1	M: NS W: 2.59	M: NS W: 3.34	Age, race

TABLE 2-continued

Prospective studies of LDL particle concentration:
Comparison of relative risk with LDL cholesterol level
(adapted from Contois et al., 2009, Clin. Chem. 55: 407-419)

Study	Comparison	LDL-P	LDL-C	Matching and/or Adjustment Variables
Rosenson 2002	Above v. below the median	2.1 (0.7-5.8)	1.4 (0.5-3.9)	Age, race, baseline lumen diameter
E1Harchaoui 2006	Q4 v. Q1	1.78 (1.34-2.37)	1.22 (0.92-1.61)	Smoking, SBP, LDL-C or LDL-P
Otvos 2006	Baseline, 1 SD	1.20 (1.05-1.37)	1.10 (0.97-1.25)	Treatment group, age, HTN,
	On-Trial, 1 SD	1.28 (1.12-1.47)	1.08 (0.95-1.23)	smoking, BMI, diabetes
Cromwell 2007	1 SD	M: 1.24 (1.10-1.39) W: 1.33 (1.17-1.50)	M: 1.06 (0.94-1.20) W: 1.18 (1.02-1.37)	Age, SBP, DBP, smoking, medication use
Mora 2007	Q5 v. Q1	2.51 (1.91-3.30)	1.74 (1.40-2.16)	

Abbreviations:
apo B, apolipoprotein B;
NS, not significant;
M, men;
W, women;
T, tertile;
Q, quartile or quintile;
SD, standard deviation;
TC, total cholesterol;
TG, triglycerides;
BP, blood pressure;
SBP, systolic blood pressure;
DBP, diastolic blood pressure;
LDL-C, low-density lipoprotein cholesterol;
LDL-P, low-density lipoprotein particle concentration;
BMI, body mass index;
HDL-C, high-density lipoprotein cholesterol;
HTN, hypertension;
HbA1c, hemoglobin A1c;
TIA, transient ischemic attack;
PVD, peripheral vascular disease.

[0010] In an attempt to quantitate LDL, researchers have disclosed techniques such as ultracentrifugation, electrophoresis or selective precipitation, to separate LDL from other lipoproteins. However, these techniques are generally cumbersome, and thus lack the ease of implementation required for routine assay. Gambert described a method for measuring LDL-apo B using electrophoresis to separate LDL from other lipoproteins and then using electro-immunodiffusion to measure apo B (U.S. Pat. No. 5,064,769). Anderson described a method for measuring LDL-apo B by precipitating VLDL and IDL with anti-apo CI antibody, and then measuring the remaining apo B in solution (presumably associated with LDL) by rocket electrophoresis (Anderson, 1998, J. Lipid Res. 29:377). Vrga et al. described the isolation of LDL using an immunoseparation kit from Genzyme Diagnostics (Cambridge, Mass.) (Vrga et al., 1997, Clin. Chem. 43:390). The method employed anti-apo A-I and anti-apo E antibodies complexed to polystyrene beads as a means to separate VLDL and HDL from LDL. A filtrate containing the isolated LDL was obtained by centrifugation, and apo B in the filtrate was measured by an immunoassay. Schriewer et al. determined LDL cholesterol and LDL-apo B concentrations following precipitation of VLDL in blood serum with phosphotunstic acid and magnesium chloride (Schriewer et al., 1984, J Clin. Chem. Clin. Biochem. 22: 35). Caulfield et al. described a method for measuring LDL particle concentration by ion mobility analysis (Caulfield et al., 2008, Clin. Chem. 54:1307). Koren et al. described a number of monoclonal antibodies, including one antibody directed against an apo B epitope that was reportedly recognized on LDL but not VLDL particles (US Patent Application No. 2004/0053321). Slater et al. also described a monoclonal antibody based assay for LDL-apo B using a monoclonal antibody that displayed relative specificity for apo B associated to LDL (Slater et al., 1985, Clin. Chem. 31:841). These antibodies, or similar monoclonal antibodies directed at LDL-apo B, have yet to be widely adopted.

[0011] In a different approach, some researchers have attempted to estimate LDL-P based on total apo B measurements. Clendenen et al. described the use of total apo B to estimate LDL particle concentration, which may then be used to determine the particle concentrations of LDL subfractions separated by gradient gel electrophoresis (US Patent Application No. 2007/0072302). The method assumed a 1:1 relationship between total apo B and LDL-P, which is only a rough approximation. Similarly, Baca and Warnick developed a mathematical formula that estimates LDL-apo B based on total apo B and triglyceride concentrations (Baca &

Warnick, 2008, Clin. Chem. 54: 907), and Kulkarni described a similar mathematical equation to estimate apo B (U.S. Pat. No. 7,521,248).

[0012] In summary, there is great interest in expeditiously determining LDL particle concentrations in a blood sample as a means to routinely monitor lipid levels and estimate risk for future CHD events in the subject. Unfortunately, there remains need for an accurate method of specifically measuring LDL particle numbers or concentrations in biological samples, where such method may be implemented in standard chemistry laboratories without the need for cumbersome purification procedures or expensive analytical instrumentation. The present invention fulfills this need.

SUMMARY OF THE INVENTION

[0013] In one aspect, the invention includes a method of measuring the concentration of lipoprotein particles in a biological fluid of a subject, wherein an apolipoprotein is structurally associated with said lipoprotein in the form of lipoprotein-apolipoprotein.

[0014] In one embodiment, the method comprises mixing the biological fluid with Reagent R1, wherein Reagent R1 comprises a surfactant, to generate Solution S1; Solution S1 is then incubated for a period of time t1 at a set temperature T1; Solution S1 is then mixed with Reagent R2, wherein Reagent R2 comprises an antibody against the apolipoprotein, to generate Solution S2. Solution S2 is then incubated for a period of time t2 at a set temperature T2, to generate an apolipoprotein antibody complex. A calibration curve is then generated for quantitating binding of the antibody to the apolipoprotein with an immunoassay, using at least one standard solution comprising a known concentration of the apolipoprotein. Thus, the antibody-bound apolipoprotein is quantitated in Solution S2 in the immunoassay using the calibration curve, and, therefore, the concentration of the lipoprotein-apolipoprotein in Solution S2 is assessed, and, therefore, the concentration of the lipoprotein-apolipoprotein in the biological fluid is determined, and, therefore, the concentration of the lipoprotein particles in the biological fluid is assessed.

[0015] In another embodiment, the method comprises mixing the biological fluid with Reagent R1 to generate Solution S1; Solution S1 is then incubated for a period of time t1 at a set temperature T1; Solution S1 is then mixed with Reagent R2, wherein Reagent R2 comprises an antibody against the apolipoprotein and a surfactant, to generate Solution S2. Solution S2 is then incubated for a period of time t2 at a set temperature T2, to generate an apolipoprotein antibody complex. A calibration curve is then generated for quantitating binding of the antibody to the apolipoprotein with an immunoassay, using at least one standard solution comprising a known concentration of the apolipoprotein. Thus, the antibody-bound apolipoprotein is quantitated in Solution S2 in the immunoassay using the calibration curve, and, therefore, the concentration of the lipoprotein-apolipoprotein in Solution S2 is assessed, and, therefore, the concentration of the lipoprotein-apolipoprotein in the biological fluid is determined, and, therefore, the concentration of the lipoprotein particles in the biological fluid is assessed.

[0016] In yet another embodiment, the method comprises mixing the biological fluid with Reagent R2, wherein Reagent R2 comprises an antibody against the apolipoprotein and a surfactant, to generate Solution S2. Solution S2 is then incubated for a period of time t2 at a set temperature T2, to generate an apolipoprotein antibody complex. A calibration curve is then generated for quantitating binding of the antibody to the apolipoprotein with an immunoassay, using at least one standard solution comprising a known concentration of the apolipoprotein. Thus, the antibody-bound apolipoprotein is quantitated in Solution S2 in the immunoassay using the calibration curve, and, therefore, the concentration of the lipoprotein-apolipoprotein in Solution S2 is assessed, and, therefore, the concentration of the lipoprotein-apolipoprotein in the biological fluid is determined, and, therefore, the concentration of the lipoprotein particles in the biological fluid is assessed.

[0017] In one embodiment, the subject is human.

[0018] In one embodiment, the biological fluid is blood. In another embodiment, the biological fluid is serum. In yet another embodiment, the biological fluid is plasma.

[0019] In one embodiment, the lipoprotein is LDL and the apolipoprotein is apo B. In another embodiment, the lipoprotein is HDL and the apolipoprotein is selected from the group consisting of apo A-I, apo A-II, apo A-IV, apo A-V, apo C-I, apo C-II, apo C-III, apo C-IV, and apo E.

[0020] In one embodiment, the surfactant is an ionic surfactant. In another embodiment, the surfactant is a non-ionic surfactant. In yet another embodiment, the non-ionic surfactant is selected from the group consisting of a POE polymer, POP polymer, POE-POP block copolymer, PEG polymer, Brij® surfactant, Igepal® surfactant, Tween® surfactant and Triton® surfactant.

[0021] In one embodiment, the surfactant in Solution S1 varies in concentration from about 0.001% to about 10%. In another embodiment, the surfactant in Solution S1 varies in concentration from about 0.005% to about 1%.

[0022] In one embodiment, the surfactant in Solution S2 varies in concentration from about 0.001% to about 10%. In another embodiment, the surfactant in Solution S2 varies in concentration from about 0.005% to about 1%.

[0023] In one embodiment, Reagent R1 further comprises a PEG polymer. In another embodiment, the PEG polymer varies in concentration in Solution S1 from about 0.1% to about 10%. In yet another embodiment, the PEG polymer varies in concentration in Solution S1 from about 1% to about 8%.

[0024] In one embodiment, Reagent R2 further comprises a PEG polymer. In another embodiment, the PEG polymer varies in concentration in Solution S2 from about 0.1% to about 10%. In yet another embodiment, the PEG polymer varies in concentration in Solution S2 from about 1% to about 8%.

[0025] In one embodiment, Solution S2 further comprises a PEG polymer. In another embodiment, the PEG polymer varies in concentration in Solution S2 from about 0.1% to about 10%. In yet another embodiment, the PEG polymer varies in concentration in Solution S1 from about 1% to about 8%.

[0026] In one embodiment, Reagent R1 optionally further comprises one or more components selected from the group consisting of PEG, dextran sulfate, α-cyclodextrin sulfate, EDTA, an azide salt, and a divalent cation.

[0027] In one embodiment, Reagent R2 optionally further comprises one or more components selected from the group consisting of PEG, dextran sulfate, α-cyclodextrin sulfate, EDTA, an azide salt, and a divalent cation.

[0028] In one embodiment, Solution S2 optionally further comprises one or more components selected from the group

consisting of PEG, dextran sulfate, α-cyclodextrin sulfate, EDTA, an azide salt, and a divalent cation.

[0029] In one embodiment, Solution S1 comprises surfactant Pluronic® F-68 (0.5%), PEG 4000 (2.5%), and PBS buffer, pH 7.4. In another embodiment, Solution S1 comprises surfactant Brij® 700 (0.005%), PEG 8000 (3%), and PBS buffer, pH 7.4. In yet another embodiment, Solution S1 comprises surfactant Pluronic® F-127 (0.01%), PEG 8000 (5%), and PBS buffer, pH 7.4.

[0030] In one embodiment, Solution S2 comprises surfactant Pluronic® F-68 (0.5%), PEG 4000 (2.5%), and PBS buffer, pH 7.4. In another embodiment, Solution S2 comprises surfactant Brij® 700 (0.005%), PEG 8000 (3%), and PBS buffer, pH 7.4. In yet another embodiment, Solution S2 comprises surfactant Pluronic® F-127 (0.01%), PEG 8000 (5%), and PBS buffer, pH 7.4.

[0031] In one embodiment, the period of time t1 is about 5 minutes and the set temperature T1 is about 37° C.

[0032] In one embodiment, the period of time t2 is about 3 minutes and the set temperature T2 is about 37° C.

[0033] In one embodiment, the immunoassay is immunoturbidimetry or immunonephelometry. In another embodiment, the immunoassay is an ELISA assay. In one embodiment, at least one standard solution has known concentration expressed in mg/dL units. In another embodiment, the concentration of the lipoprotein-apolipoprotein in the biological fluid is calculated in mg/dL units. In yet another embodiment, the concentration of the lipoprotein-apolipoprotein in the biological fluid is calculated in nmoles/L units. In yet another embodiment, the concentration of the lipoprotein particles in the biological fluid is calculated in nmoles/L units.

[0034] In another aspect, the invention includes a composition comprising a non-ionic surfactant selected from the group consisting of a POE polymer, a POP polymer, a POE-POP block copolymer, a PEG polymer, a Brij® surfactant, a Igepal® surfactant, a Tween® surfactant and a Triton® surfactant, wherein the concentration of said non-ionic surfactant varies from about 0.001% to about 10%; in a buffer with a pH value ranging from about 6.5 to about 8.5.

[0035] In one embodiment, the composition optionally further comprises a PEG polymer varying in concentration from about 0.1% to about 10%. In another embodiment, the composition optionally further comprises one or more components selected from the group consisting of PEG, dextran sulfate, α-cyclodextrin sulfate, EDTA, an azide salt and a divalent cation. In yet another embodiment, the composition further comprises a biological fluid from a subject. In yet another embodiment, the composition further comprises an antibody against an apolipoprotein.

[0036] In yet another aspect, the invention includes a kit for measuring the concentration of lipoprotein particles in a biological fluid of a subject, wherein an apolipoprotein is structurally associated with the lipoprotein in the form of lipoprotein-apolipoprotein. The kit comprises: (a) at least one composition comprising a known amount of said apolipoprotein; (b) a composition comprising a non-ionic surfactant selected from the group consisting of a POE polymer, a POP polymer, a POE-POP block copolymer, a PEG polymer, a Brij® surfactant, a Igepal® surfactant, a Tween® surfactant and a Triton® surfactant, wherein the concentration of the non-ionic surfactant varies from about 0.001% to about 10%; in a buffer with a pH value ranging from about 6.5 to about 8.5; this composition optionally further comprises a PEG polymer varying in concentration from 0.1% to about 10%; and optionally further comprising one or more components selected from the group consisting of PEG, dextran sulfate, α-cyclodextrin sulfate, EDTA, an azide salt and a divalent cation; and (c) a composition comprising an antibody against the apolipoprotein and optionally further comprising one or more components selected from the group consisting of a surfactant, PEG, dextran sulfate, α-cyclodextrin sulfate, EDTA, an azide salt and a divalent cation; wherein the kit further comprises an applicator and an instructional material for the use of the kit.

BRIEF DESCRIPTION OF THE DRAWINGS

[0037] For the purpose of illustrating the invention, there are depicted in the drawings certain embodiments of the invention. However, the invention is not limited to the precise arrangements and instrumentalities of the embodiments depicted in the drawings.

[0038] FIG. **1** is a graph representing the effect of surfactant Pluronic® P123, as a component of Reagent R1, in the reaction of anti-apo B antibody with VLDL and LDL particles, as measured by immunoturbidimetry. In all reactions, Reagent R1 contained 2.7% of PEG 4000. The extent of reaction for 0% Pluronic® P123 was normalized to 100%.

[0039] FIG. **2** is a graph representing the effect of surfactant Pluronic® L121, as a component of Reagent R1, in the reaction of anti-apo B antibody with VLDL and LDL particles, as measured by immunoturbidimetry. In all reactions, Reagent R1 contained 2.7% of PEG 4000. The extent of reaction for 0% Pluronic® P123 was normalized to 100%.

[0040] FIG. **3** is a graph representing the effect of PEG 4000, as a component of Reagent R1, in the reaction of anti-apo B antibody with VLDL and LDL particles, as measured by immunoturbidimetry. In all reactions, Reagent R1 contained 0.05% of Pluronic® P 123.

[0041] FIG. **4** is a graph representing the effect of PEG 600, as a component of Reagent R1, in the reaction of anti-apo B antibody with VLDL and LDL particles, as measured by immunoturbidimetry. In all reactions, Reagent R1 contained 0.8% of Pluronic® F68.

[0042] FIG. **5** is a graph representing the effect of PEG 4000, as a component of Reagent R1, in the reaction of anti-apo B antibody with VLDL and LDL particles, as measured by immunoturbidimetry. In all reactions, Reagent R1 contained 0.8% of Pluronic® F68.

[0043] FIG. **6** is a graph representing the effect of surfactant Pluronic® F68, as a component of Reagent R1, in the reaction of anti-apo B antibody with VLDL and LDL particles, as measured by immunoturbidimetry. In all reactions, Reagent R1 contained 3% PEG 4000.

[0044] FIG. **7** is a graph representing the effect of surfactant Pluronic® F68, as a component of Reagent R1, in the reaction of anti-apo B antibody with VLDL and LDL particles, as measured by immunoturbidimetry. In all reactions, Reagent R1 contained 3% PEG 600.

[0045] FIG. **8** is a graph and table illustrating the linear regression of observed and expected concentrations derived from dilution of concentrated LDL particles.

DETAILED DESCRIPTION OF THE INVENTION

[0046] The invention relates to the discovery that the concentration of lipoprotein particles in solution may be expeditiously determined based on the quantitation of one or more apolipoproteins associated with the lipoprotein particles of

interest, without the need for preliminary physical separation of the various types of lipoprotein particles present in the sample. The method thus advantageously avoids the use of costly and/or timely purification procedures or expensive analytical instrumentation.

[0047] The invention includes a method of measuring the concentration of LDL-apo B (e.g., apo B associated with LDL particles) in a biological fluid of a subject. The method comprises treating the biological fluid with a chemical reagent that "blocks" apo B associated with non-LDL particles (such as VLDL-apo B, i.e., apo B associated with VLDL particles) from binding to anti-apo B antibodies. Only apo B protein associated with LDL particles is then free to bind to anti-apo B antibody added to the treated sample. The method further comprises a method of quantitating the LDL-apo B concentration in the biological fluid and using that information to calculate the LDL particle concentration in the biological fluid.

[0048] The invention also includes a method of measuring the concentration of an apolipoprotein of choice bound to HDL in a biological fluid of a subject. The method comprises treating the biological fluid with a chemical reagent that "blocks" the apolipoprotein of choice (such as, but not limited to, apo A-I, apo A-II, apo A-IV, apo A-V, apo C-I, apo C-II, apo C-III, apo C-IV or apo E) that is associated with non-HDL particles (such as, but not limited to, VLDL), from binding to the corresponding anti-apolipoprotein antibodies (anti-apo A-I, anti-apo A-II, anti-apo A-IV, anti-apo A-V, anti-apo C-I, anti-apo C-II, anti-apo C-III, anti-apo C-IV or anti-apo E antibodies, respectively). The apolipoprotein of choice that is associated with HDL is then free to bind to the anti-apolipoprotein antibody added to the treated sample. The method further comprises a method of quantitating the concentration of apolipoprotein associated with HDL in the biological fluid and using that information to estimate the HDL particle concentration in the biological fluid.

[0049] The methods included in the invention may be used to monitor specific circulating levels of apolipoprotein and/or lipoprotein in the subject over time. This monitoring may be used to determine the subject's likelihood of developing coronary heart disease (CHD) and may be used as an integral part of a medical and/or lifestyle intervention, created for the individual with the objective of helping manage circulating level of the specific apolipoprotein and/or lipoprotein to ranges accepted as healthy or desirable by medical specialists.

Definitions

[0050] As used herein, each of the following terms has the meaning associated with it in this section.

[0051] Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Generally, the nomenclature used herein and the laboratory procedures in cell culture, molecular genetics, organic chemistry, lipid chemistry, and nucleic acid chemistry and hybridization are those well known and commonly employed in the art.

[0052] As used herein, the articles "a" and "an" refer to one or to more than one (i.e. to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

[0053] As used herein, the term "about" will be understood by persons of ordinary skill in the art and will vary to some extent on the context in which it is used.

[0054] As used herein, the term "PBS" refers to phosphate-buffered saline, and the term "Tris" or "tris" refers to tris (hydroxymethyl)aminomethane base.

[0055] As used herein, the term "lipoproteinX-apolipoproteinY" refers to the apolipoproteinY that is structurally associated with lipoproteinX. For example, LDL-apo B refers to the apo B apolipoprotein that is structurally associated with LDL lipoprotein. Non-LDL-apo B refers to the apo B apolipoprotein that is structurally associated with lipoproteins that are not LDL. As a consequence, non-LDL-apo B corresponds to the total apo B apolipoprotein in the sample minus the apo B apolipoprotein that is structurally associated with LDL.

[0056] As used herein, the term "surfactant" refers to a wetting agent that lowers the surface tension of a liquid, allowing easier spreading, and lowers the interfacial tension between two liquids. A surfactant is usually an organic compound that is amphiphilic, meaning it contains both hydrophobic groups ("tails") and hydrophilic groups ("heads"). Non-limiting examples of surfactants are polyoxyethylene (POE) polymers, polyoxypropylene (POP) polymers, POE-POP block copolymers, cyclodextrins, polyethyleneglycol (PEG), Brij® surfactants, Igepal® surfactants, Tween® surfactants, Triton® surfactants and dextran sulfate.

[0057] As used herein, the terms "peptide," "polypeptide" and "protein" are used interchangeably, and refer to a compound comprised of amino acid residues covalently linked by peptide bonds. A protein or peptide must contain at least two amino acids, and no limitation is placed on the maximum number of amino acids that may comprise the sequence of a protein or peptide. Polypeptides include any peptide or protein comprising two or more amino acids joined to each other by peptide bonds. As used herein, the term refers to both short chains, which also commonly are referred to in the art as peptides, oligopeptides and oligomers, for example, and to longer chains, which generally are referred to in the art as proteins, of which there are many types. "Polypeptides" include, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, fusion proteins, among others. The polypeptides include natural peptides, recombinant peptides, synthetic peptides, or a combination thereof. A protein may be a receptor or a non-receptor.

[0058] As used herein, the term "fragment," as applied to a protein or peptide, refers to a subsequence of a larger protein or peptide. A "fragment" of a protein or peptide may be at least about 10 amino acids in length; for example, at least about 50 amino acids in length; more preferably, at least about 100 amino acids in length; even more preferably, at least about 200 amino acids in length; particularly preferably, at least about 300 amino acids in length; and most preferably, at least about 400 amino acids in length.

[0059] As used herein, a "nucleic acid" refers to a polynucleotide and includes polyribonucleotides and polydeoxyribonucleotides.

[0060] As used herein, the term "homologous" refers to the subunit sequence similarity between two polymeric molecules, e.g., between two nucleic acid molecules, such as two DNA molecules or two RNA molecules, or between two polypeptide molecules. When a subunit position in both of the two molecules is occupied by the same monomeric subunit;

e.g., if a position in each of two DNA molecules is occupied by adenine, they are homologous at that position. The homology between two sequences is a direct function of the number of matching or homologous positions; e.g., if half (e.g., five positions in a polymer ten subunits in length) of the positions in two sequences are homologous, the two sequences are 50% homologous; if 90% of the positions (e.g., 9 of 10), are matched or homologous, the two sequences are 90% homologous. By way of example, the DNA sequences 3'ATTGCC5' and 3'TATGGC5' are 50% homologous. As used herein, "homology" is used synonymously with "identity."

[0061] As used herein, the term "substantially the same" amino acid sequence is defined as a sequence with at least 70%, preferably at least about 80%, more preferably at least about 90%, even more preferably at least about 95%, and most preferably at least 99% homology to another amino acid sequence, as determined by the FASTA search method in accordance with Pearson & Lipman, Proc. Natl. Inst. Acad. Sci. USA 1988, 85:2444-2448.

[0062] As used herein, the term "isolated" means altered or removed from the natural state through the actions of a human being. For example, a nucleic acid or a peptide naturally present in a living animal is not "isolated," but the same nucleic acid or peptide partially or completely separated from the coexisting materials of its natural state is "isolated." An isolated nucleic acid or protein can exist in substantially purified form, or can exist in a non-native environment such as a host cell for example.

[0063] As used herein, the term "antibody" refers to an immunoglobulin, whether natural or partly or wholly synthetically produced. The term also covers any polypeptide, protein or peptide having a binding domain that is, or is homologous to, an antibody binding domain. These may be isolated from natural sources, or may be partly or wholly synthetically produced. Examples of antibodies are intact immunoglobulin molecules, as well as fragments thereof, such as Fab, F(ab')2, Fv fragments, and single chain variable fragments (scFv), which are capable of binding an epitopic determinant. Antibody fragments refer to antigen-binding immunoglobulin peptides that are at least about 5 to about 15 amino acids or more in length, and that retain some biological activity or immunological activity of an immunoglobulin. Antibody as used herein includes polyclonal and monoclonal antibodies, hybrid, single chain, and humanized antibodies, as well as Fab fragments, including the products of a Fab or other immunoglobulin expression library, and suitable derivatives.

[0064] As used herein, an antibody "specifically binds", referring to an antibody binding to an apolipoprotein of choice, means that the antibody binds the apolipoprotein of choice, or subunit thereof, but does not bind to a biological molecule that is not the apolipoprotein of choice. Antibodies that specifically bind to an apolipoprotein of choice, or subunit thereof, do not substantially cross-react with biological molecules outside the apolipoprotein of choice.

[0065] As used herein, the term "monoclonal antibody" includes antibodies that display a single binding specificity and affinity for a particular epitope. These antibodies are mammalian-derived antibodies, including murine, human and humanized antibodies. As used herein, an "antibody heavy chain" refers to the larger of the two types of polypeptide chains present in all antibody molecules in their naturally occurring conformations. As used herein, an "antibody light chain" refers to the smaller of the two types of polypeptide chains present in all antibody molecules in their naturally occurring conformations.

[0066] As used herein, the term "anti-apolipoprotein-binding non-antibody molecule" should be construed to include organic molecules or peptides that are not antibodies and that bind to one or more of the apolipoproteins that are contemplated in the invention.

[0067] "Biologically active," as used herein with respect to anti-apolipoprotein antibodies, fragments, derivatives, homologs or analogs, or anti-apolipoprotein-binding non-antibody molecules, means that the antibodies, fragments, derivatives, homologs or analogs, or anti-apolipoprotein-binding non-antibody molecules, have the ability to bind an apolipoprotein as described herein (e.g. anti-apo B antibody, as a non-limiting example). The term "inhibit," as used herein, means to suppress or block an activity or function by at least about 10% relative to a control value. Preferably, the activity is suppressed or blocked by 50% compared to a control value, more preferably by 75%, and even more preferably by 95%.

[0068] "Derivative" includes any purposefully generated peptide that in its entirety, or in part, comprises an amino acid sequence substantially similar to a variable domain amino acid sequence of an antibody that binds one of the apolipoproteins contemplated in the invention. Derivatives of the antibodies of the present invention may be characterized by single or multiple amino acid substitutions, deletions, additions, or replacements. These derivatives may include: (a) derivatives in which one or more amino acid residues are substituted with conservative or non-conservative amino acids; (b) derivatives in which one or more amino acids are added; (c) derivatives in which one or more of the amino acids of the amino acid sequence used in the practice of the invention includes a substituent group; (d) derivatives in which amino acid sequences used in the practice of the invention or a portion thereof is fused to another peptide (e.g., serum albumin or protein transduction domain); (e) derivatives in which one or more nonstandard amino acid residues (e.g., those other than the 20 standard L-amino acids found in naturally occurring proteins) are incorporated or substituted into the amino acid sequences used in the practice of the invention; (f) derivatives in which one or more non-amino acid linking groups are incorporated into or replace a portion of the amino acids used in the practice of the invention; and (g) derivatives in which one or more amino acid is modified by glycosylation.

[0069] As used herein, the terms "subject", "individual" or "patient" refer to the mammal, preferably human, whose biological fluid may be analyzed using the methods of the invention. As used herein, the term "biological fluid" includes any liquid material that is inside the body or organs of a subject. Biological fluids may be excreted or secreted from the body, or may be removed from the body. Biological fluids include, but are not limited to, amniotic fluid, blood, blood plasma, cerebrospinal fluid, interstitial fluid, lymph, breast milk, mucus (including nasal drainage and phlegm), pleural fluid, pus, sebum (skin oil), blood serum, and genital secretions.

[0070] As used herein, the term "applicator" refers to any device including, but not limited to, a hypodermic syringe, a pipette, an automatic sample probe and the like, for administering the compounds and compositions of the invention.

[0071] As used herein, the term "instructional material" includes a publication, a recording, a diagram, a product insert or any other medium of expression that may be used to communicate the usefulness of the composition and/or compound of the invention in the kit with respect to the methods of the invention. Optionally, or alternately, the instructional material may describe one or more methods related to the present invention, including as disclosed elsewhere herein.

[0072] The instructional material of the kit may, for example, be affixed to a container that contains the compound and/or composition of the invention or be shipped together with a container that contains the compound and/or composition. Alternatively, the instructional material may be shipped separately from the container with the intention that the recipient uses the instructional material and the compound cooperatively. Alternately, the instructional material may be obtained on the Internet in a format suitable for electronic file transmission to the user. For example, the instructional material is for use of a kit; instructions for use of the compound; or instructions for use of a formulation of the compound.

Methods

[0073] The invention includes a method of measuring the concentration of an apolipoprotein associated with a lipoprotein in a biological fluid of a subject without the need to physically separate the given lipoprotein from other lipoproteins before performing the analysis.

[0074] In one embodiment of the invention, the apolipoprotein is apo B and the lipoprotein is LDL.

[0075] In another embodiment, the biological fluid is treated with a chemical reagent that "blocks" the apo B apolipoprotein associated with non-LDL particles (non-LDL-apo B) from binding to anti-apo B antibodies. Adding anti-apo B antibody to the treated sample leads to binding of the antibody only to the apo B protein associated with LDL particles (LDL-apo B). The invention includes a method of using this system to quantitate the LDL-apo B concentration in the biological fluid. The LDL-apo B concentration may then be used to calculate the LDL particle concentration in the biological fluid, using methods described herein.

[0076] In yet another embodiment, the biological fluid is treated with a chemical reagent that "blocks" the apo B protein associated with LDL particles (LDL-apo B) from binding to anti-apo B antibodies. Adding anti-apo B antibody to the treated sample leads to binding of the antibody only to the apo B protein associated with non-LDL particles (non-LDL-apo B). The invention includes a method of using this system to quantitate the non-LDL-apo B concentration in the biological fluid, which may be subtracted from the total apo B concentration to provide the LDL-apo B concentration in the biological fluid. The LDL-apo B concentration may then be used to calculate the LDL particle concentration in the biological fluid, using methods described herein.

[0077] In another embodiment of the invention, the lipoprotein is HDL, and the apolipoprotein is selected from the group consisting of apo A-I, apo A-II, apo A-IV, apo A-V, apo C-I, apo C-II, apo C-III, apo C-IV and apo E. The biological fluid is treated with a chemical reagent that "blocks" the apolipoprotein associated with non-HDL particles (non-HDL-apolipoprotein) from binding to anti-apolipoprotein antibodies. Adding anti-apolipoprotein antibody to the treated sample leads to binding of the antibody only to the apolipoprotein associated with HDL particles (HDL-apolipoprotein). The invention further relates to a method of quantitating the HDL-apolipoprotein concentration in the biological fluid. This information may then be used to estimate the HDL particle concentration in the biological fluid, based on the average number of apolipoprotein per HDL-apolipoprotein particle, using methods described herein.

[0078] The biological fluid under analysis may comprise any biological fluid isolated from a mammal, preferably a human. In one embodiment, the biological fluid is human blood. In another embodiment, the biological fluid is human serum. In yet another embodiment, the biological fluid is human plasma.

[0079] The invention includes a method of measuring the concentration of lipoprotein particles in a biological fluid of a subject, wherein an apolipoprotein is associated with the lipoprotein in the form of lipoprotein-apolipoprotein. In one embodiment, the method comprises mixing the biological fluid with Reagent R1, wherein Reagent R1 comprises a surfactant, to generate Solution S1; Solution S1 is incubated for a first period of time at a first set temperature; Solution S1 is mixed with Reagent R2, wherein Reagent R2 comprises an antibody against the apolipoprotein, to generate Solution S2. Solution S2 is then incubated for a period of time t2 at a set temperature T2, to generate an antibody-bound apolipoprotein. A calibration curve is then generated for quantitating binding of the antibody to the given apolipoprotein with an immunoassay of choice, using at least one standard solution comprising a known concentration of the apolipoprotein. Thus, the antibody-bound apolipoprotein in Solution S2 is quantified in the immunoassay of choice using the calibration curve, and the concentration in Solution S2 of the lipoprotein-apolipoprotein is assessed, and therefore, the concentration of the lipoprotein-apolipoprotein in the biological fluids determined; and therefore the concentration of the lipoprotein particles in the biological fluid of the subject is determined.

[0080] In another embodiment, the method comprises mixing the biological fluid with Reagent R1 to generate Solution S1; Solution S1 is incubated for a period of time t1 at a set temperature T1; Solution S1 is mixed with Reagent R2, wherein Reagent R2 comprises an antibody against the apolipoprotein and a surfactant, to generate Solution S2. Solution S2 is then incubated for a period of time t2 at a set temperature T2, to generate an antibody-bound apolipoprotein. A calibration curve is then generated for quantitating binding of the antibody to the given apolipoprotein with an immunoassay of choice, using at least one standard solution comprising a known concentration of the apolipoprotein. Thus, the antibody-bound apolipoprotein in Solution S2 is quantified in the immunoassay of choice using the calibration curve, and the concentration in Solution S2 of the lipoprotein-apolipoprotein is assessed, and therefore, the concentration of the lipoprotein-apolipoprotein in the biological fluids determined; and therefore the concentration of the lipoprotein particles in the biological fluid of the subject is determined.

[0081] In yet another embodiment, the method comprises mixing the biological fluid with Reagent R2, wherein Reagent R2 comprises an antibody against the apolipoprotein and a surfactant, to generate Solution S2. Solution S2 is then incubated for a period of time t2 at a set temperature T2, to generate an antibody-bound apolipoprotein. A calibration curve is then generated for quantitating binding of the antibody to the given apolipoprotein with an immunoassay of choice, using at least one standard solution comprising a known concentration of the apolipoprotein. Thus, the anti-

body-bound apolipoprotein in Solution S2 is quantified in the immunoassay of choice using the calibration curve, and the concentration in Solution S2 of the lipoprotein-apolipoprotein is assessed, and therefore, the concentration of the lipoprotein-apolipoprotein in the biological fluids determined; and therefore the concentration of the lipoprotein particles in the biological fluid of the subject is determined.

Reagent R1

[0082] The biological fluid to be analyzed may be diluted with a water-based solution, referred to as Reagent R1. The resulting solution is referred to as Solution S1. The desirable degree of dilution of biological fluid with Reagent R1 to generate Solution S1 depends, among other factors, on the concentration of the apolipoprotein of interest in the biological fluid, the components of Reagent R1 and the sensitivity of the method used for detecting antibody binding to the apolipoprotein of interest. A person skilled in the art is able to identify, with a minimal amount of experimentation, an acceptable dilution value for the biological fluid with Reagent R1, so that the binding of apolipoprotein and anti-apolipoprotein antibody may be properly monitored.

[0083] Reagent R1 may be buffered using a buffer system that is known in the art not to interfere with immunoassays in general. In one embodiment, the buffer system used in Reagent R1 has an optimal buffering range of pH about 6.5 to pH about 8.5. In another embodiment, the buffer system used in Reagent R1 has an optimal buffering range of pH about 7.0 to pH about 8.0. In yet another embodiment, the buffer system used in Reagent R1 comprises PBS. In yet another embodiment, the buffer system used in Reagent R1 comprises Tris.

[0084] In one embodiment, Reagent R1 comprises a surfactant. In another embodiment, Reagent R1 comprises a non-ionic surfactant. In yet another embodiment, the concentration of the surfactant in Reagent R1 affords a final concentration of the surfactant in Solution S1 varying from 0.001 to about 10%. In one embodiment, the concentration of the surfactant in Reagent R1 affords a final concentration of the surfactant in Solution S1 varying from about 0.005 to about 1%.

[0085] A surfactant may be ionic or non-ionic in nature. An ionic surfactant is characterized by the presence of a net charge on its head group. If the charge is negative, the surfactant is more specifically called anionic. Anionic surfactants generally have head groups based on sulfate, sulfonate or carboxylate anions. If the charge is positive, the surfactant is called cationic. Cationic surfactants generally have head groups based on quaternary ammonium cations. In the case where a surfactant contains a head with two oppositely charged groups, it is termed zwitterionic or amphoteric.

[0086] Non-limiting examples of anionic surfactants are: perfluorooctanoate (PFOA or PFO); perfluorooctanesulfonate (PFOS); alkyl sulfate salts, such as sodium dodecyl sulfate (SDS) and ammonium lauryl sulfate; sodium lauryl sulfate, also known as sodium lauryl ether sulfate (SLES); alkyl benzene sulfonate; and soaps, or fatty acid salts.

[0087] Non-limiting examples of cationic surfactants are: alkyltrimethyl-ammonium salts, such as cetyl trimethylammonium bromide (CTAB), also known as hexadecyl trimethyl ammonium bromide; cetylpyridinium chloride (CPC); polyethoxylated tallow amine (POEA); benzalkonium chloride (BAC); and benzethonium chloride (BZT).

[0088] Non-limiting examples of zwitterionic or amphoteric surfactants are: dodecyl betaine; cocamidopropyl betaine; and coco ampho glycinate.

[0089] A non-ionic surfactant has no charge groups in its head. Non-limiting examples of non-ionic surfactants contemplated by the invention are POEs (polyoxyethylene polymers), POPs (polyoxypropylene polymers), POE-POP block copolymers, POE-POB block copolymers, Brij® surfactants, Igepal® surfactants, Tween® surfactants and Triton® surfactants.

[0090] Polyoxyethylene (POE), a synthetic polymer manufactured by polymerizing ethylene oxide, is also known as polyethylene glycol (PEG) or polyethylene oxide (PEO), and has the following structure:



$$HO—(CH_2—CH_2—O—)_n—H$$

Polyoxyethylene refers to oligomers and polymers of any molecular mass, and linear POEs are commercially available from 300 g/mole to 10,000,000 g/mole. For a PEG sample, the number cited after the "PEG" term represents the average molecular weight of the molecules in the sample. Non-limiting examples of PEG contemplated by the invention are PEG 200, PEG 300, PEG 400, PEG 550, PEG 600, PEG 1,000, PEG 1,500, PEG 2,000, PEG 3,000, PEG 3,350, PEG 4,000, PEG 4,400, PEG 6,000, PEG 6,200, PEG 8,000, PEG 10,000, PEG 12,000, PEG 20,000, PEG 35,000, PEG 40,000, PEG 55,000, PEG 108,000, PEG 218,000, PEG 246,000, PEG 463,000, and PEG 511,000.

[0091] Polyoxypropylene (POP), a synthetic polymer manufactured by polymerizing propylene oxide, is also known as polypropylene glycol (PPG) or polypropylene oxide (PPO), and has the following structure:



$$HO—(CH_2—CH(CH_3)—O—)_n—H$$

[0092] Polyoxybutylene (POB) is a synthetic polymer manufactured by polymerizing butylene oxide, and may have the following structure:

$$HO—(CH_2—CH(CH_2CH_3)—O—)_n—H$$

[0093] Non-ionic block copolymer surfactants may be made from butylene oxide, propylene oxide and ethylene oxide. The hydrophilic block is typically polyoxyethylene (POE), and the hydrophobic block is selected from polyoxypropylene (POP) and/or polyoxybutylene (POB). A typical POE-POP block copolymer, also known as poloxamer or Pluronic® (BASF, Florham Park, N.J.), has the following general structure (J. Am. Oil Chem. Soc. 1994, 71:777) with a central POP moiety and the two flanking hydrophilic POE groups:



$$HO(CH_2CH_2O)_y(CH_2CH(CH_3)O)_x(CH_2CH_2O)_zH \text{ or}$$

$$HO(POE)_y(POP)_x(POE)_zH.$$

As evident from the general structure, POE-POP surfactants may vary widely in molecular weight and hydrophobicity, depending on the relative amounts of POE and POP. Also, the POE-POP surfactants may be chemically modified on the free hydroxyl groups, by esterification or alkylation, for example. A POP-POB block polymer has a similar structure to that of a POE-POP block polymer, wherein the POP residues are replaced with POB residues.

[0094] The composition of poloxamer or Pluronic® surfactant may be described by abbreviated nomenclature. Poloxamers are commonly named with the letter "P" (for poloxamer) followed by three digits: the first two digits, multiplied by 100, give the approximate molecular mass of the polyoxypropylene core, and the last digit, multiplied by 10, gives the percentage of polyoxyethylene content. For example, P-407 is a poloxamer with a polyoxypropylene molecular mass of 4,000 g/mol and a 70% polyoxyethylene content. For the Pluronic® tradename, the first letter in the code name refers to its physical form at room temperature: L=liquid, P=paste, F=flake (solid), and is followed by two or three digits. The

first digit in a two-digit number or the first two digits in a three-digit number, multiplied by 300, indicates the approximate molecular weight of the hydrophobic block; and the last digit, multiplied by 10, gives the percentage of polyoxyethylene content. For example, L-61 is a Pluronic® surfactant with a polyoxypropylene molecular mass of 1,800 g/mol and a 10% polyoxyethylene content. Based on these conventions, poloxamer 181 (P-181) corresponds to Pluronic® L-61.

[0095] Non-limiting examples of Pluronics contemplated within the invention are: Pluronic® 10R5; Pluronic® 17R2; Pluronic® 17R4; Pluronic® 25R2; Pluronic® 25R4; Pluronic® 31R1; Pluronic® F-108; Pluronic® F-127; Pluronic® F-38; Pluronic® F-68; Pluronic® F-7 ; Pluronic® F-87; Pluronic® F-88; Pluronic® F-98; Pluronic® L-10; Pluronic® L-101; Pluronic® L-121; Pluronic® L-31; Pluronic® L-35; Pluronic® L-43; Pluronic® L-44; Pluronic® L-61; Pluronic® L-62; Pluronic® L-64; Pluronic® L-81; Pluronic® L-92; Pluronic® N-3; Pluronic® P-103; Pluronic® P-104; Pluronic® P-105; Pluronic® P-123; Pluronic® P-65; Pluronic® P-84; and Pluronic® P-85. Table 3 correlates Pluronic® and poloxamer nomenclatures, for a block polymer of formula $HO(C_2H_4O)_A(C_3H_6O)_B(C_2H_4O)_AH$.

TABLE 3

Correspondence of selected Pluronic ® and poloxamer surfactants.

Pluronic ®	Poloxamer	"A" value	"B" value
L-44	P-124	12	20
F-68	P-188	80	27
F-87	P-237	64	37
F-108	P-338	141	44
F-127	P-407	101	56

[0096] Brij® (ICI Americas, Wilmington, Del.) surfactant is a polyoxyethylene (POE) ether. Non-limiting examples of Brij® surfactants are: Brij® 30 (main component is tetraethylene glycol dodecyl ether, M_n~362); Brij® 52 (main component is diethylene glycol hexadecyl ether, M_n~330); Brij® 56 (main component is decaethylene glycol hexadecyl ether, M_n~683); Brij® 700 (M_n~4,670); Brij® 72 (main component is diethylene glycol octadecyl ether); Brij® 78 (main component is eicosaethylene glycol octadecyl ether); Brij® 92V (main component is diethylene glycol oleyl ether); Brij® 93 (M_n~357); Brij® 97 (molecular formula $C_{18}H_{35}$—O—$(CH_2CH_2)_xH$ where x~10, M_n~709); Brij® 98 (M_n~1,150); Brij® 010 (main component is decaethylene glycol oleyl ether); Brij® S10 (main component is decaethylene glycol octadecyl ether, M_n~711); and Brij® 58 (M_n~1124), where M_n is the number average molecular weight, e.g., the total weight of all the polymer molecules in the sample divided by the total number of polymer molecules in the sample.

[0097] Igepal® (Rhodia, Cranbury, N.J.) surfactants are homologous octylphenoxypoly(ethyleneoxy)ethanols, all derived from the same hydrophobic material (octylphenol) and varying lengths of hydrophilic tails (ethylene oxide). Their chemical structure is illustrated by the following formula:



C_8H_{17}-p-phenyl-O—$(CH_2CH_2O)_nH$

wherein "n" denotes the number of moles of ethylene oxide per mole of octylphenol. Changes in the hydrophobic-hydrophilic balance, linked to the value of "n", influence wetting detergency, emulsification, solubility or foam, and some applications may require the mixing of two or more of the products for a specific use. Non-limiting examples of Igepal® surfactants are: CA-210 (n=1.5, with 24% ethylene oxide); CA-420 (n=3, with 40% ethylene oxide); CA-520 (n=5, with 50% ethylene oxide); CA-620 (n=7, with 60% ethylene oxide); CA-630 (n=9, with 65% ethylene oxide); CA-720 (n=12, with 73% ethylene oxide); CA-887 (n=30, with 87% ethylene oxide); CA-890 (n=40, with 90% ethylene oxide); and CA-897 (n-40, with 90% ethylene oxide).

[0098] Tween® surfactants (ICI Americas, Wilmington, Del.) are polysorbates, defined as oily liquids derived from PEG-ylated sorbitan (a derivative of sorbitol) esterified with fatty acids. Surfactants that are esters of plain (non-PEG-ylated) sorbitan with fatty acids are usually referred to by the name Span®. Non-limiting examples of Tween® surfactants are Polysorbate 20 [Tween® 20 or polyoxyethylene (20) sorbitan monolaurate]; Polysorbate 40 [Tween® 40 or polyoxyethylene (20) sorbitan monopalmitate]; Polysorbate 60 [Tween® 60 or polyoxyethylene (20) sorbitan monostearate]; and Polysorbate 80 [Tween® 80 or polyoxyethylene (20) sorbitan monooleate]. The number following the "polysorbate" term is related to the type of fatty acid associated with the polyoxyethylene sorbitan part of the molecule—monolaurate is indicated by 20, monopalmitate is indicated by 40, monostearate by 60 and monooleate by 80. The same numbering is followed in their Span® equivalents (Span® 20, Span® 40, Span® 60 and Span® 80). The number 20 following the "polyoxyethylene" term refers to the total number of oxyethylene —(CH_2CH_2O)— groups found in the molecule.

[0099] As mentioned above, Tween® 20 (Polysorbate 20) is a polyoxyethylene derivative of sorbitan monolaurate, with the molecular formula $C_{58}H_{114}O_{26}$ and the molecular mass of 1,227.5 g/mole.



Tween® 20

w + x + y + z = 20

[0100] Tween® 80 (Polysorbate 80) is a polyoxyethylene derivative of sorbitan monooleate, with molecular formula of $C_{64}H_{124}O_{26}$ and molecular mass of 1,310 g/mole.



Tween® 80

w+x+y+z=20

[0101] Triton® X-100 (Dow Chemical, Midland, Mich.) has the molecular formula $C_{14}H_{22}O(C_2H_4O)_n$ and is a nonionic surfactant with a hydrophilic polyethylene oxide group (n~9.5) and the lipophilic 4-(1,1,3,3-tetramethylbutyl)-phenyl group.

[0102] Reagent R1 may optionally comprise a polyethylene glycol polymer (PEG). PEGs are commercially available over a wide range of molecular weights from 300 g/mol to 10,000,000 g/mol. In one embodiment, the concentration of PEG in Reagent R1 affords a final concentration of PEG in Solution S1 varying from about 0.1% to about 10%. In another embodiment, the concentration of PEG in Reagent R1 affords a final concentration of PEG in Solution S1 varying from about 1% to about 8%.

[0103] Reagent R1 may optionally comprise one or more components selected from the group consisting of PEG, dextran sulfate, α-cyclodextrin sulfate, EDTA, an azide salt and a divalent cation. In one embodiment, the concentration of dextran sulfate in Reagent R1 affords a final concentration of dextran sulfate in Solution S1 varying from about 0.1 g/L to about 3.0 g/L. In another embodiment, the concentration of α-cyclodextrin sulfate in Reagent R1 affords a final concentration of α-cyclodextrin sulfate in Solution S1 varying from about 0.1 g/L to about 3.0 g/L. In yet another embodiment, the concentration of the azide salt in Reagent R1 affords a final concentration of azide in Solution S1 varying from about 0.01% to about 0.1%. In yet another embodiment, the azide salt is sodium azide. In yet another embodiment, the concentration of EDTA in Reagent R1 affords a final concentration of EDTA in Solution S1 varying from about 1 mM to about 50 mM. In yet another embodiment, the concentration of the divalent cation in Reagent R1 affords a final concentration of divalent cation in Solution S1 varying from about 1 mM to about 20 mM. In yet another embodiment, the divalent cation is magnesium. In yet another embodiment, the divalent cation salt is magnesium chloride.

Solution S1

[0104] Upon mixing of Reagent R1 with the biological sample, the resulting Solution S1 may be incubated at a preset temperature T1 for a defined period of time t1 in order to allow equilibration between the various components of Solution S1. During this period of time, the surfactant molecules interact with the lipoproteins present, reaching equilibrium between unbound surfactant and lipoprotein-bound surfactant. One skilled in the art may easily determine the optimal time and temperature for this incubation by running parallel experiments with varying time and temperature values and determining which combinations of incubation temperature and incubation time provide a reproducible reading for the subsequent antibody binding measurement. One skilled in the art will also easily recognize that the optimal time and temperature for this incubation are dependent on the lipoprotein and surfactant used, as well as on the nature of the remaining components contained in Solution S1. In one embodiment of the invention, the incubation time t1 is about 5 minutes. In another embodiment, the incubation temperature T1 is about 37° C.

Reagent R2

[0105] Solution S1 may then be contacted with Reagent R2, to generate Solution S2. Reagent R2 comprises an anti-apolipoprotein antibody. In one embodiment, the anti-apolipoprotein antibody is anti-apo B antibody. In another embodiment, the anti-apolipoprotein antibody is anti-apo A-I antibody. In yet another embodiment, the anti-apolipoprotein antibody is anti-apo A-II antibody. In yet another embodiment, the anti-apolipoprotein antibody is anti-apo A-IV antibody. In yet another embodiment, the anti-apolipoprotein antibody is anti-apo A-V antibody. In yet another embodiment, the anti-apolipoprotein antibody is anti-apo C-I antibody. In another embodiment, the anti-apolipoprotein antibody is anti-apo C-II antibody. In yet another embodiment, the anti-apolipoprotein antibody is anti-apo C-III antibody, In yet another embodiment, the anti-apolipoprotein antibody is anti-apo C-IV antibody. In yet another embodiment, the anti-apolipoprotein antibody is anti-apo E antibody.

[0106] Using conventional techniques, the skilled artisan may use the nucleotide and amino acid sequences of the apolipoprotein to prepare an antigenic peptide for use in generating corresponding anti-apolipoprotein antibody. The human apo B cDNA sequence (SEQ ID NO:1) is disclosed in Higuchi et al., 1988, Proc. Natl. Acad. Sci. USA 85 (6):1772-

1776. Likewise, the cDNA sequences for human apo A-I (SEQ ID NO:2), apo A-II (SEQ ID NO:3), apo A-IV (SEQ ID NO:4), apo A-V (SEQ ID NO:5), apo C-I (SEQ ID NO:6), apo C-II (SEQ ID NO:7), apo C-III (SEQ ID NO:8), apo C-IV (SEQ ID NO:9) and apo E (SEQ ID NO:10) are known in the art.

[0107] Alternatively, the skilled artisan may utilize a commercially available antibody against the apolipoprotein (such as apo B). Anti-apo B and other anti-apolipoprotein antibodies are available from Midland Bioproducts (Boone, Iowa), US Biological (Swampscott, Mass.), Santa Cruz Biotechnology (Santa Cruz, Calif.), Millipore (Billerica, Mass.), R&D Systems (Minneapolis, Minn.) and Rockland Immunochemicals (Gilbertsville, Pa.), among others. The skilled artisan may also obtain commercially available anti-apolipoprotein antibodies and modify them using conventional methods such as coupling to other antibodies, partial digestion, pegylation or covalent modification. Modified antibodies may then be used in the methods of the invention as described herein. Antibodies useful in the practice of the present invention may be polyclonal, monoclonal, synthetic or fragments of any of the above.

[0108] It will be appreciated that the anti-apolipoprotein antibody used in the invention may be monovalent, divalent or polyvalent in order to achieve apolipoprotein binding. Monovalent immunoglobulins are dimers (HL) formed of a hybrid heavy chain associated through disulfide bridges with a hybrid light chain. Divalent immunoglobulins are tetramers (H2L2) formed of two dimers associated through at least one disulfide bridge.

[0109] The invention also includes functional equivalents of the antibodies described herein. Functional equivalents have binding characteristics comparable to those of the antibodies, and include, for example, hybrid and single chain antibodies, as well as fragments thereof. Methods of producing such functional equivalents are disclosed in PCT Application Nos. WO 1993/21319 and WO 1989/09622. Functional equivalents include polypeptides with amino acid sequences substantially the same as the amino acid sequence of the variable or hypervariable regions of the antibodies raised against apolipoproteins, according to the practice of the present invention.

[0110] Functional equivalents of the anti-apolipoprotein antibodies further include fragments of antibodies that have the same, or substantially the same, binding characteristics to those of the whole antibody. Such fragments may contain one or both Fab fragments or the F(ab')2 fragment. Preferably the antibody fragments contain all six complement determining regions of the whole antibody, although fragments containing fewer than all of such regions, such as three, four or five complement determining regions, are also functional. The functional equivalents are members of the IgG immunoglobulin class and subclasses thereof, but may be or may combine any one of the following immunoglobulin classes: IgM, IgA, IgD, or IgE, and subclasses thereof. Heavy chains of various subclasses, such as the IgG subclasses, are responsible for different effector functions and thus, by choosing the desired heavy chain constant region, hybrid antibodies with desired effector function are produced. Preferred constant regions are gamma 1 (IgG1), gamma 2 (IgG2 and IgG), gamma 3 (IgG3) and gamma 4 (IgG4). The light chain constant region can be of the kappa or lambda type.

[0111] The monoclonal antibodies may be advantageously cleaved by proteolytic enzymes to generate fragments retaining the apolipoprotein binding site. For example, proteolytic treatment of IgG antibodies with papain at neutral pH generates two identical so-called "Fab" fragments, each containing one intact light chain disulfide-bonded to a fragment of the heavy chain (Fc). Each Fab fragment contains one antigen-combining site. The remaining portion of the IgG molecule is a dimer known as "Fc". Similarly, pepsin cleavage at pH 4 results in the so-called F(ab')2 fragment.

[0112] Single chain antibodies or Fv fragments are polypeptides that consist of the variable region of the heavy chain of the antibody linked to the variable region of the light chain, with or without an interconnecting linker. Thus, the Fv comprises an antibody combining site.

[0113] Hybrid antibodies may be employed. Hybrid antibodies have constant regions derived substantially or exclusively from human antibody constant regions and variable regions derived substantially or exclusively from the sequence of the variable region of a monoclonal antibody from each stable hybridoma.

[0114] Methods for preparation of fragments of antibodies are known to those skilled in the art. See, Goding, "Monoclonal Antibodies Principles and Practice", Academic Press (1983), p. 119-123. Fragments of the monoclonal antibodies containing the antigen binding site, such as Fab and $F(ab')_2$ fragments, may be preferred in therapeutic applications, owing to their reduced immunogenicity. Such fragments are less immunogenic than the intact antibody, which contains the immunogenic Fc portion. Hence, as used herein, the term "antibody" includes intact antibody molecules and fragments thereof that retain antigen binding ability.

[0115] When the antibody used in the practice of the invention is a polyclonal antibody (IgG), the antibody is generated by inoculating a suitable animal with the apolipoprotein or a fragment thereof. Antibodies produced in the inoculated animal that specifically bind the apolipoprotein are then isolated from fluid obtained from the animal. Anti-apolipoprotein antibodies may be generated in this manner in several non-human mammals such as, but not limited to, goat, sheep, horse, rabbit, and donkey. Methods for generating polyclonal antibodies are well known in the art and are described, for example in Harlow et al. (In: Antibodies, A Laboratory Manual, 1988, Cold Spring Harbor, N.Y.). These methods are not repeated herein as they are commonly used in the art of antibody technology.

[0116] When the antibody used in the methods used in the practice of the invention is a monoclonal antibody, the antibody is generated using any well known monoclonal antibody preparation procedures such as those described, for example, in Harlow et al. (In: Antibodies, A Laboratory Manual, 1988, Cold Spring Harbor, N.Y.) and Tuszynski et al. (Blood 1988, 72: 109-115). Given that these methods are well known in the art, they are not replicated herein. Generally, monoclonal antibodies directed against a desired antigen are generated from mice immunized with the antigen using standard procedures as referenced herein. Monoclonal antibodies directed against full length or fragments of target structure may be prepared using the techniques described in Harlow et al. (In: Antibodies, A Laboratory Manual, 1988, Cold Spring Harbor, N.Y.).

[0117] The skilled artisan would further appreciate, based upon the disclosure provided herein, that the invention is not limited to the use of an antibody as the binding element for the apolipoprotein of interest. The invention also allows for the use of an anti-apolipoprotein-binding non-antibody molecule

as the element that binds to one or more of the apolipoproteins that are contemplated in the invention. The anti-apolipoprotein-binding non-antibody molecule may bind to the apolipoprotein or a fragment of the apolipoprotein. Preferred anti-apolipoprotein-binding non-antibody molecules within the invention are aptamers. Aptamers are oligonucleic acid (also referred to as nucleic acid) molecules or peptide molecules that bind a specific target molecule. Nucleic acid aptamers are nucleic acid species that have been engineered through repeated rounds of in vitro selection or equivalently, SELEX (systematic evolution of ligands by exponential enrichment), to bind to various molecular targets such as small molecules, proteins, nucleic acids, and even cells, tissues and organisms. Aptamers are useful in biotechnological and therapeutic applications as they offer molecular recognition properties that rival that of the commonly used antibodies. In addition to their discriminate recognition, aptamers offer advantages over antibodies as they can be engineered completely in a test tube, are readily produced by chemical synthesis, possess desirable storage properties, and elicit little or no immunogenicity in therapeutic applications. See Ellington, A. D. & Szostak, J. W., 1990, "In vitro selection of RNA molecules that bind specific ligands", Nature 346 (6287): 818-22; Bock et al., 1992, "Selection of single-stranded DNA molecules that bind and inhibit human thrombin", Nature 355 (6360): 564-6; Drabovich et al., 2006, "Selection of smart aptamers by methods of kinetic capillary electrophoresis", Anal Chem. 78 (9): 3171-8, all of which are incorporated herein by reference in their entireties. Aptamers useful within the invention may be selected and/or prepared according to the teachings of the art.

[0118] Reagent R2 may optionally further comprises a surfactant. In the case where Reagent R1 does not comprise a surfactant, Reagent R2 comprises a surfactant. In the case where the method does not use Reagent R1, Reagent R2 comprises a surfactant. In one embodiment, Reagent R2 comprises a non-ionic surfactant. In another embodiment, the concentration of the surfactant in Reagent R2 affords a final concentration of the surfactant in Solution S2 varying from 0.001 to about 10%. In yet another embodiment, the concentration of the surfactant in Reagent R2 affords a final concentration of the surfactant in Solution S2 varying from about 0.005 to about 1%. In yet another embodiment, the surfactant is selected from the group consisting of POEs (polyoxyethylene) polymer, POPs (polyoxypropylene) polymer, POE-POP block copolymer, PEG polymer, POE-POB block copolymer, Brij® surfactant, Igepal® surfactant, Tween® surfactant and Triton® surfactant.

[0119] Reagent R2 may optionally further comprise one or more components selected from the group consisting of a PEG polymer ("PEG"), dextran sulfate, α-cyclodextrin sulfate, EDTA, an azide salt and a divalent cation salt. The PEG may comprise any commercially available polyethylene glycol polymer ranging in molecular weight from 200 to 520,000. In one embodiment, the concentration of PEG in Reagent R2 varies from about 0.1% to about 10%. In another embodiment, the concentration of dextran sulfate in Reagent R2 varies from about 0.1 g/L to about 3.0 g/L. In another embodiment, the concentration of α-cyclodextrin sulfate in Reagent R2 varies from about 0.1 g/L to about 3.0 g/L. In yet another embodiment, the concentration of the azide salt in Reagent R2 varies from about 0.01% to about 0.1%. In yet another embodiment, the azide salt is sodium azide. In yet another embodiment, the concentration of EDTA in Reagent R2 varies from about 1 mM to about 50 mM. In yet another embodiment, the concentration of the divalent cation in Reagent R2 varies from about 1 mM to about 20 mM. In yet another embodiment, the divalent cation is magnesium. In yet another embodiment, the divalent cation salt is magnesium chloride.

Solution S2

[0120] Solution S2 may be incubated for a defined period of time t2 and at a defined temperature T2 before the interaction of the anti-apolipoprotein antibody with the apolipoprotein is measured. The incubation time should be selected to allow approximate equilibration of the antibody within the solution, without causing unwanted sample degradation. One skilled in the art may easily determine the optimal time and temperature for this incubation by running parallel experiments with varying time and temperature values, and determining which combinations of incubation temperature and incubation time will provide a reproducible reading for the antibody binding measurement. One skilled in the art may also easily recognize that the optimal time and temperature for this incubation are dependent on the lipoprotein and anti-apolipoprotein antibody used, as well as on the nature of the remaining components contained in the second analysis solution. In one embodiment of the invention, Solution 2 is incubated for about 3 minutes. In another embodiment of the invention, Solution 2 is incubated at about 37° C.

Analysis and Quantitation

[0121] Solution S2 may then be analyzed for binding of the anti-apolipoprotein antibody with the apolipoprotein contained therein. Any appropriate immunoassay to measure such an interaction is useful in the invention. Immunoassays are based on specific binding of an antibody to its antigen (in this particular case, the apolipoprotein of interest that is available to interact with the antibody). Detecting the interaction of the antibody with the antigen may be achieved using a variety of methods, of which one of the most common is to label either the antigen or antibody, and monitor the change in environment of the label upon binding. The label may comprise an enzyme (wherein binding is monitored by enzyme immunoassay or EIA), colloidal gold (wherein binding is monitored by lateral flow assays), radioisotopes such as ^{125}I radioimmunoassay (wherein binding is monitored by radiometric methods), magnetic labels (wherein binding is monitored by magnetic immunoassay or MIA) or fluorescence. Other techniques include, but are not limited to, agglutination, nephelometry, turbidimetry and Western Blot. All of these methods are known to those of skill in the art. See e.g. Harlow et al., 1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; Harlow et al., 1999, "Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press", Cold Spring Harbor, N.Y.

[0122] Immunoassays may be divided into those that involve non-labelled reagents and those that involve labelled reagents. Immunoassays that involve labelled reagents are divided into homogenous immunoassays and heterogeneous immunoassays (the latter require an extra step to remove unbound antibody or antigen from the site, usually using a solid phase reagent).

[0123] Heterogeneous immunoassays may be competitive or non-competitive. In a competitive immunoassay, the anti-

gen in the unknown sample competes with labeled antigen to bind with antibodies. The amount of labeled antigen bound to the antibody site is then measured. In this method, the response will be inversely proportional to the concentration of antigen in the unknown, since a large response indicates that there is little antigen in the unknown to compete with the labeled antigen. In noncompetitive immunoassays, also referred to as the "sandwich assay," antigen in the unknown is bound to the antibody site, then labeled antibody is bound to the antigen. The amount of labeled antibody on the site is then measured. Unlike the competitive method, the results of the noncompetitive method are directly proportional to the concentration of the antigen, since the labeled antibody will not bind if the antigen is not present in the unknown sample.

[0124] In certain embodiments, the immunoassay is selected from the group consisting of immunoturbidimetry, immunonephelometry, an ELISA assay, radioimmunoassay, chemiluminescence immunoassay, immunofluorescence, immunoprecipitation, immunoelectrophoresis, and flow cytometry-based immunoassay.

[0125] One skilled in the art will recognize that optimization studies may be easily performed to determine which chemical reagents should be present in Reagent R1 and/or Reagent R2 to allow for selective binding of the anti-apolipoprotein antibody to the apolipoprotein associated with the lipoprotein of choice over the apolipoprotein associated with other lipoproteins. The optimization studies may involve at least two lipid sources. The first lipid source comprises the apolipoprotein associated with the lipoprotein of choice, and the second source comprises the apolipoprotein associated to a lipoprotein that is not the lipoprotein of choice. The two lipid sources are incubated with Reagents R1 and R2 of differing compositions, as previously described, wherein each composition of Reagent R1 or Reagent R2 comprises varying concentrations of chemical reagents that may modulate the ability of the apolipoprotein of interest to bind to the corresponding anti-apolipoprotein antibody. Non-limiting examples of such chemical reagents are surfactants, non-ionic surfactants, divalent cation salts, dextran salts, PEG, α-cyclodextrin salts, EDTA, and azide salts. Following incubations, an immunoassay is used to determine the degree of antibody binding for each sample, and this information is used to determine the compositions for Reagent R1 and Reagent R2 that favor the binding of the antibody to the apolipoprotein associated with the lipoprotein of choice over the apolipoprotein associated with other lipoproteins. This evaluation follows standard methodologies used in analytical sciences and should not require unwarranted experimentation from those skilled in the art.

[0126] In a non-limiting example, wherein the apolipoprotein of interest is apo B and the given lipoprotein is LDL, the optimization studies are performed to identify compositions of Reagent R1 and/or Reagent R2 that "block" the apo B protein associated with non-LDL particles (non-LDL-apo B) from binding to anti-apo B antibodies. In this example, adding anti-apo B antibody to the treated sample leads to binding of the antibody only to the apo B protein associated with LDL particles (LDL-apo B). Therefore, the concentration of apo B determined in the assay corresponds to the concentration of LDL-apo B.

[0127] In another non-limiting example, wherein the apolipoprotein of interest is apo B and the given lipoprotein is LDL, the optimization studies are performed to identify compositions of Reagent R1 and/or Reagent R2 that "block" the apo B protein associated with LDL particles (LDL-apo B) from binding to anti-apo B antibodies. In this example, adding anti-apo B antibody to the treated sample leads to binding of the antibody only to the apo B protein associated with non-LDL particles (non-LDL-apo B). Therefore, the concentration of apo B determined in the assay corresponds to the non-LDL-apo B concentration, and the LDL-apo B concentration may be derived from the subtraction of the non-LDL-apo B concentration from the total apo B concentration (which may determined by an assay where the apo B from all lipoprotein particles is free to interact with the anti-apo B antibody, or any other published or known method to determine the total apo B concentration in a sample).

[0128] In yet another non-limiting example, wherein lipoprotein is HDL and the apolipoprotein of interest is selected from the group consisting of apo A-I, apo A-II, apo A-IV, apo A-V, apo C-I, apo C-II, apo C-III, apo C-IV and apo E, the optimization studies are performed to identify compositions of Reagent R1 and/or Reagent R2 that "block" the apolipoprotein of interest associated with non-HDL particles (non-HDL-apo B) from binding to anti-apolipoprotein antibodies. In this example, adding anti-apolipoprotein antibody to the treated sample leads to binding of the antibody only to the apolipoprotein associated with HDL particles. Therefore, the concentration of apolipoprotein of interest determined in the assay corresponds to the HDL-apolipoprotein concentration.

[0129] The immunoassay used to detect the interaction of the antibody with the apolipoprotein of interest may also be used to quantitate the concentration of the apolipoprotein in the sample. In a typical procedure included in the invention, a series of standard solutions containing known concentrations of the apolipoprotein of interest are prepared and analyzed by an immunoassay. The readings obtained for each standard solution are used to create a calibration curve. The unknown sample is then analyzed by the same immunoassay and its reading is compared to the standard curve in order to obtain a corresponding concentration of the apolipoprotein of interest in the sample. This concentration may be used to calculate the actual concentration of the apolipoprotein of interest in the biological fluid, taking into account the diluitions that the biological sample was subjected to for the preparation of Solution S2.

[0130] Use of the calibration curve, as described above, allows the concentration of the apolipoprotein to be determined in the same units used to express the concentration of the standard solutions. In some instances, the standard solutions have their component concentrations identified in mass/volume units (such as mg/dL units, for example). The concentration of the apolipoprotein of interest in the biological sample, determined as mg/dL from the calibration curve, may be converted to a concentration of moles/volume (such as nmol/L) based on the molecular weight of the apolipoprotein of interest. In the case where the apolipoprotein of interest is apo B, the molecular weight used for calculations is about 512,000 Daltons.

[0131] The concentration of apolipoprotein determined in the sample may be used to calculate the concentration of corresponding lipoprotein, depending on how many apolipoprotein molecules on average are contained in the lipoprotein. When the apolipoprotein of interest is apo B and the lipoprotein is LDL, there is one molecule of apo B per LDL molecule, and therefore the concentration of LDL-apo B (in molar-related units, such as nmole/L) is identical to that of LDL (in molar-related units, such as nmole/L). When there is

an average of "N" apolipoprotein molecules of interest per lipoprotein, the concentration of lipoprotein (in molar-related units, such as nmole/L) is 1/N of the value of the concentration of apolipoprotein (in molar-related units, such as nmole/L).

[0132] As evident to those skilled in the art, the present invention encompasses variations that are included within the scope. As a non-limiting example, VLDL and HDL lipoprotein particles share a number of apolipoproteins, including apolipoprotein A-I (apo A-I), apolipoprotein A-II (apo A-II), apolipoprotein A-IV (apo A-IV), apolipoprotein A-V (apo A-V), apolipoprotein C-I (apo C-I), apolipoprotein C-II (apo C-II), apolipoprotein C-III (apo C-III), apolipoprotein C-IV (apo C-IV), and apolipoprotein E (apo E). The compositions of Reagent R1 and/or Reagent R2 that "block" VLDL-apo B from binding to anti-apo B antibodies may also "block" other VLDL-apolipoproteins (wherein the apolipoprotein is selected from the group consisting of apo A-I, apo A-II, apo A-IV, apo A-V, apo C-I, apo C-II, apo C-III, apo C-IV and apo E) from binding to the corresponding anti-apolipoprotein antibodies. In this case, such compositions of Reagent R1 and/or Reagent R2 may be used to promote selective binding of such anti-apolipoprotein antibodies to HDL-apolipoprotein, and this may facilitate determination of HDL-specific apolipoprotein concentrations directly.

[0133] The skilled artisan would appreciate, based on the present disclosure, that a composition of the invention may be modified based on the needs of a particular application. By way of a non-limiting example, a particular surfactant may be excluded from a particular analyte solution if the surfactant has the potential to interfere with the assay or with one or more other components of the analyte solution. Similarly, the skilled artisan will know, based on the present disclosure, that a method of the invention may be modified based on the needs of a particular application. By way of a non-limiting example, the immunoassay may utilize an endpoint reaction, wherein the concentration of apolipoprotein-antibody complex is measured at equilibrium. By the way of another non-limiting example, the immunoassay may measure the rate of formation of the apolipoprotein-antibody complex over a period of time or at one or more time points.

[0134] The skilled artisan would further appreciate, based upon the disclosures provided herein, that the invention is not limited to any particular instrument, but rather the invention encompasses a wide plethora of instruments as are known in the art or to be developed in the future. That is, such instruments for assessing the presence and/or level of a known constituent of interest in a sample include, but are not limited to, multi-channel chemistry analyzers and nephelometers such as, for instance, the Hitachi, Integra and Cobas analyzers from Roche Diagnostics (Indianapolis, Ind.), the Synchron, UniCel and AU systems from Beckman Coulter (Fullerton, Calif.), the Dimension, BN, IMS and Advia systems from Siemens Healthcare Diagnostics (Deerfield, Ind.), the Aeroset and Architect systems from Abbott Diagnostics (Abbott Park, Ill.), the Vitros system from Ortho Clinical Diagnostics (Rochester, N.Y.), and the Polychem from Polymedco (Cortlandt Manor, N.Y.). Thus, the skilled artisan would understand, based upon the disclosure provided herein, that the invention is not limited in any way to any particular instrument, either known or to be developed. Such instruments, including serum analyzers, hand-held devices, single test devices, and the like, are well-known in the art and are not discussed further herein.

[0135] As will be understood by one of skill in the art, when armed with the disclosure set forth herein, a set of reference apolipoproteins or equivalents (also referred to as "calibration samples") may be used to create a calibration curve for a certain method and/or instrument. By way of a non-limiting example, the set of reference apolipoproteins or equivalents may be used in a two-point calibration assay. In another embodiment of the invention, the set of reference apolipoproteins or equivalents may be used in a five- or six point calibration assay. In one aspect, the set of reference apolipoproteins or equivalents may include as many or as few reference points as determined to be necessary to establish a valid and accurate reference curve.

[0136] Numerous calibration schemes may be used in the clinical laboratory. Older methods, often manually performed, employ several concentration levels throughout the assay range and typically plot the instrumental response versus concentration or use linear regression to calculate patient analyte values. These methods may still be used. However, with the increasing use and availability of computer technology, methods now often use one or two calibrator points to achieve the same results. Quite often, the one or two set point method incorporates a saline or distilled water blank as an additional set point, this latter function being dictated by the instrument or reagent manufacturer. For non-linear chemistries, the traditional approach provides five or six levels of calibrator, usually set in a non-linear fashion dictated by the mathematical model used in the final calculation of patient result. A more recent trend for non-linear chemistries is to use one calibrator containing the highest concentration of analyte measured in the assay. Using this method, the analytical system is then directed to perform the necessary dilutions of this high concentration value to generate the predetermined calibration set points on the fly when the system calibrates the analyte. A four- or five-parameter logit/log calibration curve is typically used for automated immunoassays.

[0137] Therefore, in an aspect of the present invention, there is provided a method that features the use of multiple calibrator points in order to generate a reference curve. In one embodiment, the method features the use of more than one point. In another embodiment, one of the multiple points is a zero point. In yet another embodiment, the zero point is not included as one of the multiple points, but may be included separately in a reference curve. In another embodiment, the method features the use of a single calibration point, as described in detail elsewhere herein. In yet another embodiment, the method features the use of a zero point in addition to a single calibration point.

[0138] By way of a series of non-limiting examples, the method of the invention may use a reference curve based on a single concentration for calibration, a reference curve based on a single concentration plus a zero concentration point for calibration, a reference curve based on at least two concentrations for calibration, or a reference curve based on at least two concentrations plus a zero concentration point for calibration. In yet another embodiment of the invention, the concentration of at least one calibration sample in a mixture containing at least two calibration samples is known.

Kits

[0139] The invention includes various kits that comprise a set of apolipoprotein standards or equivalent ("calibration samples"), an applicator, and instructional materials that describe use of the kit to perform the methods of the inven-

tion. Although exemplary kits are described below, the contents of other useful kits will be apparent to the skilled artisan in light of the present disclosure. Each of these kits is included within the invention.

[0140] In one embodiment, the invention includes a kit for measuring the LDL-apo B concentration in a biological sample of a subject. The kit comprises reagents that allow for the determination of LDL-apo B in the presence of non-LDL-apo B. The kit further comprises an applicator and instructional material for the use of the kit.

[0141] In another embodiment, the invention includes a kit for measuring the non-LDL-apo B concentration in a biological sample of a subject. The kit comprises reagents that allow for the determination of non-LDL-apo B in the presence of LDL-apo B. The kit further comprises an applicator and instructional material for the use of the kit.

[0142] In yet another embodiment, the invention includes a kit for measuring the concentration of a specific apolipoprotein bound to HDL in a biological sample of a subject. The kit comprises reagents that allow for the determination of HDL-apolipoprotein in the presence of non-HDL-apolipoprotein. The kit further comprises an applicator and instructional material for the use of the kit.

[0143] The kit is used pursuant to the methods disclosed in the invention. In one embodiment, the kit may be used to determine the concentration of LDL-apo B in a biological sample. This is because, as more fully disclosed elsewhere herein, the data disclosed herein demonstrates that the reagents of the invention "block" binding of anti-apo B antibody to non-LDL-apo B. This allows for the direct detection and quantitation of LDL-apo B in the sample by the methods described herein.

[0144] The kit further comprises an applicator useful for administering the reagents for use in the relevant assay. The particular applicator included in the kit will depend on, e.g., the method used to assay a lipid, as well as the particular analyzer equipment used, and such applicators are well-known in the art and may include, among other things, a pipette, a syringe, a dropper bottle, and the like. Moreover, the kit comprises an instructional material for the use of the kit.

[0145] The kit includes a kit comprising Reagent R1 and/or Reagent R2 and/or various reagents used to prepare Reagent **1** and/or Reagent **2** as disclosed elsewhere herein, including, but not limited to, one or more surfactants, and one or more biological buffers. The composition is provided in an appropriate amount as set forth elsewhere herein.

[0146] Further, the kit includes a kit comprising at least one reference composition comprising a known value of a known constituent, which may be an apolipoprotein, lipoprotein, a derivative thereof or a fragment thereof Such kits may be used to create a calibration curve for quantitation of the apolipoprotein or lipoprotein. Thus, the invention encompasses a kit comprising at least one reference composition. While the invention is not limited to any particular set, certain combinations of reference compositions are exemplified elsewhere herein.

[0147] Further, the kit optionally comprises a lipoprotein, apolipoprotein or equivalent, including, but not limited to, total cholesterol, VLDL, LDL, HDL, apo A, apo B, Lp(a) and the like, and any combination thereof, as would be appreciated by one skilled in the art based upon the disclosure provided herein.

Examples

[0148] The invention is now described with reference to the following Examples. These Examples are provided for the purpose of illustration only, and the invention is not limited to these Examples, but rather encompasses all variations that are evident as a result of the teachings provided herein.

Materials

[0149] Anti-human apolipoprotein B polyclonal antibody (goat as host) was purchased from Midland Bioproducts, Boone, Iowa. Block copolymer surfactants Pluronic® P-123, L-121 and F-68, as well as all other surfactants, were purchased from Sigma-Aldrich (St. Louis, Mo.).

[0150] Immunoturbidimetric experiments were performed on a Roche Cobas Fara analyzer (Roche Diagnostic, Indianapolis, Ind.).

Example 1

Investigative Work Towards Development of a Method for Measuring LDL-Apo B Concentration or LDL Particle Concentration in a Biological Fluid

[0151] In order to identify conditions under which the anti-apo B antibody may bind preferentially to LDL-apo B over non-LDL-apo B, experiments were performed using lipoprotein fractions isolated from a serum pool. Ultracentrifugation was used to isolate chylomicrons, if present, and VLDL fractions (d<1.006 g/mL) from the LDL/HDL fraction (d>1.006 g/ml). Chylomicrons contribute relatively little apo B, especially in the fasting state, and HDL particles do not contain apo B. Therefore, these fractions above may be characterized as, respectively, "VLDL fraction" and "LDL fraction" for the purpose of apo B analysis.

[0152] The ability of each fraction to interact with anti-apo B antibody was evaluated using the Cobas Fara chemical analyzer. In a typical procedure, each fraction (6 μL) was mixed with 285 μL of Reagent R1. The composition of Reagent R1 was varied to investigate its influence on the interaction of apo B with the antibody. For this investigation, different block copolymer surfactants, other non-ionic detergents or salts were used to prepare Reagent R1. Among the block copolymer surfactants used in this investigation were three POE-POP surfactants: Pluronic® P-123, L-121 and F-68. Reagent R1 was prepared by diluting each surfactant to a final concentration of 0.05% (in the case of P-123 or L-121), or 0.4% (in the case of F-68), in PBS, pH 7.4.

[0153] The samples were loaded onto the analyzer, transferred to the analysis cuvettes, and incubated at about 37° C. for about 5 minutes. The resulting solution was treated with 95 μL of Reagent R2, prepared by diluting 1 part of anti-apo B antiserum with 7.5 parts of 50 mM Tris base, pH 8.0. The amount of apo B/anti-apo B antibody binding for each system was measured using immunoturbidimetry, based on absorbance relative to PBS.

[0154] The influence of various components in Reagent R1 on the apolipoprotein-antibody interaction is described below. As summarized in Tables 4 and 5, each of the 3 surfactants analyzed exhibited the ability of inhibiting anti-apo B antibody binding to VLDL-apo B over LDL-apo B. As examples of typical formulations, an R1 solution comprising 0.8% POE-POP and 5% PEG in PBS allowed complete inhibition of anti-apo B binding to VLDL particles, without altering binding of anti-apo B antibodies to LDL particles.

[0155] These experiments, the results of which are shown in Tables 4 and 5, indicate that reagents such as dextran sulfate, cyclodextrins and magnesium chloride, either alone or in combination, had little effect on the binding of anti-apo

B antibody to VLDL-apo B or LDL-apo B. This result is in contrast to previously published reports (Sugiuchi, Clin. Chem. 1998, 44:522; U.S. Pat. Nos. 5,888,827 and 6,794,157) for direct LDL cholesterol measurement. Furthermore, these reagents did not influence the binding selectivity of anti-apo B antibody for VLDL-apo B or LDL-apo B in the presence of POE-POP block copolymers. This result differs from reports of assays for direct LDL cholesterol (LDL-C) and HDL cholesterol (HDL-C) measurements. In such reports, dextran sulfate, α-cyclodextrin sulfate and magnesium chloride were found to increase the selectivity that POE-POP block copolymers impart to the reactivity of enzymes used in cholesterol measurement (Sugiuchi, 1998, Clin. Chem. 44:522).

TABLE 4

Reactivity of apo B antibodies with VLDL and LDL fractions

FORMULATION	VLDL RELATIVE REACTION (%)	LDL RELATIVE REACTION (%)
PBS	100	100
P-123	31	107
P-123, DS, $MgCl_2$	33	109
P-123, αCDS, $MgCl_2$	35	117
PEG 600	100	100
PEG 600, P-123	34	108
PEG 600, P-123, DS, $MgCl_2$	33	118
PEG 600, P-123, αCDS, $MgCl_2$	33	110
PBS	100	100
L-121	63	112
L-121, DS, $MgCl_2$	77	108
L-121, αCDS, $MgCl_2$	81	109
PEG 600	100	100
PEG 600, L-121	77	121
PEG 600, L-121, DS, $MgCl_2$	73	108
PEG 600, L-121, αCDS, $MgCl_2$	78	112
PEG 4000	100	100
PEG 4000, L-121	85	116
PEG 4000, P-123	32	101
PEG 4000, F-68	24	137
PBS	100	100
αCDs	100	115
DS	101	115
$MgCl_2$	100	117
αCDs, $MgCl_2$	107	132
DS, $MgCl_2$	107	116
Triton X-114, 0.1%	44	62
Triton X-114, 0.02%	45	103
Tween 20, 0.1%	0	68
Tween 20, 0.02%	61	106

Final R1 concentrations for each reagent (if not indicated in Table 4): 0.05% P-123; 0.05% L-121; 0.4% F-68; 2.7% PEG 600; 2.7% PEG 4000; 0.15 g/L Dextran Sulfate (DS); 0.14% α-cyclodextrin sulfate (αCDs); 4.2 mM magnesium chloride ($MgCl_2$) in PBS, pH 7.4.

TABLE 5

Effect of F-68 surfactant on reactivity of anti-apo B antibodies with VLDL and LDL fractions

FORMULATION	VLDL RELATIVE REACTION (%)	LDL RELATIVE REACTION (%)
PBS	100	100
0.1% F-68	77	99
0.2% F-68	60	99
0.4% F-68	52	99
0.8% F-68	51	95
5% PEG 4000	100	100
5% PEG 4000, 0.1% F-68	67	102
5% PEG 4000, 0.2% F-68	54	102
5% PEG 4000, 0.4% F-68	34	98
5% PEG 4000, 0.8% F-68	27	96
5% PEG600	100	100
5% PEG600, 0.1% F-68	74	103
5% PEG600, 0.2% F-68	58	104
5% PEG600, 0.4% F-68	42	111
5% PEG600, 0.8% F-68	36	85

[0156] The data presented on Tables 4 and 5 also suggest that the hydrophobicity of the detergent does not have a significant effect on the relative reactivity of various formulations. This observation differs from literature reports of methods to measure lipoprotein-specific cholesterol or triglycerides (Sugiuchi, 1998, Clin. Chem. 44:522, and Wieland, U.S. Pat. No. 6,991,913).

[0157] Polyethylene glycol is typically added to immunoassay reagents to accelerate the interaction of antigen and antibody (Ritchie, "The Foundations of Immunochemistry", Chapter 5, In: "the Immunoassay Handbook", 3rd Edition, David Wild, ed., Elsevier, 2005, pp. 91-2).

[0158] The data in Table 4 demonstrate that addition of PEG 600 or PEG 4000 does not influence the selectivity that P-123 or L-121 imparts on antigen-antibody interactions for LDL over VLDL, but in a subsequent experiment formulations with 0.05% P-123 and 0%, 3% or 5% PEG 4000 suggest otherwise (FIG. **3**). The addition of PEG 4000 enhanced the recovery of LDL-apo B while inhibiting VLDL-apo B binding. Similarly, the addition of PEG 600 or PEG 4000 enhances the selectivity that F-68 imparts on the interaction of anti-apo B with LDL over VLDL (Table 4, and FIGS. **4-7**).

[0159] Non-ionic detergents other than POE-POP block copolymers, such as Brij® 30, Brij® 700, Igepal® 630, and Tween® 20, were also found to inhibit reaction of anti-apo B antibody with VLDL, as shown in Table 6.

TABLE 6

Polyoxyethylene surfactants

FORMULATION	VLDL RELATIVE REACTION (%)
PBS	100
0.6% Brij ® 30	49.3
0.6% Brij ® 700	36.6
0.8% Igepal ® 630	78.9
0.4% Igepal ® 630	68.1
0.05% Tween ® 20	55.4
PBS	100
0.3% Brij ® 700	33.4
0.3% Brij ® 700, 3% PEG 4000	35.8
0.3% Brij ® 700, 0.05% Tween ® 20	33.8
0.3% Brij ® 700, 0.9% F-68	30.4

Example 2

Method for Measuring LDL-Apo B Concentration or LDL Particle Concentration in a Biological Fluid

[0160] Based on the optimization experiments described in Example 1, three Reagent R1 formulations were selected for further study.

Reagent R1

[0161] Formulation 1: Pluronic® F-68 (0.5%); PEG 4000 (2.5%); PBS buffer, pH 7.4.

[0162] Formulation 2: Brij® 700 (0.005%); PEG 8000 (3%); PBS buffer, pH 7.4

[0163] Formulation 3: Pluronic® F-127 (0.01%); PEG 8000 (5%), PBS Buffer, pH 7.4

[0164] In a typical experiment, the assay was set up on a Cobas Fara analyzer using 6 μL sample of biological fluid, 285 μL of Reagent R1 (selected from one of the three formulations listed above), and 95 μL of Reagent R2. Reagent R2 consisted of a 1 part of apo B antiserum (Midland Bioproducts, Boone Iowa) diluted in 7.5 parts of 50 mM Tris base, pH 8.0. The biological sample was added to Reagent R1 and incubated at about 37° C. for about 5 minutes. After the "blank" absorbance measurement, Reagent R2 was added. About three minutes after Reagent R2 addition, the final reading was performed.

[0165] A four parameter log-logit calibration curve was prepared using c.f.a.s. lipid calibrators from Roche (Indianapolis, Ind.) using a serial dilution to give calibrator values of 232, 116, and 58 mg/dL, along with a normal saline zero calibrator. C.f.a.s. lipid calibrator is made from lyophilized human serum. Therefore, it is assumed to contain both VLDL and LDL apo B. This could in principle reduce the accuracy of measurement of LDL-apo B concentration, but the results of this experiment still demonstrate that the assays inhibit the reaction of VLDL-apo B with anti-apo B antibodies.

[0166] The different samples (VLDL fraction, LDL fraction and whole serum) were analyzed using the method described above and the results are shown in Table 7. Using the calibrator concentrations given above, the lipoprotein concentrations are provided in mg/dl units, which may be converted to nmole/l by multiplying by a factor of 19.5, based on a molecular weight of 512,000 for apo B (Knott et al., 1986, Nature 323:734-38; Chen et al., 1986, J. Biol. Chem. 261:12918-21; Law et al., 1986, Proc. Natl. Acad. Sci. USA 83:8142-46).

[0167] The results indicate that, for the three Reagents R1 used, the interaction of anti-apo B with VLDL was inhibited, while the interaction of anti-apo B with LDL was largely undisturbed.

TABLE 7

Quantitation of lipid fractions.

Sample	Reagent R1, Formulation 1	Reagent R1, Formulation 2	Reagent R1, Formulation 3
	concentration determined, nmole/L (mg/dL)		
VLDL (d < 1.006 g/mL)	0 (0.0)	8 (0.4)	4 (0.2)
LDL (d > 1.006 g/mL)	1539 (78.9)	1835 (94.1)	1712 (87.8)
Serum	1778 (91.2)	1913 (98.1)	1882 (96.5)

Example 3

Assay Performance

[0168] Studies were performed to determine within-run and total precision, limit of detection, limit of quantitation, and linearity. Institutional review board (IRB) approval was obtained, and sera were obtained from volunteers who provided informed consent. Enough serum was available to separate VLDL and LDL by ultracentrifugation in 19 subjects. The LDL-apoB assay was calibrated with the WHO/IFCC SP3-08 reference material. This provided a reasonably accurate standard; however, the reference material is a stabilized serum pool that contains some VLDL.

[0169] Data were collected on the Roche Cobas Fara analyzer as previously described, with the exception that 0.5 g/L dextran sulfate and 2 mM magnesium chloride were added to the R1 formulation, along with 0.6% Pluronic F-68. Within-run imprecision, assessed with three levels of QC material (52, 107, and 124 mg/dL), was 3.4%, 3.1, and 1.8%, respectively. Total imprecision, determined by measuring the same three levels of QC material in duplicate twice per day for 20 days, with four recalibration cycles, was 10.1%, 6.6%, and 6.0% for the low, medium, and high QC, respectively. The limit of detection, assessed with both normal saline and HDL supernatant (apoB particles removed from serum by precipitation with dextran sulfate-magnesium chloride) was 25 mg/dL (488 nmole/l). The limit of quantitation, defined as the concentration associated with 20% imprecision, was also <25 mg/dL. Linearity, assessed by linear regression of observed (y) and expected (x) concentrations derived from dilution of concentrated LDL, extended from about 30-183 mg/dL (FIG. **8**). The measured values are listed in Table 8.

TABLE 8

Level	Mean (mg/dL)	Expected (mg/dL)	Bias (mg/dL)
1	35.9	30.0	5.9
2	55.3	55.5	−0.2
3	76.9	80.9	−4.1
4	101.6	106.4	−4.8
5	130.6	131.8	−1.3
6	155.9	157.3	−1.4
7	188.5	182.7	5.8

[0170] Apo B in the VLDL fraction of 19 serum specimens, separated by ultracentrifugation, was also measured. Unlike initial studies using a serum pool, the addition of a small amount of dextran sulfate (0.5 g/L) and magnesium chloride (2.0 mM) improved the selectivity of the antiserum for LDL in most serum samples, especially those with elevated triglycerides. This was observed by Sugiuchi et al. for the direct LDL cholesterol assay, as well (Clin Chem 1998, 44:522-531) (Table 9). The assay was modified by increasing the sample: reagent volume ratio to increase low-end sensitivity and provide a limit of detection<1.0 mg/dL. Mean±SD concentration for VLDL-apo B measured with total apoB assay was 10.4±11.8. The mean VLDL-apo B concentration measured with the LDL-P assay was 1.1±3.5; indicating that the LDL-P reagent had successfully blocked binding of VLDL-apoB with the antiserum (Table 9). The exception was specimen 17, which had a triglyceride concentration of 632 mg/dL.

TABLE 9

VLDL-apoB measured with a total apoB assay and with the LDL-apoB (LDL-P) assay

ID	TRIG	Total APOB	LDL-P	LDL-P (+DS/$MgCl_2$)
1	141	4.6	1.4	0.1
2	160	4.6	2.1	0.3
3	88	4.4	0.1	0.0
4	208	14.1	2.3	1.0

TABLE 9-continued

VLDL-apoB measured with a total apoB assay and with the LDL-apoB (LDL-P) assay

ID	TRIG	Total APOB	LDL-P	LDL-P (+DS/$MgCl_2$)
5	50	9.1	0.1	0.1
6	121	19.6	1.1	0.1
7	158	1.9	1.2	0.2
8	174	10.5	2.0	0.2
9	111	12.3	0.7	0.0
10	173	9.6	2.2	0.4
11	111	1.8	0.4	0.2
12	282	10.1	5.7	1.3
13	177	7.7	1.5	0.3
14	70	2.1	0.1	0.0
15	25	0.8	0.1	0.0
16	160	10.3	1.4	0.2
17	632	54.6	33.0	15.5
18	256	13.2	2.6	0.8
19	151	6.9	0.9	0.1
Mean ± SD		10.4 ± 11.8	3.1 ± 7.4	1.1 ± 3.5

INCORPORATION BY REFERENCE

[0171] The disclosures of each and every patent, patent application, and publication cited herein are hereby incorporated herein by reference in their entirety.

[0172] While the invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of this invention may be devised by others skilled in the art without departing from the true spirit and scope of the invention. The appended claims are intended to be construed to include all such embodiments and equivalent variations. claims

SEQUENCE LISTING

```
<160> NUMBER OF SEQ ID NOS: 10

<210> SEQ ID NO 1
<211> LENGTH: 42645
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

attcccaccg ggacctgcgg ggctgagtgc ccttctcggt tgctgccgct gaggagcccg     60

cccagccagc cagggccgcg aggccgaggc caggccgcag cccaggagcc gccccaccgc    120

agctggcgat ggacccgccg aggcccgcgc tgctggcgct gctggcgctg cctgcgctgc    180

tgctgctgct gctggcgggc gccagggccg gtgagtgcgc ggccgctctg cgggcgcaga    240

gggagcggga gggagccggc ggcacgaggt tggccggggc agcctgggcc taggccagag    300

ggagggcagc cacagggtcc agggcgagtg gggggattgg accagctggc ggcccctgca    360

ggctcaggat ggggggcgcg ggatggaggg gctgaggagg gggtctccgg agcctgcctc    420

cctcctgaaa ggtgaaacct gtgccggtgg tccccctgtc gggccctagc acccgctggg    480

aagacgtggg aagctcacag atttctttct cctgtcttac agaagaggaa atgctggaaa    540

atgtcagcct ggtctgtcca agtaaggcat ctgcgcatgg ggcgtggaag ggcgcccagc    600

cccgtgcact ctcctacacc cgggtccctg agggcctccc actctacagg gctgagatgg    660

catcgtggtg tgccttgctc tgaccccagg aagcaagttc cctgagcctc tgcccacacc    720

caagggatgc caactctctt ctacctggcc ttctgttctg tcccaaaagt tcagcctggg    780

ggcgggggag ggaagggatt gtctctccgc tggcctgtgc acactttgaa gaaacatcac    840

tgtcctgttt atcagtgact agtcattgat tcgaagcatg tgagggtgag gaaatactga    900

ctttaacctt tgtgaagaaa tcgaacctcc accccccttcc tatttacctg acccctgggg    960

gttaaaggaa ctggcctcca agcgcgaccc tgtgtgctgg agccgcgggg cggacttctg   1020

atggggcagc accgccatct agtggccgtc tgtcatcact gcagctggac tcaggaccca   1080
```

-continued

```
gatgttcttt ttcttcaatt gttcagaaaa ttcctctcaa ctacagtgga aacctccaga   1140
aattcttttc taggagtttg ttaagttagt tacgcttaat gcttaatgaa ctttgcctta   1200
agtatttggt agtcttagag tcacggaatt acggcgtgtt caagctaaaa aagcattaga   1260
gatagtacta tttgcgtaat gttgtcatct cttaatttgc cagagggtct ctcatgcaga   1320
ttttctgagc cccattactt gacacttgtc actcccttcc ctgtgcctca gatgagatat   1380
tcaagacatg ccagccaatt taaacattag cctcagcaaa aacataatgg agaagtcaaa   1440
tctataaagg aaaattaagt ataaagtcaa ttaaaaaata atttgagttg aattaccatt   1500
tttaattctc tatgccactg cccctctctg cccagaattg gctgtccttg ggagagctat   1560
ttctgctatg tggctgacgt atttctcccc acgttagaag atgcgacccg attcaagcac   1620
ctccggaagt acacatacaa ctatgaggct gagagttcca gtggagtccc tgggactgct   1680
gattcaagaa gtgccaccag gatcaactgc aaggtatgga ggatgcaggc aggagggacc   1740
tagagcccac agctttcccc cagccctgtt ccagcgggcg cccaacacgc gaccttcccg   1800
gagggtgtgt actgagcaaa cgcagaacat cccagaactg ttgtaatctg atcaaagcac   1860
tgggactttg cctctgtttg taagtcagcc acattgctga gatgtggtct gcccccacca   1920
aatttcgcaa gtcagaagta ttttcccgtt aacttcccag atgcaatagg aatccatgat   1980
ctagattagc agcagtgtgg gtctgtagat ttcagcgtga gagaggccca gtaggtgagc   2040
tatgggaggc aggcaactcg gaatcgcact gtgaaatgca gtttttataa tttaagtcaa   2100
acagaatctg ttgctgaaaa atgaatggaa agaagaaaaa aatataaaca tacagtttgt   2160
tctaaaataa aactttgctt attattgaga ctggttgtac tcatgttaca tacatgtgga   2220
gcagatctac aggctgctat tggggtttgg gtggggaaga gaagtcaagc tgagcagtca   2280
cctttttta gagagtaccg tagctcttgt atgtgctgtc caatatggta gacatgagcc   2340
acattgggct atttaaatgg aatgaaatta aaaattcata ttcgttgtca cattagctgc   2400
atttcaactg ctcaacagcc accctggcta ctggctccca tattgaacag cacacatgta   2460
caacatttct ataaagttat ttgaatagtg ctggataata agtaggaatc cgttgaaact   2520
ccagctatat gcaaagctct aaataggccc taatagatat aaccagtttt ttgggtgaca   2580
ttaaggagac atttgctgtg gaaacgaagg atggccctct tcctgctttc tgtttttctt   2640
cttcactttc actcctagtc tgcagcgctt ctatttaacc acagctcttt ataattaaag   2700
tgagtaactt tagaaccaat aaaaggacat cctccttccc atgcctaggg gcaaacttaa   2760
gaaatgtgtt acccgggagg gggaaaacgt cagcaatagg actaagtcta ggttggtgca   2820
cagagaaccc aggaggcatg ttgataaggc atgtggtgtt gaggcgcagg cagtggtgtt   2880
cccagcacca ttccctttgg tgctctgatt agagattaag ccctgggctt caggggccac   2940
ctctcattct tgatagacaa cctcaatgct ctgctaccct gaattctcag gttgagctgg   3000
aggttcccca gctctgcagc ttcatcctga agaccagcca gtgcaccctg aaagaggtgt   3060
atggcttcaa ccctgagggc aaagccttgc tgaagaaaac caagaactct gaggagtttg   3120
ctgcagccat gtccaggtaa gtcatgttgt acatgagcac acgcatgtgt gtgtgtccgc   3180
tgaggtatga acttgtgtgt ttgcaccagg cacggatgtg actgtaagta tttgtattcc   3240
gtatccatcg tggatcaggg aattactgag ttttcacaat catcaaaaag agagaagcat   3300
tagttaacct tccctagtta ggttccttta attatcattt tcatgtgttt ctaaaaatct   3360
```

-continued

```
catgctttaa acttcttgag attataaaac tgagatgctt tgtttaaaca agtgaattct   3420
tatttaaaga actagtcaag actagtgctt ggtggtcttt ggtgtggggt cccagaggca   3480
ctggctgctg tggccggcac atggcggggc agggtctgtt caccgcaggg cagaggagca   3540
ccaaggcttc ggtggctccc cctcctaggc tggcattcag ccactgcacg ctgatcggcc   3600
actgcagctg catctctgct gactggtcag ggcccatgtc gcacccattg taaatatttt   3660
caacatcacc cctgcctcat cctcaatcac agtttgtagg gtcctaggtg tgtatgaata   3720
caggcaggat agagttgtta acttggtagc atcagaaaac tctgtctgta ttagtctgtt   3780
ttcatgctgc tgataaagac atacctgaga ctgggcaatt tacaaaagaa aggtttattg   3840
gactcacagt tccacgtggc tggggaggtc tcacaatcat ggcggaaggt gagggacagc   3900
aagtcacatc ttatgtagat ggtggctggc aaagagagct tgtgcagaga aactcctgtt   3960
tttagaacca tcagatctcc cgacacccat ctgcaatcac gagaacagca cgggaaagac   4020
ctgcccccat gattcaatca cctccccccg ggtccctccc acaacacgtg ggaattatga   4080
gagctacgag acgaaatttg ggtggggacg cagagccaaa ccatatcacc atccttgccc   4140
atttttcagt tttgctaaac attagattca gatgccagtc ctttcttgcc aaaataggct   4200
gtgaggcttc tttctttcct atgctttatt ttctccaaga cttaactgta tatgagggag   4260
aggggtatgg tggcaggagg aaagagtggt ttattttttg gtccttggtc ttctccaaat   4320
acagaagaga ctcctgttct tgaaaaggag ggctttccat gtttgcatct tcatgacttt   4380
aactgtcttt tttaaaaatt gacatacaat aattatacat atttattgag aacatagtga   4440
tattttgata catgtaatgt atggtgatca gatcagagta attagcatac ccatcatctc   4500
aaacatttat catttcttcg tgttgggaac tttctgagag agtgtaggct gtgggagata   4560
agtccgtcac ctttttcctcc tgatgtaacc agagtggctg cagccaggtc ctcagaaact   4620
cagagagtac ccagtgggaa atccctaaga ccaaagtcag catgggcttc agccatggcc   4680
tgacaccata caaaagaatg actgtccaac aagtgtatga aaataagctc caattcactg   4740
gtagtcaaga aatgcgaatt aatgtaacaa caagatattt atctgctttt acccatcata   4800
ctgcaaaact ggaaaacagt gatagcacct gttgctggca ggccagtgag gaaaagtgtg   4860
ctgtcctgag ctgctggtgg aaacgagagc catcaggcaa tatctactgt aatttaaaat   4920
acttaatacc ctttgacaca gatattttag tctttgggac tctagcccat gaaaataaaa   4980
gcagtaatgt gtgaagatag gcacataagg atgtttgttt tggtattgtt tgtgtggttt   5040
aaaaaaaatc cagaaagaga gagggcaaat gccatcaaat ggggcaatgt gtgaataaat   5100
tatatttagc catggaatgg aatgttctgc atgcagcttt taaaaaaatc tgttagagct   5160
gtaccaagtg actcagaagg atttttgtga agtataatta agtgagaaaa acaagataaa   5220
agtatgcata atacaatgcc acttgtataa aacaaacaat ggcaaaatct ttgtatgact   5280
ctgtttgcac tcacccatgt ttacagagga ttgtatgagt gtgcagaaac aaatggaaca   5340
accactcggg tgtccgtatg gggaggatgg gcaaagagac tgatatgggt ggagaacaga   5400
gcagggctgg atgagccaag caaaaaaagt taaaacacag ctggacctgg tggctcatgc   5460
ctgtagtccc agcactttgg gaggccgagg agggagaatc acctgaggtc aggagtttga   5520
gaccagcctg gccaacatgg tgaaaactgt ctctactaaa aatacaaaaa ttagctgggt   5580
gtgatggcac atgccagtag tcctagctac tccggaggct gaggcaggag aatcacttga   5640
```

-continued

```
tcccaggagg tggaggttgc agtgagctga ggttgcgcca ttgcactcca gcccgggcga   5700
ccgagcgaga ctccatttca aaaaaagaaa aagaaaaaag aaaaaaagaa aaaaaaagaa   5760
tcaccaaaac ttatgtatat gtgcatactt ttttgaaaat gtatgtctat gtgtagctat   5820
attctatatt tacaaataaa tgatgtcaga agaacaattg gttaaaaaaa tatgagaaaa   5880
gaaacttcag tgccacccag cttacttcca gcaagttgta atggagaagg acatttccgt   5940
gaccatcctc tctctgggac aggtatgagc tcaagctggc cattccagaa gggaagcagg   6000
ttttccttta cccggagaaa gatgaaccta cttacatcct gaacatcaag aggggcatca   6060
tttctgccct cctggttccc ccagagacag aagaagccaa gcaagtgttg tttctggtga   6120
ggatttagaa agctgatagc agtggccctt gaaactcatc ttcatgtgtt agagaccagt   6180
cctaccatat acaaagcaga tcactgagtc agctccatga ctagttacat aggaagccct   6240
ggattggcgt gaaatactgg tgcccgaggt tcctcctgcc ccttaggctc actgacagat   6300
catcccaagc aggcttatca ggttgggtct aattttaaaa cagtcattga ggagtcctgg   6360
ccaccccacc cctgcttttg tttgatgctt cacctgtgtt tgctgggtta tggtgtacac   6420
agtaaatcct gtgtgtattt taaacaccaa aaataatggg atctgttgct ggtctctttt   6480
acgaatttca ggtttcactg tgagacagaa ttcatttcac ctcagtccca tgagcacttt   6540
tgtgtgttct aatttctcta cgacaccata atgggagaag acaccgatgc aacctgcgga   6600
ggcctttctg cagacccacc tttaactggt tttctctctc ccaacttggg ctggccaggc   6660
actagcaaga ccacactctg catagaaga aaaagaaagt ccctcccaaa gctagattcc   6720
ttctgctttt tctttcacga tccccacccc atccctccca agtacccaag gatgttgccc   6780
gtgttgaata catgtggttg catcttcttc ctccatagga taccgtgtat ggaaactgct   6840
ccactcactt taccgtcaag acgaggaagg gcaatgtggc aacagaaata tccactgaaa   6900
gagacctggg gcagtgtgat cgcttcaagc ccatccgcac aggcatcagc ccacttgctc   6960
tcatcaaagg catggtaagt cccatgtcag cactgtcgtg cacagcaagg agcatcctct   7020
tattaataca attccagaac ttttgagcta gtgggcacct ttgaggacag cctgccctgg   7080
ctgtttttta tacagactag agataggacc ctgagcaggc acgggaaggt ctgcccaggc   7140
ttcacggcct gggatcagtt gagccaaggc ttgagtcagg ctcctccctc ccagcccaga   7200
gctctgtctt tcctcctgtc cttctgtcac tggcaccaaa ctgcctctaa tctcatcact   7260
tgagagtaat gactactcac ctctgagaag gttccgggga tggatgtagg gcagcaaaac   7320
caccttctgt tcttttctgc acaaggactc cttgtgccag ctccaagcct ctggcctttg   7380
aagaagtccc aagacctgtg ttctccccct ctccctcatc ccatgaagtg gagtgactta   7440
gagtgctcca gcttcttgtc cttccacccc cagtaccacc ctgaccaaac atggccccac   7500
tgccaccggc ctggagcacc ctctcctctc tgttaactgg ggccatggag caccatatta   7560
cctgagcctg cctgacccct gcaacatctt ccctgatatg agccccagcc tgtctcagtg   7620
aacatgaata acttgggcaa tcactgtcat gctgggcgct gttcctggtc attgtcctta   7680
gggttgaaaa cagggagtct gatgaccatg agtgccacag tcagaagagg ataatgcact   7740
ggcttagggg tcttttctga gcatctgctg tttgctcaac cccactctgg gcagcaccaa   7800
ggaagggaca gtggcagatg aaccatggac cttcccctca ggatgcttcc agtctaatgc   7860
aggagccagg tcaataaagt atacgtggta tactcaataa ggtgataagc tgaacagtgc   7920
```

-continued

```
agacaagaag tcctgggcct gaccaggaag gagaaagaat tattcatgta gctcagcggg   7980
caacatttca tggaagatgt ggagcaggaa cccaaaaaat gcaaagaata tgtaaatgaa   8040
agagacatgt aagaatgggc ttttgggcaa agaaaagtta ctgagcaggt gtgtgagggg   8100
ctatgtggtg ggatgggcat gtggaggata caaagtttag acattgtcca gtgagggtgg   8160
aaaaagagga gtctacagct tgactcagct ttggggatgc cgacttgttg cacccccctgg  8220
tctaaatgtc aagtacccag ttatcttctt tctctgagtt tatctagtgg tacaggactc   8280
ctgctcccctt ctaccttgaa ggtaaatgct tttaacagaa gatacaggga ctgatcaaaa  8340
tgctcgtctc caatctcttt catagacccg cccccttgtca actctgatca gcagcagcca  8400
gtcctgtcag tacacactgg acgctaagag gaagcatgtg gcagaagcca tctgcaagga   8460
gcaacacctc ttcctgcctt tctcctacaa gtaggtcatg tgatgcaccc ctgatttgtc   8520
atttaatggg tcagtgtgaa ctgaacactt ctcaagtgct ctgttccagg caaacctgtg   8580
cctgggaggg aggaatggag agggataaaa tgccgcccct ccctgtcccc ctttttaagc   8640
gaacaggcca tttggcagaa aagtcctagg catgcaaaac aatccaagac caacaaaaga   8700
tatctaagac ccattcttta agggctgtag atccagaaaa cctgaggatc actgcagggt   8760
accctggtta gaaaaggttt catggaagat ttgggatact gactggaaac ttgtgtatcc   8820
aaatccactt tgaaaactga taatcaatga atatatattg agtaactgcc atattcttgg   8880
ctctatgttg tggaagatac gaaagaattt tgagacattg cactagttcc tacctctggc   8940
cactccagac tagtggagag tataaggcac gcatgtcttt ttgatgggag gataactagc   9000
gtgaccagga agaggtggat gttattcatt cagggccaac aatggctgga tttacccatg   9060
ctttgaaaga tgggcaggac ttgggtagat gcagagacag ggaaaacctt caacatggaa   9120
agaatagtat gttctggcca tccgtgacat ggtgtgcttc cttggttacc aggaataagt   9180
atgggatggt agcacaagtg acacagactt tgaaacttga agacacacca aagatcaaca   9240
gccgcttctt tggtgaaggt aagagtttct gtccacatag ttgctggaaa atctactcaa   9300
gatgtgccta tcatggctta gccacttgct gagccctgtt aaatgtctgc tgactaacaa   9360
gtgatacaga cactggtgtt ctggctacct ctagtgagaa agcaaactca tttcatgatg   9420
tcaagttgca atggcataaa ggaaaagaag ttcccaaagc tacttaggca tttgtaaata   9480
gaaaactgga atcctaagtt taacatgaca tatttgatag aactgacatc acccatcctg   9540
tgataagatc cagagctgtc ccagacgagg tggaccaagt gggagagaac cttcagagtc   9600
tggccagata gtaacctcag gagtcagtct ttagaggtag aaggaactct aacaatctca   9660
agtccaaccc ttacccagta ttgtattgta tttatatctg tccaaattcc ttcttgtaca   9720
ttacctcatt gtcctttttg ctcatagcaa cctgtgatgt caggtggtag agatgtgatt   9780
ttatacctat tctacagagg agacagtgac acagagaggc ttagagtttg atgtagtcaa   9840
ggccgcagaa tattagaggg gggaaaataa gtgccaggtt gtaatctaag ccaggactat   9900
tctcattaca ccacatttcc atgatgactt ttacctctct tcctggcata ggtcacagta   9960
ggtggtggag aggatacaaa agtgtctccc ctccccacaa gctgctggta gacccaatta  10020
gaagaaatgg tgataagcac ccatgtgcct ggtcccagtt gtaaccatgt caacagtagc  10080
acctcctcac caattatttc aagctaaggg taacctgatg atagactcag acaagtctgg  10140
attccacttt agctctacct cttagaccct gagagctctt gggaaaccta agttgctcat  10200
```

-continued

```
ctctgggtca cacttcctca tctctgggtc tcatctcttt gtctcatctc tgggactcag  10260
agctgagatc cagggatgag caatttacat ggcccaaaaa ctctgtgggt ctcagaagca  10320
gggctgaatt tatcattaaa ttgaacaata atgccacccc acagggatag gatgatgagt  10380
cagtgaaaac aagtcaatca cctatggcag agccagatct agcaggcatt gaatacagga  10440
tagtttcttt cccttttccc ctgtgctgat actccacaat ttccagcttc cagtagacaa  10500
agatatggtt gagatgaaga aagctagagt tcctttgaca ctttccatct tccaggtact  10560
aagaagatgg gcctcgcatt tgagagcacc aaatccacat cacctccaaa gcaggccgaa  10620
gctgttttga agactctcca ggaactgaaa aaactaacca tctctgagca aaatatccag  10680
agagctaatc tcttcaataa gctggttact gagctgagag gcctcagtga tgaagcagtc  10740
acatctctct tgccacagct gattgaggtg tccaggtatc taatggttac agctcaactt  10800
tttataaaac tgatggtaac tgactgaact ttcaaacctt ggccaaatgg agaatctcag  10860
ggaccatttg gatatcaatc cagttaatca attagtcaat cagttcatga ttgctggata  10920
gagaactatc agctgctgcg ctgagttcca tgaaacacac acgcgcatac tgtgttcaag  10980
gcagctatgt atttgtgtgt taaaacagaa ggagaatagt tcccacattt tgatgggtaa  11040
cttttaattc ctaggtctat tgcaggtgct ctccagaagc ttataggctg gtggagagag  11100
aactcagacg aaaaatataa tatgatttct ctacccttca aggcactggc tttaagtgct  11160
atgaaggtga gagaagggac tgaggccagg aatgagaccc agctaatgtt ggccaggcat  11220
attctgtgtg ctggccaaag gactgtgata acagtcttct tgttgctaca gatccacagt  11280
cccctcttgg aacttttctc gattgggctt cttctgtggg taatattcct aaggaaagca  11340
tcatggttct gagctccaag ttgggttttg aagttagatt tgaatagtga atgaggtgat  11400
taagggctct cctggcagag gacacaccat gagcaatatt ttatgtgccc tgaaggtggt  11460
ctgtataact ttatccatgt ctttcttctc agccccatca ctttacaagc cttggttcag  11520
tgtggacagc ctcagtgctc cactcacatc ctccagtggc tgaaacgtgt gcatgccaac  11580
cccccttctga tagatgtggt cacctacctg gtggccctga tccccgagcc ctcagcacag  11640
cagctgcgag agatcttcaa catggcgagg gatcagcgca gccgagccac cttgtatgcg  11700
ctgagccacg cggtcaacaa gtgagtttcc acactgtatt tctcctccta ggagcagagg  11760
aacatcttgc acctctgtgc atctctgtat taaaactgaa cccctccttc cactttcaaa  11820
ctctgctcct tactcttgtg ttttttcttg atcatttttg gggtaatgac ttgaaataag  11880
aaatcagcaa acacaaattg aatttttaaa aatatttttct ctacattata ttataaaagt  11940
ttttgaacat agcaaagttg acagaatttc acagggaaaa cccctagaaa accagctatc  12000
tcctactatt taagtgttat tatatttgct ttatcacata tacatccatc cattaattca  12060
tcttattttc tgaagcattt caaagtaaat tgcaaacatc aacacacttt cccctaagta  12120
ttacagcttg catattatta acttcagttc aatattagtt agcagttttt tcctctgaat  12180
tttttgttt gtttgttttg ttttttttg ttgttgttgt tttttgaga tggtctcact  12240
gtgtcaccca ggctggagtg cagtgatgca gtcacggctc actgaagcct caaattcctg  12300
ggctgaagtg atcctcccac ctcagcctcc tgagtagctg ggaccacagg tgcatgctac  12360
catgccctgg ctaatttttg tattcttggt agatacaggg tttcaccatg ttgctcaggc  12420
tagcaggttt ttcctttgat gaaatttttt ggctttttct tttttacatt tttatataaa  12480
```

-continued

```
tttatgtgga acaagtgtaa ttttgttaca tgaatagatt gtgcagtagt taagtcaggg  12540
ctttcagggt atccatcacc cagacaacat atagtgtacc cactaagtaa tttctcacca  12600
tccatctccc tccacttcca caccttctga gtctcaattg tctatcattc cacacactat  12660
gtccttgtgt gcacattatt tcactcccac ttataaatga caacacgcaa tatttgtctt  12720
tctgtgactg tcctgtttca cttaagacaa tgacctccag ttccatccat gttgctgcaa  12780
atgacatgat ttattcttt ttatggccga atagtatttt attgcctata catttcacat  12840
ttttaatcca atcgtccatt gatagacact taggttgatt ccatgtcttt gctattgtga  12900
atagtgctgt gataaacata tgggtgcagg tttcctttgg atataatgat ttcttttcct  12960
ttaggtatat acccagtaat gggattgttg gatttattgg tagttctatt tttagttctt  13020
tgagaaatct ctgtattgtt ttccatagtg gttgtactta tttacaatcc catcaacagt  13080
gattaactgt ttcctttct ctgtatcctc accaacaact gttatttttt gtcttttgaa  13140
taatggccct cctgactctt gtaagatgtt atctcattgt ggttttaatt tacatttctc  13200
taatgattag taatgttatg catttttca tatgcctatt gccatttgta tgtcttcttt  13260
tgaaaaaaat gtctattcat gtcctttgcc tactttttaa tgggattatt tgggggattt  13320
ttttgttgag ttgtttgaat tgcttgtaca ttccggatat tagtacccca ttggatgaat  13380
agtttgcaaa tattttctcc cattctgcag gttaccaccc tgttgattat ttgttttact  13440
gtgcagaaac tttttacttt aattaagttc tatttgtcta ttttttgttt ttgttgtctt  13500
tgcctttgag gtcttattca cgaattcttt gtctaggcca atgtccagag aagttttccc  13560
taggttttct tcttgcattt ttatagtctc aggtcttata tttaagtctt tgatccatct  13620
tgagttgatt tttttatatg gtgacagata ggagtccagt tttattcttc tgcatatggc  13680
aatccatctt tcccagcacc acttattgaa aagggtgtcc tttccctagt gtatgttttt  13740
gtcaattttg tcaaagatcc gttgactgta agtatgtgac tttatttctg ggttcagtat  13800
tctgttccat tgatctatgt gtctattttt atgccagtac catgctgttt agattactat  13860
agccttgttg tataatctga agtcaggtaa tgtgatgcct ccagctatgt tctttttgct  13920
taaaattgct tcagctattc aggctctttt tggattccat atgaatttta taattatttt  13980
ttctaattca caagtttggg ttttaagaca aacctaactg gggttaccaa gtcctgactc  14040
tcttctctta ttctgtagct atcataagac aaaccctaca gggacccagg agctgctgga  14100
cattgctaat tacctgatgg aacagattca agatgactgc actggggatg aagattacac  14160
ctatttgatt ctgcgggtaa tctcagtctt ttatatgaca tacatcattt cagaagcact  14220
tttcctggac accttttact tccctctcct gcaccctgat gggttcttgt ttcttttctt  14280
caatgcaggt cattggaaat atgggccaaa ccatggagca gttaactcca gaactcaagt  14340
cttcaatcct gaaatgtgtc caaagtacaa agccatcact gatgatccag aaagctgcca  14400
tccaggctct gcggaaaatg gagcctaaag acaaggtaaa gtccacaaga agaggtctga  14460
aagtgaaagt ttattaacaa ggatttggaa ggtactaggg gaatgagact ctagatttca  14520
tctactgact ttattctgct gtttctttcc tttccttcct tccttccttc cttccttcct  14580
ccctccctcc ctttcttctt tccttccttc cttccttctt tcgagatgga atctcactct  14640
attgcccagg ctggagtgca gtggcatgat ctcggctcac tgcaacttct gcctcctggg  14700
ttcaagcaat tctctctgcc tcagcctcct gagtaactgg gattacaggc atgtgccatt  14760
```

-continued

```
acacccagct aatttttgta ttttttagta gagatggagt tttgccatgt tggccaggct  14820
ggtcttgagc tcctgacctc aggtgatccg cctgcctcag ccttgcaaag tgctgggatt  14880
acaggcgtga gccactgcac ctggcctcta ctgttttcta attgcaaatt tcaacaagcc  14940
tattgacttg actgcctagc agtatgtgac gtgagagaaa tacttgactt tgctgctatg  15000
tcaacatgca gaacgtgaga tgtttttgct tcctaccgtc cacctaccag attgaccatc  15060
cctctcatca tggaaaaaca tgcttaattt tcccccaata agcttaggct aggatagcca  15120
acttggcccc ctcttaggtg caaagactcc agaactttgg aaactaccct atttattagc  15180
cccaaactct tactacccct tctcatcttt atcctcacat taaaataact tacgttaaaa  15240
caacttgatt ttcacttagt ggtggatctc caaacaaatc acaacttggc cataatttat  15300
gtgttttaat ggaattgaat tcaacaggca ttccacaggc tttttctggg aacccttact  15360
tgatagtgct ctaggaaaca ctggcaagaa gattcaatac cagcatttga agaacgatta  15420
cagagaaatt agacctgtgc ttaagaaaga gctagcagac aatgccagtg tttgccaggc  15480
atgttctgtg ttctgaccac aggacagtga taaccatctc ctcttttgac tgcaggacca  15540
ggaggttctt cttcagactt tccttgatga tgcttctccg ggagataagc gactggctgc  15600
ctatcttatg ttgatgagga gtccttcaca ggcagatatt aacaaaattg tccaaattct  15660
accatgggaa cagaatgagc aagtgaagaa ctttgtggct tcccatattg ccaatatctt  15720
gaactcagaa gaattggata tccaagagta agtaagagct attcacccca tataccactg  15780
agggccctga gctggaattc caaccctagg ttttggcata gccactgtct gcccttgctt  15840
ctgaaacaaa cacttgtgca aatgtgtagc agatctagac ccaaagactt agggtcaatg  15900
aaatcaagac attttggtag tgattggaaa tccatattta cttggggtgc aagagtcaaa  15960
ggataataac atggtgtgtc agctcaaaat atacttcttc ttatctagtc tgaaaaagtt  16020
agtgaaagaa gctctgaaag aatctcaact tccaactgtc atggacttca gaaaattctc  16080
tcggaactat caactctaca aatctgtttc tcttccatca cttgacccag cctcagccaa  16140
aatagaaggg aatcttatat ttgatccaaa taactacctt cctaaagaaa gcatgctgaa  16200
aactaccctc actgcctttg gatttgcttc agctgacctc atcgaggtaa gtgtgaagag  16260
tttgaggttc tctagcccat tttgtacagc atcataaaca gagagtccct gggagccagg  16320
agctacccag aggaaaacta agaaccacca ggcacttcct accatgattc tgaggctttc  16380
ttctttccct ccttccccgc cttcctctct ccccgctagg ggtcacctga agcatgactt  16440
cttaacatta atagaaatgc aggcctggcg aggtggctca ctcctgtaat cccagcactt  16500
tgggaggccg aggcgggtgg atcatgaggt caggatatcg acaccatcct ggctaacacg  16560
gtgaaagccc atctctacta aaaatacaaa aaattagccg ggcgtggtgg caggcacctg  16620
tagtcccagc tacttgggag gatgaggcag gagaatggcg tgaacccagg aggctgagct  16680
tgcagtgagc cgagagattg cgccactgcg ctccagcctg ggcgacagag caagactcca  16740
tctcaaaaaa aaaaaaaaaa aaaaaaattg aaatgcaaat gtctcgtctt taagtcccaa  16800
agccaaggaa gcatatgtgc tgcctagtca gatctgcttc aaatctcaaa tcactcccaa  16860
ctctgaatcc tttgttgaat tatttgtcct atctgaacct tagctgcctc ttctagaaaa  16920
aagcaagtaa taaggtcaag attctagtga gattttaata aagcagctcc tgtgaaatgc  16980
taaggtcagc tcctggcctg tggtattcaa atacttgttt agataaatgg acatcaagag  17040
```

-continued

```
tggggactac taggctggca tacaacaaag aaacctgatg ccattttctt gtctgatttt  17100
ctttctcaga ttggcttgga aggaaaaggc tttgagccaa cattggaagc tctttttggg  17160
aagcaaggat tttcccaga cagtgtcaac aaagctttgt actgggttaa tggtcaagtt  17220
cctgatggtg tctctaaggt cttagtggac cactttggct ataccaaaga tgataaacat  17280
gagcaggtgt gtatttgtga agtatcttct taaggaaagc tttgggtctc aatgcaaaaa  17340
caattctttt ctaagcatgg aagtcctcaa aatactatct aactgaaggg ataactatgg  17400
tttttatcaa ccagacctgc tggggtaagg gccagtatcc tctgcagtta aagatctcct  17460
gaattcagtg tgcccagaaa ccagactcac aataagtact ctaggataac aagagtatga  17520
actctgggct gggtgtggtg gttcatgcct gtaatcccag cactttggga ggccaaggtg  17580
ggcagatcac aaggtcagga atttgagacc agcctggcca acatactgaa accccgtctc  17640
tactaaaaat acaaaaaaac tagctgggca tggtagtggg tgcctgtaat cctagctact  17700
cgggaggctg agacaggaga attgcttgaa cccgggaggt ggaggttgca gtgagccgag  17760
atcacgccgt tacactccag cccgggtgac agtgtgagac tgtatcttaa aaaaaaaaaa  17820
agtatgaact ctgggcatag atttaattct aacttccctg tcttgaagct gtgcgcactt  17880
ggggaagttg gttgatatta tgtgtatctg tttctgtctg tatcccagac tactaataac  17940
agtccaaacc tcacaaggtt atttaaagac aatgaaataa ggcatctaaa atgccaagca  18000
cagtgcctga tgctggcatt ggttgttcaa taagcagaca ctattacgag ttctaaatta  18060
atattttcat tattattaac tgctgtcttt ggctctcact cccatcagtg cactagcaaa  18120
tgagaccaaa cttccacttt gaagctagca atgagccccc atttaaggag ggaaataggt  18180
tgtatgatct ggagcttatt cttgaatttt ttgctaccca aagtgtggtc tggtcagaaa  18240
tacagcttct catgcttcac ccacaatcta ctgaatcaga agcgcatttt agcaagacct  18300
catgtgactt gtatgcacat tcaactttgc agagcaaggc agtaatttac ccctccaggc  18360
tcactgttga gcacgagctc catcttctaa tttcctgacc cccacttgag gccgaggatc  18420
tttgatctgc tttgagtctg tcagtttcac attttttttt tcccaatgcc tgggcatcca  18480
tctctgagat tcttcttctc tctgagaaga acttgtctag gatcaagtgt ttttcaaact  18540
tctggtgaat ttatataaca gctacatttt cttaagaaac accttgtagt cttcactggt  18600
caaagaagag aaggctaagc agggaacggg tgggggatag aggatcttct aatcttgagg  18660
atcctggcat actggagaat agggacccct cctctcatcc caccacatct tactatgtct  18720
acagattttt taattaagaa tagctttagg agtgccacta tccctgacaa gaccttagtt  18780
ctttaatctc tgcttagagg aattagcctg gacttcagtg tctccctgtt cctcacctgg  18840
agcatttttt aggcccatcc tggctgcatc agacaggtcc cacattggga actgaaaggt  18900
gtttgacatt gctgacatct cactggccat tttattacta aactctcagg atatggtaaa  18960
tggaataatg ctcagtgttg agaagctgat taaagatttg aaatccaaag aagtcccgga  19020
agccagagcc tacctccgca tcttgggaga ggagcttggt tttgccagtc tccatgacct  19080
ccagctcctg ggaaagctgc ttctgatggg tgcccgcact ctgcagggga tcccccagat  19140
ggtaagtcag caggccccac tgggggccca tgagaccaga cgttggtttt tttttagatc  19200
gcccagactc ccttacgatc ccagctgcac aagcccgaaa agatgcttgt actttcttca  19260
gagatggagg tttgccttga atttcactga agatgactct tggatcacat ggaaatgtta  19320
```

-continued

```
acatttagaa attaagctat tcataatgtt agctgtattt ttaagagcat taatttattc  19380
atctggaaaa caatgttcgg tataccttcc tctacctttg ctgaaggtcc ttttattttt  19440
atttttattt ttttaatttt ttgagatgga gtcttgctcc caggctggag tgcagtgata  19500
caatctcggc tcactgcaac tctgccttcc gggttcaagc aattctcctg cctcagcctc  19560
ccaagtagct gggactgtgg acgtgcacca gcatgcccgg ctaatttgtg tatctttagt  19620
agagacaagc ctgttgacaa ccatgtcagg ctggtttcga actcctgacc tcaagtgatc  19680
ctccagcctg ggcctcccac agtgctggaa taacaggtgt gagccactgc acctgacctg  19740
aaggtccttt taagattgaa atgatacaat gattataaaa gaaagtattt ggcaaactat  19800
aattcactat ctaaatatgc tataattttt attattaatt cataaaagga aatatataaa  19860
tgtactccta tggcttgatt aaaaaaatgt tgactttaag aaaacaggtc tcaagctatt  19920
ttattgaaat attatttaaa aaataaaacc caatgcaaat tgatatgtac atcatctcaa  19980
taggcctttg gtttcaaaaa attgatttta tcataatata atacatttca agtacacctt  20040
cacttacagt cagactccag aacaccagaa ttaagccatg gcatatatga tacttaaagt  20100
ccataaagct ctgaggccca gcaatattct taagagcctt ctgagtccac ttgaaaatga  20160
catgatatct atctagtgaa atttcttata tcctgattca ctgaaaacgg taaaaacatc  20220
agtttgatct ttatttatca aactattcag ctcatcaaaa tatgctagtc cttcctttcc  20280
agataaagag gaattactct ccaatgtatg ggaggttgta attaacaaaa ccgactttaa  20340
aaagacttac ttttatttgc tctccccttgt tgggtctaca gattggagag gtcatcagga  20400
agggctcaaa gaatgacttt tttcttcact acatcttcat ggagaatgcc tttgaactcc  20460
ccactggagc tggattacag ttgcaaatat cttcatctgg agtcattgct cccggagcca  20520
aggctggagt aaaactggaa gtagccaacg taagattctg tttgcctttt gatttcttag  20580
gttattactt tcttccaggg tgcatttctt gttaaaacat atttaaaaat gtgtttccac  20640
ttcaagacaa aatgcttcat cattgtaatc acctcattat ttttttatga aaaacttcaa  20700
gcttccacca gaatgcacta cctcactagc tccagtagtg gtatggccat aagacaagaa  20760
ctcagttctc tcaacaaatg agtattccta tcatcttttt aatctggttt tgcctcacgt  20820
taactcaggt gctttctagt tctgggtagt atactccaac tctagagaac tgagaactcg  20880
ctttccttct tccaaacaaa tcccagtaat gtttccaaag gtctgagtta tccaggaaat  20940
ctttgcccgg aggtgagaaa gggtggttga tctgactgac aggggactga agtatttaat  21000
gaatctgaat aggttgtttt ctgacttata gatgcaggct gaactggtgg caaaaccctc  21060
cgtgtctgtg gagtttgtga caaatatggg catcatcatt ccggacttcg ctaggagtgg  21120
ggtccagatg aacaccaact tcttccacga gtcgggtctg gaggctcatg ttgccctaaa  21180
agctgggaag ctgaagttta tcattccttc cccaaagaga ccagtcaagc tgctcagtgg  21240
agggtaattc tttcagccaa gtctgcctag ccagtttgaa agagagaaca gagaatgtac  21300
ctgcagaatt ttgccaggct aaacagttga ttgagatcat tcaggtcctg aggaagcagg  21360
agaggagtag aaaggaaaga ttccgggtta cctattttaa ttctagccta gacttactac  21420
ataactacat aattaccttt cttctacttt tcacatttta ctaaactgtc ctttatcttt  21480
ctgctttgag acttattaag acctactgct taattagttt ttattaagtt gtgatttttt  21540
gttatctatt tgttttgaga atgaagaaac aatagctctg gagagatcat ctttggaaaa  21600
```

-continued

```
ttaatatttt ccccccccaaa aaatacctaa gaacatattg atttgaggta gctaggtagg  21660
taaagcatga aactcctaac ctcgtgataa tggaatacag cctcttttgg agagttccat  21720
tttaagtggc accctcaacc attgatttgc cttagttttc atattttaga cacattcatg  21780
tgttcattca aaaataatat ttaattggcc agccacggtg gttcatgcct gtaatcctag  21840
cactttggga gccccaggtg gatggatcgc ttgagccctg gtgtttggat accagcctgg  21900
gcaacatggc aaaaccccat ctctacaaaa aaaattaaat aaataacaaa attagccagt  21960
cgtggtggca catgcctgta gctccagcta ctcagaaggc tgagatggga ggatcaactg  22020
agcccaagag ttcaagcctt cagtgaacca tgcttgcacc actgcactcc agcctgggag  22080
acagagcaag atcctgtctc acaaaaaaca aaaaatagta tatttaattg cctaatatat  22140
accacgtatg ttgagtgaga cacacaaggt ccctgacctt tgaacgctta cattttataa  22200
gggagacaca caattaagca agcagtaatc atagagtaag ggctaagtta tagaaagtat  22260
tagagtacca tgaaatttta tatcatgtag cctgtgctag tcagggaatg cattctgaag  22320
caagtgtact tgacctgata actgaggact gtgtcagagt catttaggca aaggagaaag  22380
gagtgagtgt tccaggcaaa aggaaaagca tgtaatggcc tgaaggtaaa ggaatatggt  22440
tcaaggaact ggaagaagtg cagaatggta aggggctcag agatgatggg gagaggtagg  22500
caggggagag agcatgccca gctgcgaaag ccatcctaag gagtttggac tcttttgaag  22560
gcacaggagt tgaaaagggg agcagaaata agataggggt gatgttttag aagaaatact  22620
ctgactctag tgtggaagat gggtgagaag gaggcacagc tggacacgaa gagaccattg  22680
gacatctctt acgatcctat gtggctaaga gctgataatg gcctgcagtg gagaaaagcc  22740
aggtatagaa aggagtgagc agattctaca actttctaag aggcagaatc ataagtactg  22800
ggtgattaac tgggtatggg gacaaggcaa aagaaagaag aaaagaggaa ggaggcgccc  22860
ttcattttaa taagaactac agtgggagag cttctggttt caaggaaagt gacaaattca  22920
gttttggatg tgctgtattt gatgtcctcc tatgaaacaa ccagtttaga aatctagctg  22980
tcaaatagac ctatggatct gagcccagta aagaggcttg ggctccacat atggatttgg  23040
gaatcattag tatacagagg ttgttgtggt taaacagcaa ctggtataga gtgagacatg  23100
agagatgagg acagaaatat ggagaagaca aacatataaa ggaagaaggg gaataaccag  23160
caatgagtta gaagaagtga ccagagaagc agaaggagaa ccaaagccat aaaaggtcac  23220
agaagccaaa gagcagccac aggggagatc accccatggg taggcgaaag ctggcattag  23280
gactccagca catcagcaaa gcttggtctt gtggcacccc caacttggag aaacaatact  23340
tggaggaaaa tgtgctattt caaagaaagc atccttagaa aaaaccaggc caatgttgaa  23400
ctttcttaca tgtactaagt ttttaagtac acacttggaa ggaaggtgcc atcatctctt  23460
cagatgtgag aggctccagc gtcttagtct ggtcatgagt gcgcaactct atggaaggct  23520
tctgggaggt caaggaagat gaaacctaaa tatgcccatt ggatgtagga gcaaggaggg  23580
cattagagac attgatgaaa gcattttcag gagatggagt gagcagtcag agcacattgg  23640
gaggaagtag agactgcaaa ggcagacaac tcttgatggt gaggaagatg agaaagcaag  23700
aaaagaaaga aaggagcata ggggaggggc acaggggaag agacttgagc gtgcttaatg  23760
caggtggaag gaagcaggta gagagtagga gatttcatat gaaagagaca gtttctcttg  23820
ccctgcattg taggaaggaa ggggcacact gaagttcagc cccagtgatc agctatttaa  23880
```

-continued

```
catctctgag cctctgcttc tgtaaaatga gaaccataag cctactgttg tggggattac  23940
aggtaacaga tggaaagaac tcagccagaa gcttcagagt cactctcatg gcttgtcatg  24000
ttgatgttct ttctaatatt atttgtttct cagtaaatta aatagttaga gataggtgtg  24060
gactgaggga agacaggagg ataagggggt atttgcaccc tgagaatttg tgatgtccat  24120
tttgattcat gacttggcaa taactcaggt atttttgttc ttcaccagca acacattaca  24180
tttggtctct accaccaaaa cggaggtgat cccacctctc attgagaaca ggcagtcctg  24240
gtcagtttgc aagcaagtct ttcctggcct gaattactgc acctcaggcg cttactccaa  24300
cgccagctcc acagactccg cctcctacta tccgctgacc ggggacacca ggttagagat  24360
gctcagtgcc tgacccagca ttttctcacc ttccacatca tggccaccta gcatggcaca  24420
ggaaaaaata ctctgtgttg taagaccctg tcactagcct tctgggtttg caccatcttt  24480
gggtatttaa agcagggtcc tctggccaac acattgggtg tcaccttttg cttccttgtg  24540
catgggatgg gatcacagca cagatcccaa tttgctccta attcagtgtc catgtttctg  24600
agcctccaga cccatcgcta tgagcttcct ggagcccacc aatgtgcttg aagccttcac  24660
cgtacttagg tggctccctg tcttcagccc ccaagttcca gtgcttgttc tcagctttgc  24720
tgaaacaacc agccaactcc tgctctgctt gtccaaagtc ttgggaatcc tggtgtctgc  24780
ccttgccttg ggttcttgta ggactgaggg atcaaaaaga tcatcttagt taagggcaag  24840
agacaatgtt aaaataagga ccatattttt gttgcatttg aggctgaatt gttttgggaa  24900
cataatcacc atccttgaaa gctctaacat tatgcactgt cttcattgta atgtctttag  24960
attagagctg gaactgaggc ctacaggaga gattgagcag tattctgtca gcgcaaccta  25020
tgagctccag agagaggaca gagccttggt ggataccctg aagtttgtaa ctcaagcaga  25080
aggtgagtat tcaaaacaca gctgcctcat ctctgctcgc agtctcaggt tcagaattca  25140
tgaggagaag acatgtaatt taacctattt aacaaatagg ttaactgagt acccactaag  25200
cggcaggcct attctaagac ctgggttaac tgagtaccca ataagcggca ggcctattct  25260
aagacctggg gctagaacag tgaacaatgg agtctctgcc ttcatggaag ttacagtgaa  25320
caaccaaaca agttaatatt tggaatatca gataagtact gaggaggaaa acagagcgta  25380
gactggtcta tggagggcta ggagtaggag ggaggaagaa gggcagggaa agcagtgcat  25440
ttggaataat aagggaaagt ctccctggta aagtgagcat aaggagacct atcagaaata  25500
agaggagaag ccgtgtggta agactgttaa caggcagagg gaccagcaag tgcaaaggcc  25560
ctgaggctga cacactacta ccatgtttca aggaaaggaa ggaagacagt atggctggag  25620
cagaaagacc agggagaaaa gaggtagaag atgaggacag agagatatgg agaggtgaag  25680
gaaggataat ctcataggcc atggtaagaa ctttggcttt ttctatgaat taaacgaaag  25740
ccattgggga gtcctcatga tttgatttat gtttatgttg agaaaagact atgggcagac  25800
aagggcagag aaactaatat gtaggttatc acaataatcc aggcaggaat cagtgttgtt  25860
ttggatcagg gcaatggcag aagagatatg agaaggggat ggattctggc catattttga  25920
agattaggct gacaagattt gctgatacag tggatgttga gtgtaagagg aaaaggggaa  25980
tgaagacaaa cctaaggttt ttggcccggg caactgaaaa atggaacttc catttattga  26040
gatggaaagg gctactggag gagcaggttt tagggaatgg gagaaattta ggtgttcact  26100
ttggaaaaaa aattatatag ggatagcgag gagcaggttt tagggaatgg ggcacattta  26160
```

-continued

```
ggtgttcact ttggaaaaat ttttatatag ggatagcata tcacagaatt aaactaggaa  26220
gaaaatccca tgatagaaag cactggagga gcagggcacg ctggggaaat agtgtttggt  26280
aaacattgtt ttacgaagga tataaaatgg accagcctat ggattgaagg acgcccggga  26340
atcttgttac aaagaaaggg ggagttgggg agatggagcc cagggcaagg gcagcaagga  26400
accaggacag gcatcttggg tagaaagtaa tatagagatg tcgtgtcttc ctggcccaga  26460
agggctgcga gcctttgctg ttccacaaac aagctaagtg ctccccattt cagggccttt  26520
gcattcctga ccttctgcct ggaatgtgct cctcccagaa ctcagcgtgg ctccaacctc  26580
ttttcattct ggtctctgcc cacatgtgcc cttatcagag agaatttctc tgaccaccaa  26640
gtatgaaata acacttcttc tatccctttc ttttatcctt gtatccagtt ttactcttct  26700
tcataacatt cattaccatc tgacatgagc aagttacttg tttattgcct gtacacctcc  26760
cccactagaa ggtaagcccc atgaaagcaa ggattcccca gtaccaagag cagtgcccag  26820
cacacaatag gctcataaca ggcaatccat aaagacttgc atacatgaac acaactgagt  26880
ttaaaattat cagtaaatga gacccattaa aaaattttaa tgagaaaaaa aaaattcagt  26940
aaaatcctga actgtgtttt tgtttaagca cattgattcc ttggagtttc tctacctttt  27000
cctctctttc cttccaaaac atagcttctt tatttattta tttatttatt tgtttgttta  27060
tttatttatt tatttattta tttatttttt gagatggagt ctcgctcttt tgcccaggct  27120
gcagtgcagt ggtgccatct cggctcactg caagccccgc ctcccgggtt catgccattc  27180
tcctgcctca gcctcctgag tagctgggac tacaggcacc caccaacgcg cccggctaat  27240
tttttgtatt tttagtagag acggggtttc accatgttag ccagaatggt cttgatctcc  27300
tgacctcatg atctgcccgc cttggcctcc caaagtgctg ggattacagg tgtgagccac  27360
cgcacccggc ccaaaacata gcttcttacc acacatctct tgattctctt atacactcgt  27420
ccaggtgcga agcagactga ggctaccatg acattcaaat ataatcggca gagtatgacc  27480
ttgtccagtg aagtccaaat tccggatttt gatgttgacc tcggaacaat cctcagagtt  27540
aatgatgaat ctactgaggg caaaacgtct tacagactca ccctggacat tcagaacaag  27600
aaaattactg aggtcgccct catgggccac ctaaggtaaa gaaggccgag ggtcatctga  27660
cctgcactgc aggcctgggt ggttcttttc attattcctc ttccacttca tacctgacca  27720
agccatgttc tcccctagtc tacaatcaga gtggcagaga gagccctcaa caattttttt  27780
tttttttgag atggagtctc actctgtcac caggctggag tgcagtggca caatctcggc  27840
tcactgcaac ctccgcctcc cgagttcaag tgattctcct gcttaagcct cccaaggagc  27900
tggaactata ggtgcatgcc accacaccca gctaattttt atatttttag tagagacagg  27960
gtttcaccat attgaccagg atggtctcga tctcctgacc tcgtgatcca cctgccttgg  28020
cctcccaaag tgctgggatt acaggtgtaa gccactgcac ccggccaagc tctcaacatt  28080
ttaaccctct gcgcatgtcc agttggattt tcctaccatt tatcaggcac ttactattca  28140
tgtatcaagc acagtgctgg gtgctttaaa gaaattatct cggtcctcac aataaactgc  28200
gaggtcactg tgagttttcc tgtttcatgg ataaggaaat ggtagctcag aggggttaaa  28260
tcatttggtc aaaatcacag agctagtaaa tagcagagca ggattcaaac agttttcaaa  28320
aaacttctct ttctcctaaa cctgtttgca aagtccttaa tttgtgctga atgttggctt  28380
tagaagttga tgagtttgat ctgtggctgt ttctctgaac catccttgta tctggttttg  28440
```

-continued

```
atcaccacaa atggaacttc tgtttaatcc tgcatatctc cattgaaagg acaaaatcat  28500
tggtgccaac tgattttctt taccatagtt gtgacacaaa ggaagaaaga aaaatcaagg  28560
gtgttatttc catacccgt ttgcaagcag aagccagaag tgagatcctc gcccactggt  28620
cgcctgccaa actgcttctc caaatggact catctgctac agcttatggc tccacagttt  28680
ccaagagggt ggcatggcat tatggtatgt gtctcttccc ctgtgtgagc acttccaaag  28740
taatgcaggt gttgagacct gtggttacag gctgaactag taccattcac aactatttcc  28800
tacgtatttt cagatgaaga gaagattgaa tttgaatgga acacaggcac caatgtagat  28860
accaaaaaaa tgacttccaa tttccctgtg gatctctccg attatcctaa gagcttgcat  28920
atgtatgcta atagactcct ggatcacaga gtccctcaaa cagacatgac tttccggcac  28980
gtgggttcca aattaatagt tgtaagtatg agtctgccag tcaataaata catggatata  29040
agtgctaatt acatcctcaa ctctgagcta ggtgcaggaa ggtttccaaa gatgtataag  29100
gcatgcttcc ttccccccag ggaattcttg ggagaaaaaa aaaactttca caagtgtgta  29160
gttacccagt tacacaaagc tgaatgtgat acatatcaaa gagatgctac taagtagaac  29220
agttctttgc ctagtggtat caaaggaagc ttcaggacac cagctaggag gctgactatg  29280
ttagacattc cttttataaa tatggacagt gatcagtgac tggcaacgaa gattcataat  29340
tttctgttat ttatttttaa ctttcagtgc attgtccagc ttaataatta acttgtcaaa  29400
tcggtatttt tgcctaatgt tcattgctct ttgaggctca tccaagccca ttaccttaaa  29460
aatctcctgt cattttgtag gcaatgagct catggcttca gaaggcatct gggagtcttc  29520
cttataccca gactttgcaa gaccacctca atagcctgaa ggagttcaac ctccagaaca  29580
tgggattgcc agacttccac atcccagaaa acctcttctt aaaaaggtaa aagaagaaag  29640
cagcaaggct tcttgaacca tgcaaagtaa atgaaagatt ttacatagca tgatttagac  29700
atttttttaa atttttaaag gaaataattt aagcatttta aggagattaa taactatagc  29760
acaaacactg tggcatcttt gcattagtaa acatgagaac accaaccctg tcaggaagaa  29820
tctaagaaag tcattagagg attctggtac tttcacccta agatatttta ttcagtacaa  29880
cctgttataa gcaaattctc cctctgactg tgaagaattc agaatggcta gaggcgttat  29940
tgactacagg cttgctgtta agctagagag agtcagaaca gccattgagc actaaatgga  30000
ggcagcattc tgagaaaata ctttaaccca ggcttactga cttccatacc tatgttcttt  30060
ccacaaatca agttgtctca attcagttta gcaaatttgt atcaagtatc ccctatgtgc  30120
aaaatgctag actaggtaca gtgagaagat agaaactggg taaggtatag ccttttcttt  30180
caagaagata ccatggagac atcaacaaat gagaaataat taattatata agcaaaatta  30240
tgacatgctc tttgagaaag gtgcaaggga ctatgtaact gtaagaatga gacaaattgg  30300
ctatgactta ggtgggatgg taatgataag gagtggccct tagaagagct ttgtcaggat  30360
ttgagtgttt gacaggtgga ggtaaaagca aaggggtcca ggcataggag tagcacaaag  30420
aaaagtgcag agtggctttg ggaatggggc aagtacaata ttgttgtgaa ggtcagaggc  30480
agagaacttt gaatgactga tgtctgactg tggggatgtt atctttgttg ttcatttcag  30540
cgatggccgg gtcaaatata ccttgaacaa gaacagtttg aaaattgaga ttcctttgcc  30600
ttttggtggc aaatcctcca gagatctaaa gatgttagag actgttagga caccagccct  30660
ccacttcaag tctgtgggat tccatctgcc atctcgagag ttccaagtcc ctacttttac  30720
```

-continued

```
cattcccaag ttgtatcaac tgcaagtgcc tctcctgggt gttctagacc tctccacgaa  30780
tgtctacagc aacttgtaca actggtccgc ctcctacagt ggtggcaaca ccagcacaga  30840
ccatttcagc cttcgggctc gttaccacat gaaggctgac tctgtggttg acctgctttc  30900
ctacaatgtg caaggtgagc tatgctcagg taaagggtgc accgggctag ttcatggcag  30960
gctctaagag gagagcctcc tccagggagg aaaggacttt ggctttctag cagataatct  31020
tccttgctac ttggaagtct tttattttat tcaacaaata gaaatattta ttaaacatat  31080
cacgtgtatt aaatattcta gtaggcagta acagaaagta gacagataag ccagcaatta  31140
taattcagtg tgagaggtgc tatgataaag tgtagtatat aagtataagg tagagtggaa  31200
gcactcaaca agggaaccta aacaaagcct gtggtggtca ggcaaggctt cctggaggaa  31260
tgccttttgc tatcagattt tatctttgca ttacagatgg aggagtctat tgcacaattg  31320
gcccagaaaa atggggcttt attattgaaa gactttcaac atagagattg ctctggaaat  31380
gtactgctta atttaaccaa tgtcttttca tttttatgtt aggatctgga gaaacaacat  31440
atgaccacaa gaatacgttc acactatcat gtgatgggtc tctacgccac aaatttctag  31500
attcgaatat caaattcagt catgtagaaa aacttggaaa caacccagtc tcaaaaggtt  31560
tactaatatt cgatgcatct agttcctggg gaccacagat gtctgcttca gttcatttgg  31620
actccaaaaa gaaacagcat ttgtttgtca aagaagtcaa gattgatggg cagttcagag  31680
tctcttcgtt ctatgctaaa ggcacatatg gcctgtcttg tcagagggat cctaacactg  31740
gccggctcaa tggagagtcc aacctgaggt ttaactcctc ctacctccaa ggcaccaacc  31800
agataacagg aagatatgaa gatggaaccc tctccctcac ctccacctct gatctgcaaa  31860
gtggcatcat taaaaatact gcttccctaa agtatgagaa ctacgagctg actttaaaat  31920
ctgacaccaa tgggaagtat aagaactttg ccacttctaa caagatggat atgaccttct  31980
ctaagcaaaa tgcactgctg cgttctgaat atcaggctga ttacgagtca ttgaggttct  32040
tcagcctgct ttctggatca ctaaattccc atggtcttga gttaaatgct gacatcttag  32100
gcactgacaa aattaatagt ggtgctcaca aggcgacact aaggattggc caagatggaa  32160
tatctaccag tgcaacgacc aacttgaagt gtagtctcct ggtgctggag aatgagctga  32220
atgcagagct tggcctctct ggggcatcta tgaaattaac aacaaatggc cgcttcaggg  32280
aacacaatgc aaaattcagt ctggatggga aagccgccct cacagagcta tcactgggaa  32340
gtgcttatca ggccatgatt ctgggtgtcg acagcaaaaa cattttcaac ttcaaggtca  32400
gtcaagaagg acttaagctc tcaaatgaca tgatgggctc atatgctgaa atgaaatttg  32460
accacacaaa cagtctgaac attgcaggct tatcactgga cttctcttca aaacttgaca  32520
acatttacag ctctgacaag ttttataagc aaactgttaa tttacagcta cagccctatt  32580
ctctggtaac tactttaaac agtgacctga aatacaatgc tctggatctc accaacaatg  32640
ggaaactacg gctagaaccc ctgaagctgc atgtggctgg taacctaaaa ggagcctacc  32700
aaaataatga aataaaacac atctatgcca tctcttctgc tgccttatca gcaagctata  32760
aagcagacac tgttgctaag gttcagggtg tggagtttag ccatcggctc aacacagaca  32820
tcgctgggct ggcttcagcc attgacatga gcacaaacta taattcagac tcactgcatt  32880
tcagcaatgt cttccgttct gtaatggccc cgtttaccat gaccatcgat gcacatacaa  32940
atggcaatgg gaaactcgct ctctggggag aacatactgg gcagctgtat agcaaattcc  33000
```

-continued

```
tgttgaaagc agaacctctg gcatttactt tctctcatga ttacaaaggc tccacaagtc  33060
atcatctcgt gtctaggaaa agcatcagtg cagctcttga acacaaagtc agtgccctgc  33120
ttactccagc tgagcagaca ggcacctgga aactcaagac ccaatttaac aacaatgaat  33180
acagccagga cttggatgct tacaacacta aagataaaat tggcgtggag cttactggac  33240
gaactctggc tgacctaact ctactagact ccccaattaa agtgccactt ttactcagtg  33300
agcccatcaa tatcattgat gctttagaga tgagagatgc cgttgagaag ccccaagaat  33360
ttacaattgt tgcttttgta aagtatgata aaaaccaaga tgttcactcc attaacctcc  33420
catttttga gaccttgcaa gaatattttg agaggaatcg acaaaccatt atagttgtac  33480
tggaaaacgt acagagaaac ctgaagcaca tcaatattga tcaatttgta agaaaataca  33540
gagcagccct gggaaaactc ccacagcaag ctaatgatta tctgaattca ttcaattggg  33600
agagacaagt ttcacatgcc aaggagaaac tgactgctct cacaaaaaag tatagaatta  33660
cagaaaatga tatacaaatt gcattagatg atgccaaaat caactttaat gaaaaactat  33720
ctcaactgca gacatatatg atacaatttg atcagtatat taaagatagt tatgatttac  33780
atgatttgaa aatagctatt gctaatatta ttgatgaaat cattgaaaaa ttaaaaagtc  33840
ttgatgagca ctatcatatc cgtgtaaatt tagtaaaaac aatccatgat ctacatttgt  33900
ttattgaaaa tattgatttt aacaaaagtg gaagtagtac tgcatcctgg attcaaaatg  33960
tggatactaa gtaccaaatc agaatccaga tacaagaaaa actgcagcag cttaagagac  34020
acatacagaa tatagacatc cagcacctag ctggaaagtt aaaacaacac attgaggcta  34080
ttgatgttag agtgctttta gatcaattgg gaactacaat ttcatttgaa agaataaatg  34140
acgttcttga gcatgtcaaa cactttgtta taaatcttat tggggatttt gaagtagctg  34200
agaaaatcaa tgccttcaga gccaaagtcc atgagttaat cgagaggtat gaagtagacc  34260
aacaaatcca ggttttaatg gataaattag tagagttggc ccaccaatac aagttgaagg  34320
agactattca gaagctaagc aatgtcctac aacaagttaa gataaaagat tactttgaga  34380
aattggttgg atttattgat gatgctgtca agaagcttaa tgaattatct tttaaaacat  34440
tcattgaaga tgttaacaaa ttccttgaca tgttgataaa gaaattaaag tcatttgatt  34500
accaccagtt tgtagatgaa accaatgaca aaatccgtga ggtgactcag agactcaatg  34560
gtgaaattca ggctctggaa ctaccacaaa aagctgaagc attaaaactg tttttagagg  34620
aaaccaaggc cacagttgca gtgtatctgg aaagcctaca ggacaccaaa ataaccttaa  34680
tcatcaattg gttacaggag gctttaagtt cagcatcttt ggctcacatg aaggccaaat  34740
tccgagagac cctagaagat acacgagacc gaatgtatca aatggacatt cagcaggaac  34800
ttcaacgata cctgtctctg gtaggccagg tttatagcac acttgtcacc tacatttctg  34860
attggtggac tcttgctgct aagaacctta ctgactttgc agagcaatat tctatccaag  34920
attgggctaa acgtatgaaa gcattggtag agcaagggtt cactgttcct gaaatcaaga  34980
ccatccttgg gaccatgcct gcctttgaag tcagtcttca ggctcttcag aaagctacct  35040
tccagacacc tgattttata gtcccccctaa cagatttgag gattccatca gttcagataa  35100
acttcaaaga cttaaaaaat ataaaaatcc catccaggtt ttccacacca gaatttacca  35160
tccttaacac cttccacatt ccttccttta caattgactt tgtagaaatg aaagtaaaga  35220
tcatcagaac cattgaccag atgctgaaca gtgagctgca gtggcccgtt ccagatatat  35280
```

-continued

```
atctcaggga tctgaaggtg gaggacattc ctctagcgag aatcaccctg ccagacttcc  35340
gtttaccaga aatcgcaatt ccagaattca taatcccaac tctcaacctt aatgattttc  35400
aagttcctga ccttcacata ccagaattcc agcttcccca catctcacac acaattgaag  35460
tacctacttt tggcaagcta tacagtattc tgaaaatcca atctcctctt ttcacattag  35520
atgcaaatgc tgacataggg aatggaacca cctcagcaaa cgaagcaggt atcgcagctt  35580
ccatcactgc caaaggagag tccaaattag aagttctcaa ttttgatttt caagcaaatg  35640
cacaactctc aaaccctaag attaatccgc tggctctgaa ggagtcagtg aagttctcca  35700
gcaagtacct gagaacggag catgggagtg aaatgctgtt ttttggaaat gctattgagg  35760
gaaaatcaaa cacagtggca agtttacaca cagaaaaaaa tacactggag cttagtaatg  35820
gagtgattgt caagataaac aatcagctta ccctggatag caacactaaa tacttccaca  35880
aattgaacat ccccaaactg gacttctcta gtcaggctga cctgcgcaac gagatcaaga  35940
cactgttgaa agctggccac atagcatgga cttcttctgg aaaagggtca tggaaatggg  36000
cctgccccag attctcagat gagggaacac atgaatcaca aattagtttc accatagaag  36060
gacccctcac ttcctttgga ctgtccaata agatcaatag caaacaccta agagtaaacc  36120
aaaacttggt ttatgaatct ggctccctca acttttctaa acttgaaatt caatcacaag  36180
tcgattccca gcatgtgggc cacagtgttc taactgctaa aggcatggca ctgtttggag  36240
aagggaaggc agagtttact gggaggcatg atgctcattt aaatggaaag gttattggaa  36300
ctttgaaaaa ttctcttttc ttttcagccc agccatttga gatcacggca tccacaaaca  36360
atgaagggaa tttgaaagtt cgttttccat taaggttaac agggaagata gacttcctga  36420
ataactatgc actgtttctg agtcccagtg cccagcaagc aagttggcaa gtaagtgcta  36480
ggttcaatca gtataagtac aaccaaaatt tctctgctgg aaacaacgag aacattatgg  36540
aggcccatgt aggaataaat ggagaagcaa atctggattt cttaaacatt cctttaacaa  36600
ttcctgaaat gcgtctacct tacacaataa tcacaactcc tccactgaaa gatttctctc  36660
tatgggaaaa aacaggcttg aaggaattct tgaaaacgac aaagcaatca tttgatttaa  36720
gtgtaaaagc tcagtataag aaaaacaaac acaggcattc catcacaaat cctttggctg  36780
tgctttgtga gtttatcagt cagagcatca aatcctttga caggcatttt gaaaaaaaca  36840
gaaacaatgc attagatttt gtcaccaaat cctataatga aacaaaaatt aagtttgata  36900
agtacaaagc tgaaaaatct cacgacgagc tccccaggac ctttcaaatt cctggataca  36960
ctgttccagt tgtcaatgtt gaagtgtctc cattcaccat agagatgtcg gcattcggct  37020
atgtgttccc aaaagcagtc agcatgccta gtttctccat cctaggttct gacgtccgtg  37080
tgccttcata cacattaatc ctgccatcat tagagctgcc agtccttcat gtccctagaa  37140
atctcaagct ttctcttcca gatttcaagg aattgtgtac cataagccat atttttattc  37200
ctgccatggg caatattacc tatgatttct cctttaaatc aagtgtcatc acactgaata  37260
ccaatgctga actttttaac cagtcagata ttgttgctca tctcctttct tcatcttcat  37320
ctgtcattga tgcactgcag tacaaattag agggcaccac aagattgaca agaaaaaggg  37380
gattgaagtt agccacagct ctgtctctga gcaacaaatt tgtggagggt agtcataaca  37440
gtactgtgag cttaaccacg aaaaatatgg aagtgtcagt ggcaacaacc acaaaagccc  37500
aaattccaat tttgagaatg aatttcaagc aagaacttaa tggaaatacc aagtcaaaac  37560
```

-continued

ctactgtctc ttcctccatg gaatttaagt atgatttcaa ttcttcaatg ctgtactcta 37620

ccgctaaagg agcagttgac cacaagctta gcttggaaag cctcacctct tacttttcca 37680

ttgagtcatc taccaaagga gatgtcaagg gttcggttct ttctcgggaa tattcaggaa 37740

ctattgctag tgaggccaac acttacttga attccaagag cacacggtct tcagtgaagc 37800

tgcagggcac ttccaaaatt gatgatatct ggaaccttga agtaaaagaa aattttgctg 37860

gagaagccac actccaacgc atatattccc tctgggagca cagtacgaaa aaccacttac 37920

agctagaggg cctctttttc accaacggag aacatacaag caaagccacc ctggaactct 37980

ctccatggca aatgtcagct cttgttcagg tccatgcaag tcagcccagt tccttccatg 38040

atttccctga ccttggccag gaagtggccc tgaatgctaa cactaagaac cagaagatca 38100

gatggaaaaa tgaagtccgg attcattctg ggtctttcca gagccaggtc gagctttcca 38160

atgaccaaga aaaggcacac cttgacattg caggatcctt agaaggacac ctaaggttcc 38220

tcaaaaatat catcctacca gtctatgaca agagcttatg ggatttccta aagctggatg 38280

taaccaccag cattggtagg agacagcatc ttcgtgtttc aactgccttt gtgtacacca 38340

aaaaccccaa tggctattca ttctccatcc ctgtaaaagt tttggctgat aaattcatta 38400

ttcctgggct gaaactaaat gatctaaatt cagttcttgt catgcctacg ttccatgtcc 38460

catttacaga tcttcaggtt ccatcgtgca aacttgactt cagagaaata caaatctata 38520

agaagctgag aacttcatca tttgccctca acctaccaac actccccgag gtaaaattcc 38580

ctgaagttga tgtgttaaca aaatattctc aaccagaaga ctccttgatt cccttttttg 38640

agataaccgt gcctgaatct cagttaactg tgtcccagtt cacgcttcca aaaagtgttt 38700

cagatggcat tgctgctttg gatctaaatg cagtagccaa caagatcgca gactttgagt 38760

tgcccaccat catcgtgcct gagcagacca ttgagattcc ctccattaag ttctctgtac 38820

ctgctggaat tgtcattcct tcctttcaag cactgactgc acgctttgag gtagactctc 38880

ccgtgtataa tgccacttgg agtgccagtt tgaaaaacaa agcagattat gttgaaacag 38940

tcctggattc cacatgcagc tcaaccgtac agttcctaga atatgaacta aatggtaaga 39000

aatatcctgc ctcctctcct agatactgta tattttcaat gagagttatg agtaaataat 39060

tatgtattta gttgtgagta gatgtacaat tactcaatgt cacaaaattt taagtaagaa 39120

aagagataca tgtataccct acacgtaaaa accaaactgt agaaaatcta gtgtcattca 39180

agacaaacag ctttaaagaa aatggatttt tctgtaatta ttttaggact aacaatgtct 39240

tttaactatt tattttaaaa taagtgtgag ctgtacattg catattttaa acacaagtga 39300

aatatctggt taggatagaa ttctcccagt tttcacaatg aaaacatcaa cgtcctactg 39360

ttatgaatct aataaaatac aaaatctctc ctatacagtt ttgggaacac acaaaatcga 39420

agatggtacg ttagcctcta agactaaagg aacatttgca caccgtgact tcagtgcaga 39480

atatgaagaa gatggcaaat atgaaggact tcagtatgga gcttttattg aattgaaacc 39540

ttataccttt tgaaaactca ttgtgatttt cttcatctcc atacccottt cgtgatagct 39600

catctgtttt tctgctttca gggaatggga aggaaaagcg cacctcaata tcaaaagccc 39660

agcgttcacc gatctccatc tgcgctacca gaaagacaag aaaggcatct ccacctcagc 39720

agcctcccca gccgtaggca ccgtgggcat ggatatggat gaagatgacg acttttctaa 39780

atggaacttc tactacagcc ctcaggtaaa taccacctaa tgagtgacac gcccccaaga 39840

-continued

```
gcgagtggag aattggggca gatacattta attcaggacc aaatattcag agattcccca  39900
aactaggtga aagacaggcg gtaagcaact tcttctctga ggaaatattc tctagaaagt  39960
attacaatga gtccttgatt gattttaatg tttagatgca cacatgacat cccatcagca  40020
ctattattta ttaattctgg gcaaatccag gaagatgagg gttatacctc atcatctaaa  40080
tcataggcaa gctcagccat aggcagggta tatttttcag agaggactgg tttctgtagt  40140
atttaaaact ttaaaattct tccccacaat agaattgcta gatgagatac atcaaattcc  40200
tctcatgtca tttacaagct ctgccagggc caaatcaagg gtgacattac cagaggagaa  40260
gaccaaacat ggttctatga ctgttactaa aagtttgtca tgggcttgga gaatgcgtac  40320
tgatgttggg attctgggtc tctgcagggt gggctccaac ttgccttttt tgctatttct  40380
tcttttccta tctgtcattt cctgactctt cttctctctc ctcttctttc tcttcccccc  40440
actcctcttc cagttttcag tcctaggaag gctttaattt taagtgtcac aatgtaaatg  40500
acaaacagca agcgtttttg ttaaatcctt tctggggcat gtgataaaga gaaattaaca  40560
acagtagact tatttaacca taaaacaaac acatgaactg acatatgaaa gataaatccc  40620
tttcagtata tgaaagattc tctgatcttt atttttaact gctaatgaag ttttagtgta  40680
ctatattgtg taattggagt aattgaaaac atgttatttt tttttttctc tctgtttagt  40740
cctctccaga taaaaaactc accatattca aaactgagtt gagggtccgg gaatctgatg  40800
aggaaactca gatcaaagtt aattgggaag aagaggcagc ttctggcttg ctaacctctc  40860
tgaaagacaa cgtgcccaag gccacagggg tcctttatga ttatgtcaac aagtaccact  40920
gggaacacac agggctcacc ctgagagaag tgtcttcaaa gctgagaaga aatctgcaga  40980
acaatgctga gtgggtttat caaggggcca ttaggcaaat tgatgatatc gacgtgaggt  41040
tccagaaagc agccagtggc accactggga cctaccaaga gtggaaggac aaggcccaga  41100
atctgtacca ggaactgttg actcaggaag gccaagccag tttccaggga ctcaaggata  41160
acgtgtttga tggcttggta cgagttactc aagaattcca tatgaaagtc aagcatctga  41220
ttgactcact cattgatttt ctgaacttcc ccagattcca gtttccgggg aaacctggga  41280
tatacactag ggaggaactt tgcactatgt tcataaggga ggtagggacg gtactgtccc  41340
aggtatattc gaaagtccat aatggttcag aaatactgtt ttcctatttc caagacctag  41400
tgattacact tcctttcgag ttaaggaaac ataaactaat agatgtaatc tcgatgtata  41460
gggaactgtt gaaagattta tcaaaagaag cccaagaggt atttaaagcc attcagtctc  41520
tcaagaccac agaggtgcta cgtaatcttc aggacctttt acaattcatt ttccaactaa  41580
tagaagataa cattaaacag ctgaaagaga tgaaatttac ttatcttatt aattatatcc  41640
aagatgagat caacacaatc ttcagtgatt atatcccata tgtttttaaa ttgttgaaag  41700
aaaacctatg ccttaatctt cataagttca atgaatttat tcaaaacgag cttcaggaag  41760
cttctcaaga gttacagcag atccatcaat acattatggc ccttcgtgaa gaatattttg  41820
atccaagtat agttggctgg acagtgaaat attatgaact tgaagaaaag atagtcagtc  41880
tgatcaagaa cctgttagtt gctcttaagg acttccattc tgaatatatt gtcagtgcct  41940
ctaactttac ttcccaactc tcaagtcaag ttgagcaatt tctgcacaga aatattcagg  42000
aatatcttag catccttacc gatccagatg gaaaagggaa agagaagatt gcagagcttt  42060
ctgccactgc tcaggaaata attaaaagcc aggccattgc gacgaagaaa ataatttctg  42120
```

-continued

```
attaccacca gcagtttaga tataaactgc aagatttttc agaccaactc tctgattact  42180

atgaaaaatt tattgctgaa tccaaaagat tgattgacct gtccattcaa aactaccaca  42240

catttctgat atacatcacg gagttactga aaaagctgca atcaaccaca gtcatgaacc  42300

cctacatgaa gcttgctcca ggagaactta ctatcatcct ctaatttttt aaaagaaatc  42360

ttcatttatt cttcttttcc aattgaactt tcacatagca cagaaaaaat tcaaactgcc  42420

tatattgata aaaccataca gtgagccagc cttgcagtag gcagtagact ataagcagaa  42480

gcacatatga actggacctg caccaaagct ggcaccaggg ctcggaaggt ctctgaactc  42540

agaaggatgg catttttgc aagttaaaga aaatcaggat ctgagttatt ttgctaaact  42600

tgggggagga ggaacaaata aatggagtct ttattgtgta tcata                 42645
```

```
<210> SEQ ID NO 2
<211> LENGTH: 1870
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 2

agagactgcg agaaggaggt gcgtcctgct gcctgccccg gtcactctgg ctccccagct     60

caaggttcag gccttgcccc aggccgggcc tctgggtacc tgaggtcttc tcccgctctg    120

tgcccttctc ctcacctggc tgcaatgagt gggggagcac ggggcttctg catgctgaag    180

gcaccccact cagccaggcc cttcttctcc tccaggtccc ccacggccct tcaggatgaa    240

agctgcggtg ctgaccttgg ccgtgctctt cctgacgggt aggtgtcccc taacctaggg    300

agccaaccat cggggggctt tctccctaaa tccccgtggc ccaccctcct gggcagaggc    360

agcaggtttc tcactggccc cctctccccc acctccaagc ttggcctttc ggctcagatc    420

tcagcccaca gctggcctga tctgggtctc ccctcccacc ctcagggagc caggctcggc    480

atttctggca gcaagatgaa cccccccaga gcccctggga tcgagtgaag gacctggcca    540

ctgtgtacgt ggatgtgctc aaagacagcg gcagagacta tgtgtcccag tttgaaggct    600

ccgccttggg aaaacagcta aagtaaggac ccagcctggg gttgagggca ggggtagggg    660

gcagaggcct gtgggatgat gttgaagcca gactggccga gtcctcacct aatatctgat    720

gagctgggcc ccacagatgg tctggatgga gaaactggaa tgggatctcc aggcaggtc     780

acagcccatg tcccctgcaa aggacagacc agggctgccc gatgcgtgat cacagagcca    840

cattgtgcct gcaagtgtag caagcccctt tcccttcttc accacctcct ctgctcctgc    900

ccagcaagac tgtgggctgt cttcggagag gagaatgcgc tggaggcata gaagcgaggt    960

ccttcaaggg cccactttgg agaccaacgt aactgggcac tagtcccagc tctgtctcct   1020

ttttagctcc tctctgtgcc tcggtccagc tgcacaacgg ggcatggcct ggcggggcag   1080

gggtgttggt tgagagtgta ctggaaatgc taggccactg cacctccgcg gacaggtgtc   1140

acccagggct cacccctgat aggctggggc gctgggaggc cagccctcaa cccttctgtc   1200

tcaccctcca gcctaaagct ccttgacaac tgggacagcg tgacctccac cttcagcaag   1260

ctgcgcgaac agctcggccc tgtgacccag gagttctggg ataacctgga aaaggagaca   1320

gagggcctga ggcaggagat gagcaaggat ctggaggagg tgaaggccaa ggtgcagccc   1380

tacctggacg acttccagaa gaagtggcag gaggagatgg agctctaccg ccagaaggtg   1440

gagccgctgc gcgcagagct ccaagagggc gcgcgccaga agctgcacga gctgcaagag   1500
```

-continued

aagctgagcc cactgggcga ggagatgcgc gaccgcgcgc gcgcccatgt ggacgcgctg 1560

cgcacgcatc tggcccccta cagcgacgag ctgcgccagc gcttggccgc gcgccttgag 1620

gctctcaagg agaacggcgg cgccagactg gccgagtacc acgccaaggc caccgagcat 1680

ctgagcacgc tcagcgagaa ggccaagccc gcgctcgagg acctccgcca aggcctgctg 1740

cccgtgctgg agagcttcaa ggtcagcttc ctgagcgctc tcgaggagta cactaagaag 1800

ctcaacaccc agtgaggcgc ccgccgccgc ccccttccc ggtgctcaga ataaacgttt 1860

ccaaagtggg 1870

<210> SEQ ID NO 3
<211> LENGTH: 357
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 3

acagacacca aggacagaga cgctggctag gccgccctcc ccactgttac caacatgaag 60

ctgctcgcag caactgtgct actcctcacc atctgcagcc ttgaaggagc tttggttcgg 120

agacaggcaa aggagccatg tgtggagagc ctggtttctc agtacttcca gaccgtgact 180

gactatggca aggacctgat ggagaaggtc aagagcccag agcttcaggc cgaggccaag 240

tcttactttg aaaagtcaaa ggagcagctg acacccctga tcaagaaggc tggaacggaa 300

ctggttaact tcttgagcta tttcgtggaa cttggaacac agcctgccac ccagtga 357

<210> SEQ ID NO 4
<211> LENGTH: 3482
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 4

gtcatggtta cctccccacc tccccagctg caaggaggat tcatccggca accagttgag 60

gctagattct cagcagcttt attgaatatt gagaggtggt ctcacctccc actggacatg 120

tgtcctcaag ttcataccag aacttctttg ggacagacag acagacaggt ggcagggcag 180

ggcaggtgtc cacgagggtg gggccagtgc accaggggca gctcagctct ccaaaggggc 240

cagcatctgc acctgctcct gctgctgctc ctgctgctgt tcctgctgtt gctccagctc 300

agggagggag agagtcttgt cctggctctc tttctccttg aaggtgctga agaaggagtt 360

gaccttgtcc ctcaggtcct tctccaggaa gctcaagtgg ccttccacgt cccccgcatg 420

gggcccagt ttctgcctga gctgttccat ctgctgcacc agggctttgt tgaagttttc 480

cccgtagggc tccacccggc gtcggaactc ctccacctgc tggtccaggt gcccacccag 540

ctctgccagt gacttctgca gcccctcggt gttgcccctc aggttgccac gcacgtcctc 600

ggccaagggc gccagcctct gccgcagctc ctcggcactg gccgagatcc tggccttgag 660

ctcctcggcg ttcttcttca tctggaaggt caggccctca agctggtggt tgagcttctc 720

ctgcgtgtcc tgagcatagg gagccaggct gcggcgcagc tcctccacgg tctggtcaat 780

cttgactttg aattcgtcag cgtagggcgt aaggcgtccc ttgagctcct ccacgttctg 840

gtcgatcttg gccttgagct cgtcggcgtg gggcctcagc gaggcctgca ggctgtcggc 900

gttctcccgc agcactctct ccatgcgctg tgcgtagggg gtcagctggc gccgcagctg 960

ctcggcctgc gtgttgacct gggtgcgcag ctggtccgcg tagggctcca ggcgctgctg 1020

-continued

```
aagctctcgc aggttgtccc cgatcttctg gctcacctca ttggcatggg gcagcagccg   1080
ggccctcagc tcctccagct ccttcccaat ctcctccttc agtttctccg agtccttggc   1140
caggcgttca tgcagctcgg tggcaaaggg caccagcttc ttctgcaggt cacctgcgta   1200
agtgttcact tctccaagtt tgtcctggaa gagggcactg tggggaaggg cacaaggagg   1260
ccacgttaca tttggcattt acacggcaag actttgtctg cttgtatacc actcgcctta   1320
tgcacacgtg ctaagacagg tgagtgctca gaggtaccga gttcaccctc cctatggtgg   1380
tgcagattgg agaggatggg tgtcacagac taagttacga tgctgaattt ctatctcagg   1440
atctcccaca tagtttgtct cagaatctac ccaccatgtc acctccagca gtttgctttc   1500
ccctccttgt ctgcagaggg tgggactttg aggtccttcc cagagggagt gttctgggcc   1560
ataggatcac attgtgtaac acaatgttgt cttcttgacc tctgctgggg tcttccagtg   1620
gcacaaggtg ctgctttcct tgcctgtgcc caggggcctc ccaaatattc ccacctccct   1680
ccccttgatt ccactggggc ctgtctttct gaaacgtatt agaaatcagc tcacatgaca   1740
ttttcctccc tccctctctt ccatgagcct gaatgatagg atgtggccat ttgtcaaact   1800
ctagaacgtc aaagcaaaag gacatggcag ggattattcg gtccaaactt ccggtttaca   1860
tatgtggatc ctaggttcag aggcccggcc agttagtggc agggcagtgg gtatcctaag   1920
ctcagggctc ctgtctctaa gctcaaccct tgccagtaca ttgcatggcc tttaagaatt   1980
ccccgtcacc accgcacact gtagtccctc ttacttgagt tgctgggtga gttcagattt   2040
ctggagatgt tccacggcct ccttggcatt gttgctcagc tggctgaagt agtcccacat   2100
cactgtggcc acctggtcag cactgacctc agccctggct cctgggtggt aacagagagc   2160
aattcatgag gccccgtctc ctgtgtggcc cctctgctcc agctctgagc tgcagactgg   2220
atgatggtgg gggtgcctca acctgccatt ttccctgtct gagcttagct ttttggaagc   2280
cacagggata tgtgaaactg gtatagcacc aatgccaatg ggcccaccac tgggactggg   2340
ccagctctcc tgtgagccac ttggcagcca ggcagacctc atgtccagct gggggctgat   2400
gggcactcag aagtgtcctt ttgctttggc tcagcctcca tcctgcacta ctcagagcag   2460
cagcccagga gtgccatcca aagacagctt ctactcaccg gcgacagcca ccagggccag   2520
ggtcaggacc acggccttca ggaacatcct gagctgcttg ctgggctgga ggagtttctt   2580
gccacactgg atcctcccta caatcagggg agctgacaga gaggtcctca ggagagctca   2640
cctgcgctgc agtgggaact gactgaagct cagagccagc cagacattta aactctctcc   2700
ctatcgccac cccccctggct gccctcccct cctccttcct cagtgtgact ccacgctgga   2760
aggtgacaca ttcccaagag gcctcttgga cttttgtgac cctgagacta cgtggaagct   2820
gacagcagat cagggctcag gcgatagtta gaagtggtgg ctgttccgtg cgtgggcacc   2880
cccaccccca ccccaccaac ctcagcatgg aagggaggag gggaacggaa aacagtagga   2940
gaaacacctc agggagccca tgagcccggg actgatgcct cgaggccctg ctggcggctc   3000
tgggtttgtg ccgggctcat ggggggcaaa gtccacatct cctctgtcta ccccagtgaa   3060
gacaggtccc cccagtctcc acatccgcca ctaatgctga ctccatctca gagcaccaga   3120
cactggagtg ggaccatcca ggactgcaga cagcatagtg agctaaaatc taggtctctt   3180
gtcaaggtac acccaagagg agggggccct ggagagcctt tgggcagatg ggtgtgggag   3240
acagggcctt gtcctgaaag ggttaattgt agagtgcttc atgtcccact cccatgctgt   3300
```

-continued

```
gcctccttgg tctagttatt caaagccctg agcttcagtt tctcctctga acaatgggat   3360

ggttcagtac attaaagaag acattgcttg cgaagtgggt agtacggtca tctctcagtc   3420

tccatgggaa attgattcca ggaccctctg cagataccaa aatccatgga tgttcaagtc   3480

ct                                                                  3482
```

<210> SEQ ID NO 5
<211> LENGTH: 1195
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 5

```
ccaggcctcc ctccacctgt cttctcagag cagataatgg caagcatggc tgccgtgctc     60

acctgggctc tggctcttct ttcagcgttt tcggccaccc aggcacggaa aggcttctgg    120

gactacttca gccagaccag cggggacaaa ggcagggtgg agcagatcca tcagcagaag    180

atggctcgcg agcccgcgac cctgaaagac agccttgagc aagacctcaa caatatgaac    240

aagttcctgg aaaagctgag gcctctgagt gggagcgagg ctcctcggct cccacaggac    300

ccggtgggca tgcggcggca gctgcaggag gagttggagg aggtgaaggc tcgcctccag    360

ccctacatgg cagaggcgca cgagctggtg ggctggaatt tggagggctt gcggcagcaa    420

ctgaagccct acacgatgga tctgatggag caggtggccc tgcgcgtgca ggagctgcag    480

gagcagttgc gcgtggtggg ggaagacacc aaggcccagt tgctgggggg cgtggacgag    540

gcttgggctt tgctgcaggg actgcagagc cgcgtggtgc accacaccgg ccgcttcaaa    600

gagctcttcc acccatacgc cgagagcctg gtgagcggca tcgggcgcca cgtgcaggag    660

ctgcaccgca gtgtggctcc gcacgccccc gccagccccg cgcgcctcag tcgctgcgtg    720

caggtgctct cccggaagct cacgctcaag gccaaggccc tgcacgcacg catccagcag    780

aacctggacc agctgcgcga agagctcagc agagcctttg caggcactgg gactgaggaa    840

ggggccggcc cggaccccca gatgctctcc gaggaggtgc gccagcgact tcaggctttc    900

cgccaggaca cctacctgca gatagctgcc ttcactcgcg ccatcgacca ggagactgag    960

gaggtccagc agcagctggc gccacctcca ccaggccaca gtgccttcgc cccagagttt   1020

caacaaacag acagtggcaa ggttctgagc aagctgcagg cccgtctgga tgacctgtgg   1080

gaagacatca ctcacagcct tcatgaccag ggccacagcc atctggggga cccctgagga   1140

tctacctgcc caggcccatt cccagcttct tgtctgggga gccttggctc tgagc        1195
```

<210> SEQ ID NO 6
<211> LENGTH: 8690
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 6

```
ctgggaatac aggcgtgagc cactgcaacc agccagtagc ccccatcttt gcccctcgct     60

gagccctact ggatgttctt ggttatgcga cagtttcccc atctattaaa gagaaacccc    120

tatagcagag gggaggatga ggttggaaaa gcaggagcat tgttatgcta ttcttgtggg    180

gtctgggaag cagacatctg ggtggatgtt tggggggtgc tgggcttagt tggggaagta    240

ggggggcccc tggggctgac agggactgga agctctgagc tggccagagg gatgttgcaa    300

tcctgccagg gtcttgtcta tgctgtcctt ttcacaacca tcccccctact gccaggctga    360
```

-continued

```
cacgtggttg cgggggcaca aggccagcca acctagagtc tgaggctagg cggaggacac    420
cctccccacc agctgccagg gtcactggcg gtcaaaggca gctggtgggg aaggcattgg    480
actccagcct tgggggacgg atgtagtgat ggtgggaagc aggcttggtg ccaggagggg    540
cgtcagaggg tgaataagag cagatagagt gtttggggga ggtagccagc caaagggggt    600
gaggcccggt ggaagggaag aagggacata cacgcagagc tttgcagctg agggttttaa    660
ttttttgaga tggggtctct gtcccaccag gctggagtgc agtggcacaa tcacagctca    720
ctgcagcctc gaactcctgg gctcaagcaa tcttcctacc tcagcctctt gagtagctgg    780
gactacaggc atgcgccacc acgctcggct aatttttgaa ctttttgta gagatgaggt    840
ctccctatat tgcccaggct ggtctcgaac tcccaggctc aagtgatcct ccctcttcag    900
cttcccaaag tgctgggatt acaggcatga gccaccatgc ctggctaatg caggtgaggt    960
ttttgcagtg tcatccagct aaggcgaccc gttcccctcc caaaaaaggg agactgagaa   1020
ccatgaagtt aagagcccag agaatatcac ggtggtctgg ggtgcttcaa gggctggtct   1080
ggaataaatt ggaggtggca cgcagggtag gagcgccggg ccaactggga gacccagcaa   1140
cataaaggaa aagttgttgg ggctgaggag gcttgctgag agaggggaag tgagggaaag   1200
aggtgatcta gggacacggt gtgaatgagg gggggatgag atcacagggt tattactggg   1260
agacccctga gggaagatgg ccacagggac aggacaaggc tgtcttctta agggaggaga   1320
ccacccctca tattgtctta tgcccaattt ctgcctccaa agaaagaaaa agtaaaaact   1380
aaaaggcaga aatgaaatcc acaagcagac agcccgcgcc acaccctggg cctggtggtt   1440
aaagattgac ccctgaccta atccgttagg ttatctatag attacagaca ttgtatagaa   1500
aagcactgtg aaaatcccta ttctgttttg ttccgatcta attaccggtg catgcagccc   1560
ccagtcacgc atcccctgct tgttcaatcg atcacgaccc tctcacgtgc acccacttag   1620
agttgtgagc ccttaaaagg aacagggatt gctcactcgg ggagctcggc tcttgagaca   1680
ggaatcttgc ccattccccg aacgaataaa ccccttcctt cgttaactca gcgtctgagg   1740
aattttgtct gcggctcctc ctgctacatt ctgagtgggg aaagggacta aggtggtctg   1800
aggaccccac agagtcagga agattgagag gtgagagtgc tgaacgggga ggggctttgg   1860
ggctaaggga agtgcccggg accccacctg accccaacgc tcacgggaca ggggcagagg   1920
agaaaaacgt gggtggacag agggaggcag gcggtcaggg gaaggctcag gaggagggag   1980
atcaacatca acctgccccg ccccctcccc agcctgataa aggtcctgcg ggcaggacag   2040
gacctcccaa ccaagccctc cagcaaggat tcaggttggt gctgagtgcc tgggagggac   2100
acccgcctac actctgcaag aaactcaaaa agggagatga ggggatcgtg ggagggaggt   2160
agggagggag gagggtgcca ctgatcccct gaacccctgc ctctgcctcc agagtgcccc   2220
tccggcctcg ccatgaggct cttcctgtcg ctcccggtcc tggtggtggt tctgtcgatc   2280
gtcttggaag gtaaaagtgg gatgggagaa ttgcggagtt ggagatttgg aagagtgaag   2340
gtggctacag gcctggggtc ccggcttaga ggacctctga gagctccggg gcccccttctg   2400
ggtcgtggtt gcctcatcgt ggtcgggtgg gtctccaggt tctcccaggc tcagtcccgc   2460
aggcgccaaa tctgcgcagg agagcactag caaccgatga cgtattgagg cccacacctc   2520
tgggattggc tgtcctgctt cgacagcctt gaaagtgggt aagctgggtg gggggctctg   2580
ggagaggtca gtgctgagta aggcaattcc cagcagcttg agccccacca ggtcactcca   2640
```

-continued

```
gtattcctcc ccattctttt tttttttttt ttttttttctc ttgagacgga gtctcgctct   2700
gtcgccgagg ctggagtgca gtggcgcgat ctcggctcac tgcaagctcc gcctccctgg   2760
ttcacgccat tctcctgcct cagcaggact acaggcgccc gccaccgcgc ccggctaatt   2820
ttttgtattt tcagtagaga cagggtttca ccgtggtctc gatctcctga ctttgtgatc   2880
cgcctgcctc gacctcccaa agtgctggga ttacaggcgt gagccaccgc gtccggccat   2940
tcctccccat tctaaccaca tgatccccaa ggatctctat ccatcccggt atcccaacct   3000
aagggggttc caataacaaa tttttggccg ggcagggtgg ctcatgcctg taatcccagc   3060
actttgggag gccgaggcgg gcagatcact tgaggtcagg agttcgaaac cagcctggcc   3120
aacatggtga aacttcgtct ctactaaaaa tacaaaaaaa ttagccaggt gtggaggcac   3180
gcgcctgtag gcccagctac tcgggaggct gaggcaggag aatcacttga acccgggagg   3240
cggaggttgc agtgagccga gatcatacca ctgcactcca gcctggctga cacagcaaga   3300
ctccgtctca aaacaaaaca aaacaaaaat agctgggtgt ggtggtgcac acctgtaatc   3360
ccagctactt gggaggctga ggcaggagaa ctgcttgaac ccgggaggtg gtggttgcag   3420
taggccgaga tcatgccact gcactccagc ttgggctaca gagcaagact ccatctccaa   3480
aaaaaaaaaa aaaaaaacaa attttgaacc cctgcccatc ttcctggcag gcccagcccc   3540
agcccagggg accccagacg tctccagtgc cttggataag ctgaaggagt ttggaaacac   3600
actggaggac aaggctcggg aactcatcag ccgcatcaaa cagagtgaac tttctgccaa   3660
gatgcggtta gaacccttcc cagggcacgg gagagctggg gtgtgttttt gggtggagcc   3720
ctggcagatg gtccaagatg aacagattga aaaaaaaaca agtcctggag aggctgacaa   3780
catccctctg gtcacacagc tagatctcaa ggtgctcaga cttcaaggac agtttccctg   3840
actcccatcc aggccatatt ttaaaagatg gtcttgggct gggcacggtg gctcatgctt   3900
gcaatcccag cacttaggga ggccgaggtg ggctgattgc ctgaggtcag gagttcgaga   3960
ccagtctgac caacatggtg aaaccttgtc tctactaaaa atacaaaaaa attaggcagg   4020
catggtggcg tgcacctgta atcccagcta gtcgggaggc tgaggcaggg gaattgcttg   4080
aaccaggaag gtgggagtta cagtgagcca acattgtgcc agcctgggtg acagaaggag   4140
actctgtctc aaaaaaaaaa aaaaaaaaaa aaaaaacaag atggtcttgc ccaggtatgg   4200
tggctcacac ctgtaattcc agcactatgg gaggctgaga tgggaggatt gcttgagccc   4260
aggagttcga gaccagcctg accaacatgg cgagatcctg tctccattta aaaaaaaaaa   4320
aaaaaagatg gttttgtgag gtaatgaaaa tgaaggcccc aagcttggcc agacctgggt   4380
ccccaggctg gagtagcacc ccttcctgtg tgatcttgac agaggggcat tactgtgagc   4440
ctcagtttcc tctcctataa actggtggtt ctacagggaa gtaaaggagc aggcctacag   4500
ggtgtctggt acatgtagat gctcagtata tcatgaaacc caccccttgcc cccttttggca   4560
agttagagag tcattcgttc tttcaaaaat atttactgag catctgctaa gtgctggaaa   4620
ctgtttcaat gtggggaata aaacagtgaa gaacgtgccg agcacggtgg ctcacacctg   4680
taaccccacc actttggaag gccgaggtgg gtggatcact tgaggtcagg agtgcgagaa   4740
ccccgtccct aatagaaatg caaaaaaaat tagctgggca tggtggccca tgcctgtagt   4800
cccagctcct tgggaggctg aggcgagagg attgcttgag cccaggagat ctaggctgca   4860
gtgcgccatg tttgtgccac tgcattccag cctgggtaac agaatgagac cctgtctcaa   4920
```

-continued

```
caaaaaaaga aaagaaaaga gaagaaaaga gaaaagaaag acagggaggg agggaggaag   4980
gaagggaggg agggagggaa aatagagcca ggcataaact tagaaagatc gtttggaggc   5040
caggcacaat ggctcacacc tgtaatccca gcactttggg aggccaaggc aagcagatca   5100
cctgaggtca ggagttcgag accagcctaa catggagaaa ccctgtctct actaaaaata   5160
caaaattagc cgggcgtggt ggtgcattcc tgtagtccta gctactcggg agcctgaggc   5220
aggagaatca cttgaacccg ggaggcggag gttgcagtga gccgagatca tgccactgca   5280
ctccagcctg ggcgacaagg cgagactcca tgccaaaaaa gaaaaaaaac tcctggcgcg   5340
gtggctcacg ccagtaatcc cagcactgtg ggaggctgag caggcggatc acgaggtcag   5400
gagttcgaga ctagcctgct caacataatg aaaccctctc tgtactaaaa atacaaaaat   5460
tagctgggtg tggtggcagg cacctgtagt cccagctact cgggaggctg aggcaggaga   5520
atggcttgaa cctgggaggc agaggttgca gtgagccgag acagtgccat tgcactccag   5580
tccaggtgac agagcgaaac tccatctcaa aaaaaaaagg aaggcattgg tagcaagaga   5640
tggcaggcct tgaaagccag gccagggtga agtgtttctt tttttttttt tttttttttt   5700
ctttttaaat tttttttttt gagacggagt ctcgctctgt cacccaggct ggattgcagt   5760
ggcctgatct cggctcactg caagttccgc ctcccgggtt catgccattc tcctgcctca   5820
ccctcccgag tagctgggac tacaggcacc tgccaccacg ccagctaatt ttttgtattc   5880
ttagtagaat gtagaattta cttagtagaa tttttgtat tcttagccag catggtctcg   5940
atctcctgac ctggtgatcc acccgcctcg gcctcccaaa gtgctgggat tacaggcgtg   6000
agccacggcg cccggcctta ttttttcttt ttgagatgta cccagactgg agtacagtgg   6060
tgcgatctcg gcttactgga acctccacct cccgggttca ggcaattctc ctgcctcagc   6120
ctcatgagta cttggaacta caggtgtgtg acaccacaca tggtattttt tgtattttta   6180
gtgaagatga catttcacca tgttgcccag gttggtctcg aactcctgac ctcaagtgat   6240
cagcctacct cggcctccca aagtgttggg attacaggcg tgagccaaat gcccagccaa   6300
gggtaaagtg tttagacttc aacgtgcttt ggtccatctg ggaaactgag gcacagaagt   6360
tggcccaccc agcccagcgg tcctcctaat cccacagaca gtggggatgg agattctgca   6420
aggggaagag gtgggagtca ggtagcaggc agaatttgga cagcctggga ggtagctgca   6480
cacagtgacc cccttcctta ttcctcccca cagggagtgg ttttcagaga catttcagaa   6540
agtgaaggag aaactcaaga ttgactcatg aggacctgaa gggtgacatc ccaggagggg   6600
cctctgaaat ttcccacacc ccagcgcctg tgctgaggac tccctccatg tggccccagg   6660
tgccaccaat aaaaatccta cagaaaattc tctcctgagt gcttctttac tctggggaag   6720
gggctgcggg agagggtagg ggcttccaga gagggcaggg tctgcaggag agggcagggg   6780
ctaaacctta ggtactcctc acaagccctc caatgcccta tctacttgcc ctgtgctgag   6840
gatgttttaa ctccatggtc tcaaaagagt cttcctaaga accctgcaaa ctgggcctta   6900
ttaatcccat aagggcattg aggcccagag aggtgaagtt acttgtataa ggtcacacag   6960
ccaggaagta gagaactgga actagattga accctcagcc tagcaatgtc actatgctac   7020
acttttccta gtgtggtcta cccgagatga ggggctgagg tttttttttg tttttgtttc   7080
tgttttgagg cagactcact ctctccccca ggatggagta cagtggtgcg atctcagctc   7140
actgcaacct ccacctccca ggttcaagag attatcctgc ctcagcctcc caagtagctg   7200
```

-continued

```
ggatttacag gtgtgcgcca ccacacccag ctaatttttg tatttttagt agagacaggg   7260
tttcatcatg ttggccaggc tggtctccaa ctcctgggct taagcaatcc tcctgccttg   7320
gcctcccaaa gtattagaat tacaggcgtg agccactgtg cctggctctt atgtaaaatt   7380
aaaccacata cacatgagaa acaaccctat gtaattaaga tttctttctt tttttttttt   7440
tttttaagag atggagtcac ccaggctgga gtgcagttgc acaatctcca ttcactgcag   7500
ccttgcaacc tccaccacct gagttcaagg gattctcctg cctcagcctc ctgagtagct   7560
gggattatag gcatgtgcca ccacgcccag ctaatttttt tgtattttta gtagagacgg   7620
aatttcccca tgttggccag gctggtctca aactcctggc cttaaatgat ccacccgtcc   7680
tggcctccca aagtgctggg attacaggtg tgagccaccg cacccagctt aagatttcat   7740
aagaaaaata tttgtaagcc acatatctaa taaccggtta atattcaggc tgggtgaagt   7800
ggctcatgcc tgtaatccca gcactttggg aagacaaggc gggcggatta cctgaagtca   7860
aaagtttgag acctgcctgg ccaacatggt gaaaccctgt ctctactaaa aatacaaaaa   7920
aattagccgg gtggggtggc acatgcctgt aatcccagct gcttgggagg ctgaggcaag   7980
agaatccctt gaacccagga gtcgaaggtt gcagtgagcc aagatggcgc cactgccctc   8040
cagcctggga gacagagtgg gactccatct caaaaaaaaa aaaaattcaa aatgtataat   8100
atacaatcct agttgggaca tcaaacactg cagccactgt ggaaaacagt atggggtttc   8160
ctcaaaacat taaagataga actctcaaat gatccttcaa tcccacttct gggtatttat   8220
tcaaaagaat tgaaatcagg accttgaaga gatacctgcc ctcccatgtt cactgcaggt   8280
ctgctcaata cccaagatat ggaaacaacc taaatgttta tcaacagatg aatgggtcaa   8340
ggaaatgtgg tctctacatg taatggaatg taacgcatcc ttaaaaagga aaccctaagg   8400
ccgggctctg tggctcacac atgttttttt ttttaaattt tatttattta tttatttatt   8460
tatttatttt ttattgatca ttcttgggtg tttctcacag agggggattt ggcagggtca   8520
taggacaata gtggagggaa ggtcagcaga taaacaagtg aacaaaggtc tctggttttc   8580
ctaggcagag gaccctgagg ccttccgcag tgtttgtgtc cctgggtact tgagattagg   8640
gagtggtgac gactcttaac gagcatgctg ccttcaagca tctgtttaac              8690
```

<210> SEQ ID NO 7
<211> LENGTH: 7576
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 7

```
aaagaggaac tgacagcaag gctaagccaa tgtctgcccc tgggggcaga aagtcacctc     60
ctgctctccc tccactgtcc acagaggtag ctcagacagg gtgggggtca caggagaacg    120
aagggagaag ggggtagttc ctgggcagca aaatcaggtg gtgaagggag gcatcagagg    180
atggcaatta gagaggccat tagaggggaa ccacaggcag acagggtgac aggagggact    240
actgacacaa ggtgaagaga tggcccagcc ggacggggtg gctcacatct gtaatcccag    300
cattttggga gcccgaggtg ggtggatcac ttgaggtcag gagttcgagg ccccaacatg    360
gcaaaacccc atctcttcta aaaatacaaa aattagccgg gcatgatggc agatgcctgt    420
aatccctgct actcgggagg ctgaggcagg aaaattgcct gaatccagga ggtggaggtt    480
gcaatgagac gagatcatga cactgcactc caccctgggc aacagagcaa gagactgact    540
```

-continued

```
ctgtctcata aaaaaaaaga aaaaagaaaa aaaaaaagag atggctgatg gttaaagagg    600
ggttagcggt caggggacac ataagggtaa aggcaggagg caagaggact ggcagggggc    660
tgcccctggg ccaccgggag cgacacagga tgagcatgga gggaaaggga gaaggggatt    720
ctagggtccc agcctaccca agttgccctc tggttccacc tagcatgcca gccagaggcc    780
caggaaggaa ccctgagccc cccaccaaag ctaaagatga gtcgctggag cctggtgagg    840
ggcaggatga aggagctgct ggagacagtg gtgaacagga ccagagacgg gtggcaatgg    900
ttctggtgag ggtgtgctgg gctgggtggt gggaggggac tcctgggtct gagggaggag    960
gggctggggc ctggacccct gagtctcagg gaggaggaaa gggtgggagt ggggctgtga   1020
cccctaggtc tgggaggagt ggagggttag agctgagagc aggaactcct aggtcacaga   1080
gaggagcgga taaatggggc agagaacacc tggggagagc tggggcctcc actgtgatgt   1140
cctctctcct gtaggagccc gagcaccttc cggggcttca tgcagaccta ctatgacgac   1200
cacctgaggg acctgggtcc gctcaccaag gcctggttcc tcgaatccaa agacagcctc   1260
ttgaagaaga cccacagcct gtgccccagg cttgtctgtg gggacaagga ccagggttaa   1320
aatgttcata aaagccaggt gtggttgtgg cgggtgcctg tagtcccagc tactcaggag   1380
gctgaggtag gatgatggct tgagcccagg agttcgagac cagcctgggc aacacagcga   1440
gatctcttgg gggtaaaaca aaaagaaaaa aaaaagttca tacttctcca ataaataaag   1500
tctcacctgt gtccctgtct ggatccttcc ccagtgtggc cagaaaaaaa cccaccccac   1560
tgcctcccag gaatcaatga gtagaagagg tgacacctga tggggaagga agagtaggga   1620
ggtcgggaag ggtatcaagg aataacaccc tattgtgggc ttgcggagaa tgggggactt   1680
caaggcgtgt cagtttcagg agggtgaggg caggagcgtg ggtggagtca gcaggtcccc   1740
atgatggccc tcactgagag cttcgccctt gtctcctaca agctctgact ccattcccag   1800
tgggcaccca gcacctccaa cccctccaca gcccccaacc cagcctctgt cggaggcgaa   1860
ttctcagagt gagggttccc tgtcacttga gagaaggttc cctgtgacgt gaccttgggg   1920
gacgtcattg ccctttctgt ccccacccac cccctccgca gttctgttgg ccaggacttt   1980
ggcctagaca aaggatgggg gttgtggctg tggagcggaa gtgggtctca accactataa   2040
atcctctctg tgcccgtccg gagctggtga ggacagcctg ccagagtctg gtaagaaagg   2100
gactcagggt gcggggacag gggggcgtca gcagggagag ggcaaagatc gataaagcag   2160
gaattttaag aggcacaata ttagaagccc gtgttggaac catgactgtg tgtgtgtgtg   2220
tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg agagagagag agagggagat ggagtctcgc   2280
tatgtagccc aggctagact caaactcctg ggctcaagca atcctcctgc ctcagcctcc   2340
ccagtagctg ggactacagg tgcaccacca cactccacaa atcacagaat ttagaactgt   2400
agactatttg agcttctgct tagagttagg gtggctgagg tggggaggat cccttgagcc   2460
caggagtttg aggatgcagt gagctgtgat cttgccaccg tgttccagcc tgggtgacag   2520
agaaacccca tttctaaaaa agagaaagaa aaagggatag gtacaatggc tcatgcctgt   2580
aatcccagca ctctgggagg ccgaggcggg tggatcactt gaggtcagga gttcgacacc   2640
agccttacca gcatggtgaa accgcatcta tactaaaaat acaaaaattg gccgggtgtg   2700
gtagcatatg cctgtaatcc cagctattcc agaggctgag acaggagaat tgcttgaacc   2760
caggaagcgg aggttgcagt gagcccagat cgtgccactg tactctagcc tgggtgacag   2820
```

-continued

```
agcaagactc agtcttggcg gaaaaaaaga atgaaaaaat ttaaaaaact aaaaaagaac   2880
tgtaggctgg gcgtggtggc ttacacttgt aatccaaacg ctttgggagg ccaaggcaaa   2940
cggatcactt gatgtcagga gttggagacc agcctggcca acatggtgaa accccgtctc   3000
tactaaaaat acaaaaatta gacaggcatg gtggtgcatg cttgtatttc cagttactca   3060
ggaggctgag gcaggagaat cgctcgaacc cggaagacag aggttgcggt gagccaaaat   3120
tgcgccatcg cactccagcc tgggcgagag aacaagacct tgtcttggaa aaaaaaaaag   3180
aattgtagac catttgcttg tgttctttct ccggggatca gatctcaccc tctttctgcc   3240
gtacttcctc atctcctacg tgtggatgat gatattgtgc cctgtgcatg ttcttcgtca   3300
ccaaaagtgc ctctctcata gagcaggtga gaactcagtg aggagatgca gggacatgag   3360
gtctgactta gggcagagcc ctaaggtaac acatttgatc tactgtaggt ccttaatggt   3420
gtctgcagag cacctccctg cactgactca gccttagcaa agggcagagg ctttgctgtg   3480
ttccctgctg ggcccagaac tgtttaggtg ctcaagaaag ccttctaggc tgggctcagt   3540
ggctcacacc tgtactccca gcaccctggg gaggccgaga tgggaggatc gcttgagccc   3600
aggagttcca gaccagcctg ggcaacaaaa caagtctccc atctctacaa aagaataaaa   3660
attagcagct gggcatggtg gctcatgcct gtaattccag cactttggga ggccaaggca   3720
ggcaaatcac ttgaggttag gagttcaaga ccagcctggc caacatggtg aaaccccatc   3780
tctactaaaa atacaaaaat caggtggggc acagtggctc aagcctgtaa tcctagcact   3840
ttgggaggcc aaggtgggcg gatcacgagg tcagaagttc gagaccagcc tggccagcat   3900
ggtgaaaccc catctctact aaaaatacaa aatattagcc gggcatggtg gcaggtgctt   3960
gtgattccag ctccttggga ggctgaggca gaagaattgc tagaaccctg gaggcagagg   4020
ttgcagtgag ccgagaacac gccactgcac tccagcctgg gtgacagagc gagactccat   4080
ctcaaaaaat acgaaaacaa aaatcagccg ggtggtggcg ggtgcctgta atcccagcta   4140
ctggggaggc tgaggcagga gaattgcttg aacctgggag gtgggggttg cagtgagcca   4200
agattgcacc actgcactcc agcctgggca acagagtgag attccatctc aaaaaagaaa   4260
aaaataataa ttaaaatgtt aaaatcagga gtagaatcac agaatgttgg aaagtgaggc   4320
ccaagaaggg ggctgtgtcc aagtccatgc atgggaaact tgactgggac accgagctca   4380
cacagagcag gatctcagtc cccccacca gagtggggcg tgaccacagg aacagccgcc   4440
tccagtcagc ctgccacatg acaccccctc aatgttccag gtctctggac actatgggca   4500
cacgactcct cccagctctg tttcttgtcc tcctggtatt gggatttggt gagtgtgggc   4560
ttccggggag ggaagccttg ggggagggaa tgagctccaa gcatcttccc agcccaggcc   4620
cttcttacct ctgcctctgc cctctcctct tcttccttcc tcctttcccc ctgctgcagc   4680
cccacgggct ctcctgacac actctccccc tgcagaggtc caggggaccc aacagcccca   4740
gcaagatgag atgcctagcc cgaccttcct cacccaggtg aaggaatctc tctccagtta   4800
ctgggagtca gcaaagacag ccgcccagaa cctgtacgag aagacatacc tgcccgctgt   4860
agatgagaaa ctcaggtagc acctgcccct ggagaaatgg ggtctggccc ataccaccga   4920
ctgcatccag gacccagaag ttcaggcccc agcccctcct ccctcagacc caggagtcca   4980
ggcctcagcc cctcctccct cagacccagg agtccaggcc cccagcccgt cctccctcag   5040
acccaggagt ccaggccccc agcccctcct ccctcagacc caggagtcca ggtccccaga   5100
```

-continued

```
cccctcctccc tcagacccag gagtccaggc ccccagcccc tcctccctct aaccatctgt   5160
gctttctccc cagggacttg tacagcaaaa gcacagcagc catgagcact tacacaggca   5220
tttttactga ccaagttctt tctgtgctga agggagagga gtaacagcca gacccccccat   5280
cagtggacaa ggggagagtc ccctactccc ctgatccccc aggttcagac tgagctcccc   5340
cttcccagta gctcttgcat cctcctccca actctagcct gaattctttt caataaaaaa   5400
tacaattcaa gttgcttctc atggatggca ctgcttttct gaggactcaa ggtgccaaga   5460
tggaggggct gactcagtcc agccaacatt taatgagcac ctactttatg tatggagctc   5520
taacccatgg gtccatggga ataaagcagt gaatagtaac aataaataat cgtaacagca   5580
attagagact aatctttatt gaagtccggc tttctctctt ttattttttt attttttgag   5640
acagggtttc actctgtcac ccaggctgga cagcagtggt gcaatctcgg ctcactgcac   5700
cctccgcctc ccaggttcca gcgattctgt gtgcctcagc ctctggagta gctgggatta   5760
tgggcatgtg ccactgtgca cggctaatgt ttgtattttt agtagggttt tgccagttgg   5820
ctaggctggt ctcaaacttc tgacctcaag tgatccaccc gcctcagcct cccaaagtac   5880
tggggtgaca ggcatgagcc accgcgccat gccaaaatcc agccttctca tttgtaaaat   5940
aacaaatcat agacacagct agtccacagt ggcctctgac agtctccagt tgttaacggt   6000
gaatggtgtc caggtttttg gcgtcctgaa caaagaactg gacaaaacgc acaaacaaag   6060
caaggaagga atgaagggat ttattgaaaa cgaacataca ctaaacagtg tgggagcggg   6120
cccaagcata tgggttcaaa agccctgtta cagaattttt gggagtttaa attcccccta   6180
gaggattccc cttccactgg ttacttctgg tacaccctat gtaaatggag aggatgaaga   6240
aaagttacaa agtcatttat ggcctaccgg agaggatgtt tcctgttata gctgaagtga   6300
attggcctta tgttccctgc ctccctattt tcctgcctta cagttgctgg actgacacat   6360
tttttatttt atttattttg ttttgagata aggtcttgct ctgtcgccca ggctgaagtg   6420
cagtggtgag atcttggctt actgtagcct tgaccttttg ggctcaagag atcctcccat   6480
ctcagcctcc caagtagttg ggactaggga tgcccactgc cacacctggc taattttttg   6540
tatttttagt agagacgggg tttcgtcaag ttgcctaggc tagtctccaa ttcctgggct   6600
caagcgatct gcccaccttg cccttccaaa gtgttgggat tacgggtgtg aaccaccgca   6660
ccaggcctgg gctgacactt taaacgtgcc attgcaatca gtgtataatg gtcccgtggc   6720
agagggagaa tggtgcccaa gtcagtactt cttggctggg acccaagaag acaaacctct   6780
agggccggcg tggtggctca cgcctgtaat cccagcactt tggttggctg aggtgggcag   6840
atcatctgag gtcaggagtt caagaccagc ctggccaaca tggtgaaacc ttgtctctaa   6900
taaaaacaca aaaattagct aggggtggcc cgcgcctgta atcccagtta cctggaggct   6960
gaggcaggag aattgcttgt accctggagg cggagatagt gccactgcac tccagcctgg   7020
gcagcagagt gagactccgt ctctaaaaaa aaaaaagaaa aacttattaa aaaaaaattg   7080
caagcaaaaa gcacagaagg cagaaggtgc aaataagcag aggctccatg gtctgaagga   7140
ggccagtgct gggaccatga atgaaggggg ctgggggcca agattcctgt atcctgaggg   7200
agtccagggt ggtactgctc cccaagtccc atgggtgggg ctattggtct ctggggatcc   7260
actgcttgta tttctcctaa tctgcttggc attaacctcc tgccaggctt tcaacaccct   7320
tggggcagtt ttcccaggtc ctgaggctgg gcagctgagt ccagtaaaaa acaggggccc   7380
```

-continued

tggagaggga ctgtgggcaa tgcccccgag tccccggggc ctgggaagaa cagaggctgc 7440

caagtgcagg gggtggtggg gaggggaaga ccctggagta acaatccctg ctgtgtccac 7500

ttggttccca cggactcaag ccaagccaaa gcactgcccg gaccagttcg gcttccaacc 7560

aatcctggtg ctggcc 7576

<210> SEQ ID NO 8
<211> LENGTH: 514
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 8

tgctcagttc atccctagag gcagctgctc caggaacaga ggtgccatgc agccccgggt 60

actccttgtt gttgccctcc tggcgctcct ggcctctgcc cgagcttcag aggccgagga 120

tgcctcccct ctcagcttca tgcagggcta catgaagcac gccaccaaga ccgccaagga 180

tgcactgagc agcgtgcagg agtcccaggt ggcccagcag gccaggggct gggtgaccga 240

tggcttcagt tccctgaaag actactggag caccgttaag gacaagttct ctgagttctg 300

ggatttggac cctgaggtca gaccaacttc agccgtggct gcctgagacc tcaatacccc 360

aagtccacct gcctatccat cctgccagct ccttgggtcc tgcaatctcc agggcttccc 420

ctgtaggttg cttaaaaggg acagtattct cagtgctctc ctaccccacc tcatgcctgg 480

ccccctcca ggcatgctgg cctcccaata aagc 514

<210> SEQ ID NO 9
<211> LENGTH: 4510
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 9

gagacggagt cttgctcttt cgcccaggct ggactgcagt ggcgcgatct cggctcaatg 60

caagctccac ctcccaggtt cacgccattc tcctgcctca gcctcccgag tagctaggac 120

tacaggcgcc tgccaccacg cctggctaat ttttcatatt tttagtagag atggggtttc 180

accgtgttag ccaagatggt ctcaatctcc tgacctcgtg atccgcctgc ctcggcctcc 240

caaagtgttg ggattacagg catgagccac cgcgcctggc caacagcaat gatctttgag 300

cacctatatt gccagtctcc acggtaagag ctttcttcat tttttgtttt gttttgtttc 360

aagacagagt cttgctctgt cacccaggct ggagtgcagt ggtgtgatcg cggctcactg 420

cagccttcac ttcccgggtt caagccattc tcctgcctca gcctcccaag tagctgggat 480

tacaggcacg catcactact tctggctaat ttttgtattt ttagtaggga cagggttttt 540

caccatgttg gccaggttgg tctcaaactc ctggcctcat atgatctgcc cacctcggcc 600

tcccaaagtg ctgggattac aggcgtgagc cactgcgcct ttctttgtat ttgttcaagt 660

aatatactga aatatgtact gtgcctccca ctttatggag gaggaaactg aggccagcaa 720

atgaggctgt catgggaggt ggagacagga tttgaacctg cctcagtgca ggaggctcaa 780

gagcctctgt cttctctcag ggcactgtgt gggagggtga gaaggaggga ggcccacaga 840

ggcatgacct ctgattgcca ctgtcacctg ggccctgctc tctgaagtct ctgccaagcg 900

gggaggtggc cgggggaggg ccctgctctg tgcagcctcc cctcccccgg cccgcagagt 960

tgagcacaga gggacagagg cacggaaccc ccagaaatgt ccctcctcag aaacaggctc 1020

-continued

```
caggccctgc ctgccctgtg cctctgcgtg ctggtcctgg cctgcattgg gggtgagaag   1080
aagtgggtgg agggatgtgg ggcccacacc tggtgggtgt gagtgtggct gtgtgtcctg   1140
tggctctgta gccacgtgag acatgagtac ggagtgtgtg cgtttcatgg cgtgcgtatg   1200
catgtgcgtg tcggggagtg tgtgtgtcgg tggctgagag tgaagtgtga atgtcacatt   1260
ggtacaaact gggatcatct gtgtgtgtgc acgtgcgtgc gtggaagtgg gagtatgcag   1320
tcgtggtaaa aaagtgcatg tctgtgtgca tatgtgtatt tgtgtgcacc tgtctctctg   1380
tggggtatgt gtgtgcaaaa tatttgagtg tgtggacatg tgtgaggggg tgagtgtgtg   1440
ctggtgtgta cgtctgtgtt ttgcatatgc attttttttt ttttttttga gacggagtct   1500
cactctgtca cccaggctgg agtgcagtgg tagcagtggt gcgatcttgg ctcactgcat   1560
catccgccta cccgtttcaa gggattctcc tgcctcagtc ttcagagtat ttgggactac   1620
agacacacgc caccatgcct ggctaatttt ttttttttga gacggagtct cgctctgtta   1680
cccaggctgg agtgcagtgg cgtgatcttg gctcactgca acgtccgcct cccgggttca   1740
cgccattctc ctgcctcagc ctcccgagta gctgggacta caggagccca ccaccacgcc   1800
tggctaattt tttgtatttt tactagagac ggggtttcgc cgtgttagcc aggatggtct   1860
ccatatcctg acctcgtgat ccgcctgcct cggccttcca aagtgctagg attataggcg   1920
tgagccactg cgcctggcca atgcctggct aattttttta tatttttggt agagacaggg   1980
ttttgccatg ttgcccaggc tggtcttgaa atcctgacct caggtgatcc gcccgccttg   2040
gcctcccaaa gtgctgggat tacaggcatg agccaccacg cccggccatg tactttatgt   2100
taaaatggga tcatattcta gatcagcatt atccagtaga aatttaaatt tttaatacag   2160
ggccaggcac ggtggctcat gcctgtaatc ccagcacttt cggaggccga ggcgggtgga   2220
tcgcaaggtc aggagatttg agatcatcct ggctaacaga tgggtaaaaa cccatctcta   2280
ctaaaaatac aaaaaattag ccatgcatgg tggcatgcgc ctgtagtccc agctactcgg   2340
gaggctgagg ccggagaatc acttgaaccc gggaggcaga ggttgcagtg agccgagatc   2400
gcgccactgc attccaacct gggtgacaga gcgagactcc gtctgaaaaa aaaaaaaaat   2460
ttaacacgta tgtagacaat gtgcaaggca ccattccatg tgcatcgtat gtagtaactc   2520
ttaattctca cgataaccct gaggtagata ttattacccc gttctacaaa aggagaaaca   2580
gtcctgggga gacaggataa gtcaccggcc aaggcacaca gccagctaca tgtggccccc   2640
gcgtgacggc tggtctctgt aggcgaggct ttgtccagat gcgtgggtag aaggtctggc   2700
ccggaaagag gaactgacag caaggctaag ccaatgtctg cccctggggg cagaaagtca   2760
cctcctgctc tccctccact gtccacagag gtagctcaga cagggtgggg gtcacaggag   2820
aacgaaggga gaagggggta gttcctgggc agcaaaatca ggtggtgaag ggaggcatca   2880
gaggatggca attagagagg ccattagagg ggaaccacag gcagacaggg tgacaggagg   2940
gactactgac acaaggtgaa gagatggccc agccggacgg ggtggctcac atctgtaatc   3000
ccagcatttt gggagcccga ggtgggtgga tcacttgagg tcaggagttc gaggccccaa   3060
catggcaaaa ccccatctct tctaaaaata caaaaattag ccgggcatga tggcagatgc   3120
ctgtaatccc tgctactcgg gaggctgagg caggaaaatt gcctgaatcc aggaggtgga   3180
ggttgcaatg agacgagatc atgacactgc actccaccct gggcaacaga gcaagagact   3240
gactctgtct cataaaaaaa aagaaaaaag aaaaaaaaaa agagatggct gatggttaaa   3300
```

-continued

```
gaggggttag cggtcagggg acacataagg gtaaaggcag gaggcaagag gactggcagg   3360

gggctgcccc tgggccaccg ggagcgacac aggatgagca tggagggaaa gggagaaggg   3420

gattctaggg tcccagccta cccaagttgc cctctggttc cacctagcat gccagccaga   3480

ggcccaggaa ggaaccccga gccccccacc aaagctaaag atgagtcgct ggagcctggt   3540

gaggggcagg atgaaggagc tgctggagac agtggtgaac aggaccagag acgggtggca   3600

atggttctgg tgagggtgtg ctgggctggg tggtgggagg ggactcctgg gtctgaggga   3660

ggaggggctg ggcctggac ccctgagtct cagggaggag gaaagggtgg gagtggggct    3720

gtgaccccta ggtctgggag gagtggaggg ttagagctga gagcaggaac tcctaggtca   3780

cagagaggag cggataaatg gggcagagaa cacctgggga gagctggggc ctccactgtg   3840

atgtcctctc tcctgtagga gcccgagcac cttccggggc ttcatgcaga cctactatga   3900

cgaccacctg agggacctgg gtccgctcac caaggcctgg ttcctcgaat ccaaagacag   3960

cctcttgaag aagacccaca gcctgtgccc caggcttgtc tgtggggaca aggaccaggg   4020

ttaaaatgtt cataaaagcc aggtgtggtt gtggcgggtg cctgtagtcc cagctactca   4080

ggaggctgag gtaggatgat ggcttgagcc caggagttcg agaccagcct gggcaacaca   4140

gcgagatctc ttgggggtaa aacaaaaaga aaaaaaaaag ttcatacttc tccaataaat   4200

aaagtctcac ctgtgtccct gtctggatcc ttccccagtg tggccagaaa aaaacccacc   4260

ccactgcctc ccaggaatca atgagtagaa gaggtgacac ctgatgggga aggaagagta   4320

gggaggtcgg gaagggtatc aaggaataac accctattgt gggcttgcgg agaatggggg   4380

acttcaaggc gtgtcagttt caggagggtg agggcaggag cgtgggtgga gtcagcaggt   4440

ccccatgatg gccctcactg agagcttcgc ccttgtctcc tacaagctct gactccattc   4500

ccagtgggca                                                         4510
```

<210> SEQ ID NO 10
<211> LENGTH: 7535
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 10

```
cagcggatcc ttgatgctgc cttaagtccg gctcagaggg gcgcagcgtg gcctggggtc     60

gctatcttcc catccggaac atctgccctg ctgggggaca ctacgggcct tcccttgcct    120

gagggtaggg tctcaaggtc acttgccccc agcttgacct ggccggagtg gctatagagg    180

actttgtccc tgcagactgc agcagcagag atgacactgt ctctgagtgc agagatgggg    240

gcagggagct gggagagggt tcaagctact ggaacagctt cagaacaact agggtactag    300

gaactgctgt gtcagggaga aggggctcaa ggactcgcag gcctgggagg aggggcctag    360

gccagccatg ggagttgggt cacctgtgtc tgaggacttg gtgctgtctg gattttgcca    420

acctagggct ggggtcagct gatgcccacc acgactcccg agcctccagg aactgaaacc    480

ctgtctgccc ccagggtctg gggaaggagg ctgctgagta gaaccaaccc caggttacca    540

accccacctc agccacccct tgccagccaa agcaaacagg cccggcccgg cactgggggt    600

tccttctcga accaggagtt cagcctcccc tgacccgcag aatcttctga tcccacccgc    660

tccaggagcc aggaatgagt cccagtctct cccagttctc actgtgtggt tttgccattc    720

gtcttgctgc tgaaccacgg gtttctcctc tgaaacatct gggatttata acagggctta    780
```

-continued

```
ggaaagtgac agcgtctgag cgttcactgt ggcctgtcca ttgctagccc taacatagga    840
ccgctgtgtg ccagggctgt cctccatgct caatacacgt tagcttgtca ccaaacatac    900
ccgtgccgct gctttcccag tctgatgagc aaaggaactt gatgctcaga gaggacaagt    960
catttgccca aggtcacaca gctggcaact ggcagagcca ggattcacgc cctggcaatt   1020
tgactccaga atcctaacct taacccagaa gcacggcttc aagcccctgg aaaccacaat   1080
acctgtggca gccaggggga ggtgctggaa tctcatttca catgtgggga gggggctccc   1140
ctgtgctcaa ggtcacaacc aaagaggaag ctgtgattaa aacccaggtc ccatttgcaa   1200
agcctcgact tttagcaggt gcatcatact gttcccaccc ctcccatccc acttctgtcc   1260
agccgcctag ccccactttc tttttttct tttttgaga cagtctccct cttgctgagg   1320
ctggagtgca gtggcgagat ctcggctcac tgtaacctcc gcctcccggg ttcaagcgat   1380
tctcctgcct cagcctccca agtagctagg attacaggcg cccgccacca cgcctggcta   1440
acttttgtat ttttagtaga gatggggttt caccatgttg gccaggctgg tctcaaactc   1500
ctgaccttaa gtgattcgcc cactgtggcc tcccaaagtg ctgggattac aggcgtgagc   1560
taccgccccc agcccctccc atcccacttc tgtccagccc cctagcccta ctttctttct   1620
gggatccagg agtccagatc cccagccccc tctccagatt acattcatcc aggcacagga   1680
aaggacaggg tcaggaaagg aggactctgg gcggcagcct ccacattccc cttccacgct   1740
tggcccccag aatggaggag ggtgtctgga ttactgggcg aggtgtcctc ccttcctggg   1800
gactgtgggg ggtggtcaaa agacctctat gccccacctc cttcctccct ctgccctgct   1860
gtgcctgggg cagggggaga acagcccacc tcgtgactgg gggctggccc agcccgccct   1920
atccctgggg gagggggcgg gacaggggga gccctataat tggacaagtc tgggatcctt   1980
gagtcctact cagccccagc ggaggtgaag gacgtccttc cccaggagcc ggtgagaagc   2040
gcagtcgggg gcacggggat gagctcaggg gcctctagaa agagctggga ccctgggaac   2100
ccctggcctc caggtagtct caggagagct actcggggtc gggcttgggg agaggaggag   2160
cgggggtgag gcaagcagca ggggactgga cctgggaagg gctgggcagc agagacgacc   2220
cgacccgcta gaaggtgggg tggggagagc agctggactg ggatgtaagc catagcagga   2280
ctccacgagt tgtcactatc atttatcgag cacctactgg gtgtccccag tgtcctcaga   2340
tctccataac tggggagcca ggggcagcga cacggtagct agccgtcgat tggagaactt   2400
taaaatgagg actgaattag ctcataaatg gaacacggcg cttaactgtg aggttggagc   2460
ttagaatgtg aagggagaat gaggaatgcg agactgggac tgagatggaa ccggcggtgg   2520
ggagggggtg gggggatgga atttgaaccc cgggagagga agatggaatt ttctatggag   2580
gccgacctgg ggatggggag ataagagaag accaggaggg agttaaatag ggaatgggtt   2640
gggggcggct tggtaaatgt gctgggatta ggctgttgca gataatgcaa caaggcttgg   2700
aaggctaacc tggggtgagg ccgggttggg gccgggctgg gggtgggagg agtcctcact   2760
ggcggttgat tgacagtttc tccttcccca gactggccaa tcacaggcag gaagatgaag   2820
gttctgtggg ctgcgttgct ggtcacattc ctggcaggta tgggggcggg gcttgctcgg   2880
ttccccccgc tcctcccccct ctcatcctca cctcaacctc ctggccccat tcaggcagac   2940
cctgggcccc ctcttctgag gcttctgtgc tgcttcctgg ctctgaacag cgatttgacg   3000
ctctctgggc ctcggtttcc cccatccttg agataggagt tagaagttgt tttgttgttg   3060
```

-continued

```
ttgtttgttg ttgttgtttt gttttttttga gatgaagtct cgctctgtcg cccaggctgg   3120
agtgcagtgg cgggatctcg gctcactgca agctccgcct cccaggtcca cgccattctc   3180
ctgcctcagc ctcccaagta gctgggacta caggcacatg ccaccacacc cgactaactt   3240
ttttgtattt tcagtagaga cggggtttca ccatgttggc caggctggtc tggaactcct   3300
gacctcaggt gatctgcccg tttcgatctc ccaaagtgct gggattacag gcgtgagcca   3360
ccgcacctgg ctgggagtta gaggtttcta atgcattgca ggcagatagt gaataccaga   3420
cacggggcag ctgtgatctt tattctccat caccccccaca cagccctgcc tggggcacac   3480
aaggacactc aatacatgct tttccgctgg gcgcggtggc tcacccctgt aatcccagca   3540
ctttgggagg ccaaggtggg aggatcactt gagcccagga gttcaacacc agcctgggca   3600
acatagtgag accctgtctc tactaaaaat acaaaaatta gccaggcatg gtgccacaca   3660
cctgtgctct cagctactca ggaggctgag gcaggaggat cgcttgagcc cagaaggtca   3720
aggttgcagt gaaccatgtt caggccgctg cactccagcc tgggtgacag agcaagaccc   3780
tgtttataaa tacataatgc tttccaagtg attaaaccga ctccccccctc accctgccca   3840
ccatggctcc aaagaagcat ttgtggagca ccttctgtgt gcccctaggt actagatgcc   3900
tggacggggt cagaaggacc ctgacccacc ttgaacttgt tccacacagg atgccaggcc   3960
aaggtggagc aagcggtgga gacagagccg gagcccgagc tgcgccagca gaccgagtgg   4020
cagagcggcc agcgctggga actggcactg ggtcgctttt gggattacct gcgctgggtg   4080
cagacactgt ctgagcaggt gcaggaggag ctgctcagct cccaggtcac ccaggaactg   4140
aggtgagtgt ccccatcctg gcccttgacc ctcctggtgg gcggctatac ctccccaggt   4200
ccaggtttca ttctgcccct gtcgctaagt cttgggggggc ctgggtctct gctggttcta   4260
gcttcctctt cccatttctg actcctggct ttagctctct ggaattctct ctctcagctt   4320
tgtctctctc tcttcccttc tgactcagtc tctcacactc gtcctggctc tgtctctgtc   4380
cttccctagc tcttttatat agagacagag agatggggtc tcactgtgtt gcccaggctg   4440
gtcttgaact tctgggctca agcgatcctc ccgcctcggc ctcccaaagt gctgggatta   4500
gaggcatgag ccaccttgcc cggcctccta gctccttctt cgtctctgcc tctgccctct   4560
gcatctgctc tctgcatctg tctctgtctc cttctctcgg cctctgcccc gttccttctc   4620
tccctcttgg gtctctctgg ctcatcccca tctcgcccgc cccatcccag cccttctccc   4680
cgcctcccac tgtgcgacac cctcccgccc tctcggccgc agggcgctga tggacgagac   4740
catgaaggag ttgaaggcct acaaatcgga actggaggaa caactgaccc cggtggcgga   4800
ggagacgcgg gcacggctgt ccaaggagct gcaggcggcg caggcccggc tgggcgcgga   4860
catggaggac gtgtgcggcc gcctggtgca gtaccgcggc gaggtgcagg ccatgctcgg   4920
ccagagcacc gaggagctgc gggtgcgcct cgcctcccac ctgcgcaagc tgcgtaagcg   4980
gctcctccgc gatgccgatg acctgcagaa gcgcctggca gtgtaccagg ccggggcccg   5040
cgagggcgcc gagcgcggcc tcagcgccat ccgcgagcgc ctggggcccc tggtggaaca   5100
gggccgcgtg cgggccgcca ctgtgggctc cctggccggc cagccgctac aggagcgggc   5160
ccaggcctgg ggcgagcggc tgcgcgcgcg gatggaggag atgggcagcc ggacccgcga   5220
ccgcctggac gaggtgaagg agcaggtggc ggaggtgcgc gccaagctgg aggagcaggc   5280
ccagcagata cgcctgcagg ccgaggcctt ccaggcccgc ctcaagagct ggttcgagcc   5340
```

-continued

```
cctggtggaa gacatgcagc gccagtgggc cgggctggtg gagaaggtgc aggctgccgt   5400
gggcaccagc gccgcccctg tgcccagcga caatcactga acgccgaagc ctgcagccat   5460
gcgaccccac gccaccccgt gcctcctgcc tccgcgcagc ctgcagcggg agaccctgtc   5520
cccgccccag ccgtcctcct ggggtggacc ctagtttaat aaagattcac caagtttcac   5580
gcatctgctg gcctccccct gtgatttcct ctaagcccca gcctcagttt ctctttctgc   5640
ccacatactg gccacacaat tctcagcccc ctcctctcca tctgtgtctg tgtgtatctt   5700
tctctctgcc cttttttttt tttttagacg gagtctggct ctgtcaccca ggctagagtg   5760
cagtggcacg atcttggctc actgcaacct ctgcctcttg ggttcaagcg attctgctgc   5820
ctcagtagct gggattacag gctcacacca ccacacccgg ctaatttttg tatttttagt   5880
agagacgagc tttcaccatg ttggccaggc aggtctcaaa ctcctgacca agtgatccac   5940
ccgccggcct cccaaagtgc tgagattaca ggcctgagcc accatgcccg gcctctgccc   6000
ctctttcttt tttagggggc agggaaaggt ctcaccctgt cacccgccat cacagctcac   6060
tgcagcctcc acctcctgga ctcaagtgat aagtgatcct cccgcctcag cctttccagt   6120
agctgagact acaggcgcat accactagga ttaatttggg gggggggtg gtgtgtgtgg   6180
agatggggtc tggctttgtt ggccaggctg atgtggaatt cctgggctca agcgatactc   6240
ccaccttggc ctcctgagta gctgagacta ctggctagca ccaccacacc cagcttttta   6300
ttattatttg tagagacaag gtctcaatat gttgcccagg ctagtctcaa accccctgggc   6360
tcaagagatc ctccgccatc ggcctcccaa agtgctggga ttccaggcat ggggctccga   6420
gcccggcctg cccaacttaa taatacttgt tcctcagagt tgcaactcca aatgacctga   6480
gattggtgcc tttattctaa gctattttca tttttttttct gctgtcatta ttctccccct   6540
tctctcctcc agtcttatct gatatctgcc tccttcccac ccaccctgca ccccatccca   6600
cccctctgtc tctccctgtt ctcctcagga gactctggct tcctgttttc ctccacttct   6660
atcttttatc tctccctcct acggtttctt ttctttctcc ccggcctgct tgtttctccc   6720
ccaacccccct tcatctggat ttcttcttct gccattcagt ttggtttgag ctctctgctt   6780
ctccggttcc ctctgagcta gctgtccctt cacccactgt gaactgggtt tccctgccca   6840
accctcattc tctttctttc tttcttttt ttttttttt ttttttttt tttttgagac   6900
agagtcttgc tctgttgccc agcctggagt gcagtggtgc aatcttggtt cactgcaacc   6960
tccacttccc agattcaagc aattctcctg cctcagcctc cagagtagct gggattacag   7020
gcgtgtccca ccacacccga ctaattttg tatttttggt agagacaagg cttcggcatt   7080
gttggccagg caggtctcga actcctgacc tcaagtaatc tgcctgcctc accctcccaa   7140
agtgctggga ttacaggcat gagccacctc acccggacca tccctcattc tccatccttt   7200
cctccagttg tgatgtctac ccctcatgtt tcccaacaag cctactgggt gctgaatcca   7260
ggctgggaag agaagggagc ggctcttctg tcggagtctg caccaggccc atgctgagac   7320
gagagctggc gctcagagag gggaagcttg gatggaagcc caggagccgc cggcactctc   7380
ttcccctccc accccctcag ttctcagaga cggggaggag ggttcccacc aacgggggac   7440
aggctgagac ttgagcttgt atctcctggg ccagctgcaa catctgcttg tccctctgcc   7500
catcttggct cctgcacacc ctgaacttgg tgctt                              7535
```

What is claimed:

1. A method of measuring the concentration of lipoprotein particles in a biological fluid of a subject, wherein an apolipoprotein is structurally associated with said lipoprotein in the form of lipoprotein-apolipoprotein, the method comprising the steps of:

incubating Solution S2, comprising said biological fluid, a surfactant, and an antibody against said apolipoprotein, for a period of time t2 at a set temperature T2, to generate an antibody-bound apolipoprotein;

generating a calibration curve for quantitating binding of said antibody to said apolipoprotein with an immunoassay, using at least one standard solution comprising a known concentration of said apolipoprotein;

quantitating said antibody-bound apolipoprotein in Solution S2 with said immunoassay using said calibration curve;

determining concentration of said lipoprotein-apolipoprotein in said Solution S2;

determining concentration of said lipoprotein-apolipoprotein in said biological fluid; and,

determining said concentration of said lipoprotein particles in said biological fluid.

2. The method of claim **1**, wherein said subject is human.

3. The method of claim **1**, wherein said biological fluid is selected from the group consisting of blood, serum and plasma.

4. The method of claim **1**, wherein said Solution S2 is generated by a method comprising the steps of:

mixing said biological fluid with Reagent R1, wherein said Reagent R1 comprises a surfactant, to generate Solution S1;

incubating said Solution S1 for a period of time t1 at a set temperature T1; and,

mixing said Solution S1 with Reagent R2, wherein said Reagent R2 comprises said antibody against said apolipoprotein, to generate said Solution S2.

5. The method of claim **1**, wherein said Solution S2 is generated by a method comprising the steps of:

mixing said biological fluid with Reagent R1, to generate Solution S1;

incubating said Solution S1 for a period of time t1 at a set temperature T1; and,

mixing said Solution S1 with Reagent R2, wherein said Reagent R2 comprises said surfactant and said antibody against said apolipoprotein, to generate said Solution S2.

6. The method of claim **1**, wherein said Solution S2 is generated by a method comprising the step of:

mixing said biological fluid with Reagent R2, wherein said Reagent R2 comprises said surfactant and said antibody against said apolipoprotein, to generate said Solution S2.

7. The method of claim **1**, wherein said lipoprotein is LDL and said apolipoprotein is apo B.

8. The method of claim **1**, wherein said lipoprotein is HDL and said apolipoprotein is selected from the group consisting of apo A-I, apo A-II, apo A-IV, apo A-V, apo C-I, apo C-II, apo C-III, apo C-IV, and apo E.

9. The method of claim **1**, wherein said surfactant is a non-ionic surfactant.

10. The method of claim **9**, wherein said non-ionic surfactant is selected from the group consisting of a POE polymer, POP polymer, POE-POP block copolymer, PEG polymer, Brij® surfactant, Igepal® surfactant, Tween® surfactant and Triton® surfactant.

11. The method of claim **1**, wherein said surfactant in said Solution S2 varies in concentration from about 0.001% to about 10%.

12. The method of claim **11**, wherein said surfactant in said Solution S2 varies in concentration from about 0.005% to about 1%.

13. The method of claim **4**, wherein said surfactant in said Solution S1 varies in concentration from about 0.001% to about 10%.

14. The method of claim **13**, wherein said surfactant in said Solution S1 varies in concentration from about 0.005% to about 1%.

15. The method of claim **1**, wherein said Solution S2 further comprises a PEG polymer.

16. The method of claim **15**, wherein said PEG polymer varies in concentration in said Solution S2 from about 0.1% to about 10%.

17. The method of claim **16**, wherein said PEG polymer varies in concentration in said Solution S2 from about 1% to about 8%.

18. The method of claim **4**, wherein said Reagent R1 further comprises a PEG polymer.

19. The method of claim **18**, wherein said PEG polymer varies in concentration in said Solution S1 from about 0.1% to about 10%.

20. The method of claim **19**, wherein said PEG polymer varies in concentration in said Solution S1 from about 1% to about 8%.

21. The method of claim **1**, wherein said Solution S2 optionally further comprises one or more components selected from the group consisting of PEG, dextran sulfate, α-cyclodextrin sulfate, EDTA, an azide salt, and a divalent cation.

22. The method of claim **4**, wherein said Reagent R1 optionally further comprises one or more components selected from the group consisting of PEG, dextran sulfate, α-cyclodextrin sulfate, EDTA, an azide salt, and a divalent cation.

23. The method of claim **4**, wherein said Reagent R2 optionally further comprises one or more components selected from the group consisting of PEG, dextran sulfate, α-cyclodextrin sulfate, EDTA, an azide salt, and a divalent cation.

24. The method of claim **1**, wherein said Solution S2 comprises a composition selected from the group consisting of: (i) surfactant Pluronic® F-68 (0.5%), PEG 4000 (2.5%), and PBS buffer, pH 7.4; (ii) surfactant Brij® 700 (0.005%), PEG 8000 (3%), and PBS buffer, pH 7.4; and, (iii) Pluronic® F-127 (0.01%), PEG 8000 (5%), and PBS buffer, pH 7.4.

25. The method of claim **4**, wherein said Solution S1 comprises a composition selected from the group consisting of: (i) surfactant Pluronic® F-68 (0.5%), PEG 4000 (2.5%), and PBS buffer, pH 7.4; (ii) surfactant Brij® 700 (0.005%), PEG 8000 (3%), and PBS buffer, pH 7.4; and, (iii) Pluronic® F-127 (0.01%), PEG 8000 (5%), and PBS buffer, pH 7.4.

26. The method of claim **1**, wherein said period of time t2 is about 3 minutes and said set temperature T2 is about 37° C.

27. The method of claim **4**, wherein said period of time t1 is about 5 minutes and said set temperature T1 is about 37° C.

28. The method of claim **1**, wherein said immunoassay is immunoturbidimetry or immunonephelometry.

29. The method of claim **1**, wherein said immunoassay is an ELISA assay.

30. The method of claim **1**, wherein said at least one standard solution has said known concentration expressed in mg/dL units.

31. The method of claim **1**, wherein said concentration of said lipoprotein-apolipoprotein in said biological fluid is calculated in mg/dL units.

32. The method of claim **1**, wherein said concentration of said lipoprotein-apolipoprotein in said biological fluid is calculated in nmoles/L units.

33. The method of claim **1**, wherein said concentration of said lipoprotein particles in said biological fluid is calculated in nmoles/L units.

34. A composition comprising a non-ionic surfactant selected from the group consisting of a POE polymer, a POP polymer, a POE-POP block copolymer, a PEG polymer, a Brij® surfactant, a Igepal® surfactant, a Tween® surfactant and a Triton® surfactant, wherein the concentration of said non-ionic surfactant varies from about 0.001% to about 10%; in a buffer with a pH value ranging from about 6.5 to about 8.5%; said composition optionally further comprising a PEG polymer varying in concentration from 0.1% to about 10%; and optionally further comprising one or more components selected from the group consisting of PEG, dextran sulfate, α-cyclodextrin sulfate, EDTA, an azide salt and a divalent cation.

35. The composition of claim **34**, further comprising a biological fluid from a subject.

36. The composition of claim **34**, further comprising an antibody against an apolipoprotein.

37. A kit for measuring the concentration of lipoprotein particles in a biological fluid of a subject, wherein an apolipoprotein is structurally associated with said lipoprotein in the form of lipoprotein-apolipoprotein, said kit comprising:

at least one composition comprising a known amount of said apolipoprotein,

a composition comprising a non-ionic surfactant selected from the group consisting of a POE polymer, a POP polymer, a POE-POP block copolymer, a PEG polymer, a Brij® surfactant, a Igepal® surfactant, a Tween® surfactant and a Triton® surfactant, wherein the concentration of said non-ionic surfactant varies from about 0.001% to about 10%; in a buffer with a pH value ranging from about 6.5 to about 8.5; said composition optionally further comprising a PEG polymer varying in concentration from about 0.1% to about 10%; and optionally further comprising one or more components selected from the group consisting of PEG, dextran sulfate, α-cyclodextrin sulfate, EDTA, an azide salt and a divalent cation;

a composition comprising an antibody against said apolipoprotein and optionally further comprising one or more components selected from the group consisting of PEG, dextran sulfate, α-cyclodextrin sulfate, EDTA, an azide salt and a divalent cation;

said kit further comprising an applicator and an instructional material for the use of said kit.

* * * * *

patsnap

专利名称(译)	测量脂蛋白特异性载脂蛋白的方法		
公开(公告)号	US20100323376A1	公开(公告)日	2010-12-23
申请号	US12/817026	申请日	2010-06-16
[标]申请(专利权)人(译)	缅因州标准		
申请(专利权)人(译)	缅因州标准COMPANY，LLC		
当前申请(专利权)人(译)	缅因州标准COMPANY，LLC		
[标]发明人	CONTOIS JOHN		
发明人	CONTOIS, JOHN		
IPC分类号	G01N33/53 G01N33/566		
CPC分类号	G01N33/92		
优先权	61/187806 2009-06-17 US		
外部链接	Espacenet USPTO		

摘要(译)

本发明涉及使用免疫测定法测量生物流体中脂蛋白颗粒和/或脂蛋白特异性载脂蛋白浓度的方法，而不需要对生物流体中存在的各种类型的脂蛋白颗粒进行初步物理分离。



w+x+y+z=20